Interaction of the PBD Dimer SJG-136 with Cognate Sequences of Oncogenic Transcription Factors by Mantaj, Julia
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 













Download date: 06. Nov. 2017
1 
 
Interaction of the PBD Dimer SJG-136 with 





A thesis presented in partial fulfilment of the requirements for the 
degree of Doctor of Philosophy 
 
Institute of Pharmaceutical Sciences 
King’s College London 
2016 
Supervisors: 
Dr Khondaker Miraz Rahman 










For my father Roman Mantaj 
 





My utmost thanks go to my primary supervisor Dr Khondaker Miraz Rahman and my 
secondary supervisor Professor David E. Thurston who both have been strongly involved 
and interested in my project. I am hugely thankful to both of my supervisors for always 
having an open mind towards my own ideas during my PhD and for our great working 
relationship. I am extremely grateful to Dr Khondaker Miraz Rahman for his excellent 
guidance, encouragement and support he gave me during the last four years. He has been 
a great supervisor. I am also deeply thankful to Professor David E. Thurston for his 
exemplary guidance, support and the valuable input he gave me during my project. In 
particular, I greatly appreciate all his hard work, support and guidance with my 
publications.  
 
I would like to thank Dr Richard Parsons for all his help with the biology aspects of my 
project and for giving me the opportunity to learn new biological techniques. I was meant 
to spend only a few weeks in his lab but stayed for one year as I have enjoyed it so much. 
Thanks also to Dr Parson’s former PhD student Dr Martin Thomas for accepting me from 
day one and treating me like a member of their group. 
 
I am extremely thankful to Dr Paul Jackson, who has carried out the molecular dynamics 
simulation, for all his hard work and involvement in my project. But more importantly, I 
am thankful for our friendship. Thank you for having always your door open for me, for 
your motivating and encouraging words and for making me laugh. 
 
I am thankful to all the members of the Thurston and Rahman research group for making 
my PhD enjoyable. 
 
I would like to thank my friends (Magda, Helene and Kasia) for all their support and 
motivation over the last few years and particularly during my writing-up period. Thanks 
also to Dr Abhinav Kumar for all the encouraging chats and for providing me with 




Finally, I am hugely thankful to the most important people in my life, my brother and his 
family, my mother Erna and my father Roman for all the love, warmth and support they 
gave me throughout my life. I would not have achieved all of this without you, and I hope 








ADC Antibody-Drug Conjugate 
AKT Protein Kinase B 
AP-1 Activating Protein-1 
ATP Adenosine Triphosphate 
AUC Area Under the Curve 
Bcl-2 B-cell like lymphoma-2 
Bcl-xL B-cell lymphoma-extra Large 
bp Base pairs 
BPTI Bovine Pancreatic Trypsin Inhibitor 
C Cytosine 
CD Circular Dichroism 
CD20 B-Lymphocyte antigen CD20 
CDK Cyclin-Dependent-Kinase 
cDNA Complementary Deoxyribonucleic Acid 
CLL Chronic Lymphocytic Leukaemia 
Cmax Maximum plasma concentration 
CREB Cyclic Adenosine Monophosphate Response Element Binding Protein 
GM-CFU Granulocyte-Macrophage Colony Forming Unit 
CML Chronic Myeloid Leukaemia 
c-myc Avian myelocytomatosis virus oncogene cellular homolog  
CR Complete Response 
Da Dalton 
ΔCt Increment in threshold cycle 
ΔTm Increment in melting temperature 
DHFR Dihydrofolate Reductase 
DLT Dose Limited Toxicity  
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic Acid 
dNTP Deoxyribose Nucleoside Triphosphate 
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Receptor 
EGR-1 Early Growth Response-1 
Elk-1 E twenty six-like transcription factor-1 
ERK Extracellular-signal-Regulated Kinase 
FAM 6-Carboxyfluorescin 
FGF Fibroblast Growth Factor 
FRET Fluorescence Resonance Energy Transfer 
G Guanine 
GAPDH Glyceraldehyde 3-Phosphate Dehydrogenase 
G-CSF Granulocyte-Colony Stimulating Factor 
GI50 Half maximal proliferation inhibitory concentration 
GPU Graphics Processing Unit 
HER-2 Human Epidermal Growth factor-2 
HIV Human Immunodeficiency Virus 
HPLC High Performance Liquid Chromatography 
HRP Horseradish Peroxidase 
6 
 
HRAS Harvey Rat Sarcoma Viral Oncogene Homolog 
I Inosine 
IC50 Half maximal inhibitory concentration 
ICL Interstrand Cross-Link 
IgG1 Immunoglobulin G1 
IKK IκB Kinase complex 
IL Interleukin 
JAK Janus Kinase 
JNK C-Jun N-terminal Kinase 
kDa Kilo Dalton 
KRAS Kirsten Rat Sarcoma Viral Oncogene Homolog 
LC Liquid Chromatography 
LC50 Half maximal lethal concentration 
LPS Bacterial Lipopolysaccharide 
MALDI-TOF Matrix-Associated Laser Desorption/Ionisation Time-Of-Flight 
MAPK Mitogen-Activated Protein Kinase 
MD Molecular Dynamics 
mdeg Millidegrees 
MED Minimum-Effective Dose 
min Minute 
MM Molecular Modeling 
mRNA Messenger Ribonucleic Acid 
MS Mass Spectrometry 
MTD Maximum-Tolerated Dose 
mTOR Mammalian Target Of Rapamycin 
MTT 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazol 
m/z Mass to charge ratio 
NCI National Cancer Institute 
NEMO NF-κB Essential Modulator 
NF-B Nuclear Factor κappa B 
NF-Y Nuclear Transcription Factor Y 
NHL Non-Hodgkin’s Lymphoma 
NIK NF-κB Inducing Kinase 
NMR Nuclear Magnetic Resonance 
NNMT Nicotinamide N-Methyltransferase 
NSCLC Non-Small Cell Lung Cancer 
p-values Probability values 
p53 Tumour protein 53 
PBD Pyrrolobenzodiazepine 
PCR Polymerase Chain Reaction 
PD Pharmacodynamic 
PDGF Platelet-Derived Growth Factor 
PI3K Phosphatidylinositol-3-OH Kinase 
PKA Protein Kinase-A 
pSTAT1 Phosphorylated STAT1 
pSTAT3 Phosphorylated STAT3 
PR Partial Response 
PTEN Phosphatase and Tensin Homolog 
Pu Purine 
Py Pyrimidine 
qPCR Quantitative Polymerase Chain Reaction 
(R) Right-handed (rectus) stereochemistry 
7 
 
Rb Retinoblastoma protein 
RNA Ribonucleic Acid 
ROS Reactive Oxygen Species 
RP Reverse Phase 
RT Retention Time 
(S) Left-handed (sinister) stereochemistry 
SAR Structure Activity Relationships 
SD Stable Disease 
SD Standard Deviation 
SDS-PAGE Sodium Dodecyl Sulfate- Polyacrylamide Gel Electrophoresis 
SH-2 Src Homology-2 
SOCS Suppressors Of Cytokine Signalling 




TF Transcription Factor 
TGI Tumour Growth Inhibition 
Tm Melting temperature 
TNF-α Tumour Necrosis Factor alpha 
tRNA Transfer Ribonucleic Acid 
tSTAT1 Total STAT1 




VEGF Vascular Epidermal Growth Factor 
VEGFR Vascular Epidermal Growth Factor Receptor 







The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are sequence-selective DNA minor-
groove interacting agents. They have a chiral centre at their C11a(S)-position which 
provides an appropriate three-dimensional shape for them to fit securely within the DNA 
minor-groove. They also possess a “soft” electrophilic imine moiety at their N10-C11 
position which can form an aminal bond between their C11-position and the C2-NH2 
group of a guanine base only when the molecule is secure within the minor groove. The 
PBD dimer SJG-136 has currently reached Phase II clinical trials in ovarian cancer and 
leukaemia in the UK and the USA, respectively. More recently, PBD dimer analogues are 
being attached to tumour-targeting antibodies to create Antibody-Drug Conjugates 
(ADCs), some which are now in early clinical trials with many others in pre-clinical 
development. 
 
Transcription factors (TFs) are sequence-specific DNA-binding proteins that bind to 
consensus DNA sequences, thereby controlling transcription. TFs regulate processes such 
as cell differentiation, proliferation and apoptosis. The interaction of a small-molecule 
with the consensus DNA sequences of TFs can prevent a TF from recognising its cognate 
sequence, thereby inhibiting the expression of genes critical for the survival and 
proliferation of cancer cells. The cognate sequences of a number of oncogenic TFs are 
unusually rich in GC sequences and provide ideal alkylation substrates (both cross-link 
and mono-alkylation modes) for both PBD dimers (e.g., SJG-136) and monomers (e.g., 
GWL-78 and KMR-28-39). There is growing evidence that PBDs exert their 
pharmacological effect through TF inhibition in addition to the arrest of the replication 
fork, DNA strand breakage, and inhibition of enzymes including endonucleases and RNA 
polymerases. For this reason, there is now interest in using PBDs as the basis for a small-
molecule strategy to target specific DNA sequences for TF inhibition as a novel 
anticancer therapy.  
 
This project initially involved the application of a reversed-phase HPLC/MS method as 
a tool to evaluate the interaction of DNA-binding PBD molecules with oligonucleotides 
of varying lengths and sequences. Using custom oligonucleotides containing the cognate 
sequences of NF-B, EGR-1, AP-1 and STAT3 transcription factors, all of which contain 
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ideal GC-rich binding sequences for the PBD dimer SJG-136, the HPLC/MS method was 
used to provide information on both kinetic and thermodynamic adduct formation. 
Interestingly, a significant difference in the rate and extent of adduct formation between 
the different cognate sequences was observed which may explain the differences in 
activity of SJG-136 in the various tumour cell lines. Furthermore, SJG-136 was found to 
form different types of adducts with the TF sequences studied indicating a preference for 
guanine binding sites within the individual sequences. In particular, the fastest reaction 
was observed with the AP-1 sequence (i.e., 100% adduct formation, and only one type of 
adduct formed) which led to guanine/inosine replacement studies to establish the precise 
DNA-binding site of SJG-136. During this study, the ability of PBD monomers (e.g., 
GWL-78) and dimers (e.g., SJG-136) to bond to a terminal guanine was demonstrated for 
the first time. 
 
Further cellular experiments, the Polymerase Chain Reaction (PCR) and Western 
blotting, were carried out to support the observations made during the biophysical 
evaluation of SJG-136 with the NF-B, EGR-1, AP-1 and STAT3 sequences. In these 
studies, SJG-136 was shown to significantly down-regulate a number of AP-1- and 
STAT3-dependent genes in the human colon carcinoma cell line HT-29 and the human 
breast cancer cell line MDA-MB-231. 
 
Overall, the findings in this project have added significantly to the knowledge of the 
mechanism of action of SJG-136 and related PBD compounds, and could be important 
for the correct interpretation of the results of future pre-clinical and clinical studies of 
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1.1.1 Cancer epidemiology 
 
Cancer is a disease of chaos characterised by a breakdown of the existing biological order 
within the body1. Cancer is an immense worldwide health burden as it was the leading 
cause of death worldwide in 20082. Various human cancers affect the population in every 
region of the world and at a socioeconomic level. In 2012, 14.1 million new cancer cases 
were diagnosed and 8.2 million cancer deaths were reported worldwide (around 13% of 
all deaths)2. Despite the overall decline of cancer death rates (20% from their peak in 
1991), the mortality rate due to cancer is estimated to rise to over 13.1 million by 20302-
3. 
 
Incidence and mortality rates of various cancers vary depending on the gender in addition 
to the country2-4. For example, lung cancer is the leading cause of cancer deaths in men 
worldwide (with about 1.4 million deaths in 2008) followed by liver and stomach cancers. 
Lung cancer is also the most frequently diagnosed cancer in most parts of Eastern Europe 
and Asia followed by prostate and colorectal cancers (Figure 1.1). Among women, breast 
cancer is the leading cause of death followed by lung cancer. Breast cancer is also the 
most commonly diagnosed cancer in most countries (e.g., Australia, Europe, America and 








Figure 1.1: Estimated incidence and mortality rates in various cancers in men and women 2012. 
(Accessed on http//globocan.iarc.fr). 
 
1.1.2 Causes of cancer 
 
Cancer is caused by spontaneous mutations in genes. Therefore, it can also be referred to 
as a genetic disease. Alterations in the genomic sequences result in the ability of cancer 
cells to acquire highly abnormal phenotypes which disobey construction and maintenance 
rules of normal and intact tissues1. The vast majority of human cancers, estimated 90%, 
are associated with population exposure to environmental risk factors including tobacco-
specific carcinogens (e.g., polynuclear aromatic hydrocarbons)5, dietary lifestyle6, 
chemical agents (e.g., asbestos7, vinyl chloride8 or aromatic amines9), bacteria10 and 
viruses11. Moreover, hormones such as oestrogen and testosterone were reported to be 
implicated in carcinogenesis of hormone-associated cancers, including breast, 
endometrium, ovary and prostate by promoting cell proliferation12. Furthermore, aberrant 
oncogene activity provokes increased production of encoded proteins, such as cell surface 
receptors (e.g., EGFR, VEGFR) that transmit extracellular signals into the inside of the 
cell as well as intracellular proteins participating down-stream in cell growth and division 
signalling pathways (i.e., HRAS, KRAS or cyclin D1), thereby driving tumour cell 
division and proliferation13. Proteins encoded by oncogenes are usually transcription 
factors (e.g., AP-1), chromatin remodelers, growth factors (e.g., PDGF), growth factor 
receptors (e.g., EGFR, VEGFR), signal transducers (e.g., AKT) or apoptosis regulators 
(e.g., Bcl-2, Bcl-xL)14.  
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1.1.3 Cancer biology 
 
The evolution of normal cells into neoplastic phenotypes is a complex multi-step process 
that normally proceeds over a period of decades. During this time, the tumour cells 
acquire a succession of various biological capabilities that are required for cancer cells to 
survive, proliferate and disseminate, and subsequently become a life-threatening disease. 
Hanahan and Weinberg proposed six key behaviours of cancer cells that rationalise the 






Figure 1.2: The six hallmarks of cancer. Taken from D. Hanahan and R.A. Weinberg; Hallmarks 
of cancer: the next generation; Cell. 2011 Mar 4;144(5):646-74.  
  
In tumour cells, dysregulation of the mitogenic signalling by a number of various 
mechanisms enables the cancer cells to defy control, hence they progress through the cell 
cycle and increase in cell size15. In addition, mutations in genes encoding tumour 
suppressors (e.g., Rb, p53) are frequently detected in various cancers and are considered 




Aberrant expression and regulation of pro- and anti-apoptotic proteins (e.g., the Bcl-2 
family16), which are fundamental for the control of apoptosis, promotes tumourigenesis. 
For instance, remarkably elevated levels of Bcl-2 are frequently observed in diffuse large 
B-cell lymphoma17, acute myelogenous leukaemia18, glioblastoma19 and lung cancer20. 
The tumour suppressor p53 may also influence the regulation of apoptosis by interacting 
with pro- and anti-apoptotic proteins in response to irreparable DNA damage or 
chromosomal abnormalities21. Consequently, loss of p53 tumour suppressor function 
results in the disruption of the programmed cell death.  
 
Moreover, tumour cells are characterised by chronically activated angiogenesis through 
disruption of the pro- and anti-angiogenic signals, commonly via the overexpression of 
VEGF22. The angiogenic switch enables them to continually form and spread new blood 
vessels that support the expansion of the neoplastic growth23.  
 
Metastasis is defined as the spread of a tumour cell from the primary neoplasm to new 
distinct anatomical sites through the blood and lymphatic system1. Despite significant 
progress in cancer diagnosis, surgical, local and systemic therapies, metastasis is the most 
threatening aspect of cancer due to its resistance to conventional treatment. 90% of all 
cancer deaths are caused by metastasis and this highlights its relevance.  
 
1.1.4 Treatment of cancer 
 
The conventional therapies for the treatment of human cancers are aggressive strategies 
as they have only one main goal, to kill rapidly dividing cells. The traditional eradication 
of malignancies consists of surgery, chemotherapy and radiotherapy. Applied since 1940, 
the 'old-school' therapeutic forms proved to be highly effective in prolonging the survival 
of cancer patients and eradicating a variety of tumours with curative outcomes. Despite 
significant improvements in understanding the insights of disease pathogenesis and 
remarkable progress in the discovery of novel targeted therapeutic options, the 
conventional methods remain, to date, the mainstay in the treatment of various 






Before the era of chemotherapy in 1940s, surgery was the only available option for the 
treatment of cancer. The principle of surgery is resection of the primary tumour, which 
also helps to reduce the risk of metastatic relapse. Of utmost importance is the fact that 
surgical treatment is not able to eradicate disseminated and metastatic tumour cells. With 
this consideration in mind, development of cytotoxic drugs became inevitable and 
emerged onwards with the ultimate goal to eradicate primary tumours as well as 




Chemotherapy applies highly effective and cytotoxic compounds for the treatment of 
human malignancies, including nitrogen mustard analogues, antimetabolites, alkylating 
agents, mitosis inhibitors and topoisomerase inhibitors. While having distinct 
mechanisms of action, the biological outcome is similar. Conventional chemotherapeutic 
drugs induce DNA damage that tumour cells cannot survive, therefore culminating in 
apoptosis. The serious side effects, such as peripheral neuropathy, kidney, liver and 
cardiac toxicity in addition to myelosuppression become apparent as these agents destroy 
rapidly dividing cells without distinguishing between normal healthy cells and malignant 
cells24. 
 
1.1.4.2.1 Antimetabolites  
 
Antimetabolites (Figure 1.3) are chemical analogues of essential metabolites that 
interfere in various ways with the normal functioning of specific metabolites or enzymes 
produced by normal and cancerous cells. Small changes in crucial metabolites that are 







Figure 1.3: Chemical structures of the antimetabolites methotrexate, 6-mercaptopurine and 
fludarabine.  
 
Antifolate drugs selectively inhibit the synthesis of thymidylate and purines by interfering 
with the dihydrofolate reductase (DHFR)25. The most striking example is methotrexate 
(Figure 1.3) which is used as single agent for the treatment of breast, ovarian, bladder 
and head and neck cancers24.  
 
Furthermore, purine analogues, such as 6-mercaptopurine and fludarabine (Figure 1.3) 
interfere with nucleoside biosynthesis, consequently creating irreparable DNA residues. 
Purine analogues are potential drugs in the treatment of leukaemia and Non-Hodgkin’s 
lymphoma1.  
 
1.1.4.2.2 Mitosis inhibitors 
 
Inhibition of the cell cycle can be achieved by interfering with the mitosis process. 
Disruption of the microtubule assembly (critical for chromosomal transport within the 
cell) results in an interruption to cell division and proliferation.  
 
Vincristine and vinblastine are natural products derived from Vinca rosea (Figure 1.4)26. 
They intervene in the assembly of microtubules through interaction with the microtubule 
organising centres. Vinca-alkaloids are used in the clinic for the treatment of lymphomas, 






Figure 1.4: Chemical structures of the mitosis inhibitors vincristine, vinblastine and paclitaxel.  
 
In contrast, paclitaxel (Figure 1.4), a natural product of Taxus brevifolia interrupts 
mitosis by blocking the breakdown of microtubules at the end of the cell division process. 
It possesses a potent therapeutic activity on a variety of commonly occurring 




Radiation therapy became an important clinical tool for the treatment of cancer after 
1960. Direct exposure to electromagnetic radiation leads to burn damage of normal and 
malignant tissue thereby controlling local and regional tumours. Furthermore, 
radiotherapy is a valuable option for reducing post-surgical relapse. Alternatively, 
radioactive compounds can be administered intravenously as part of a pharmaceutical 
drug or coupled to a monoclonal antibody.  
 
1.1.4.4 The targeted treatment of cancer 
 
Significant progress in genomics, understanding the biology of malignancies and 
improved technology, has recently led anti-cancer drug development in a completely new 
direction. Targeted therapies are rationally designed to inhibit the activity of specific 
molecular targets within cancer cells, which are usually proteins whose aberrant function 
contributes to the formation and maintenance of tumours. Specific examples of these 
targets are growth factors, signalling proteins, cell-cycle proteins, regulators of apoptosis 
and molecules that promote angiogenesis29.  
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For instance, anti-estrogenes such as tamoxifen, anastrozole and exemestane are used for 
the treatment of breast cancer patients30. 
 
The design of small-molecules aimed to selectively inhibit molecular targets that 
fundamentally contribute to carcinogenesis, tumour maintenance and metastasis. The 
most popular small-molecule inhibitors are imatinib mesylate (Gleevec®) (Figure 1.5) 
for the treatment of chronic myeloid leukaemia (CML), the epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitor gefitinib (Iressa®) (Figure 1.5), successfully 
used in clinics for the treatment of non-small cell lung carcinoma (NSCLC) and the 
vascular epidermal growth receptor (VEGFR) kinase inhibitor sorafenib (Nexavar®) 





Figure 1.5: Chemical structures of the small-molecules imatinib, gefitinib and sorafenib.  
 
Furthermore, monoclonal antibodies have become significant and indispensable tools for 
the treatment of human malignancies32. The introduction of rituximab for therapeutic use 
has revolutionised antibody design and development.  
 
Rituximab (Mabtera®, Rituxan®), a chimeric monoclonal antibody, binds with high 
affinity to the transmembrane protein CD20 that is present on the surface of almost all 
(90%) malignant B cells of Non-Hodgkin’s lymphoma (NHL)33. 
 
Trastuzumab (Herceptin®, Tykerb®), a humanised IgG1 monoclonal antibody, 
selectively interacts with the extracellular domain of the human epidermal growth factor 
receptor 2 (HER-2)34. HER-2 possesses a central position in tumorigenesis as it governs 
cell proliferation, survival and differentiation through interconnected signal transduction 
implying the activation of the PI3K-AKT and the MAPK signalling cascades35.  
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Throughout an organism’s life, individual biological processes, such as cell development, 
differentiation and cell growth are governed by highly structured and coordinated 
regulatory networks on the transcriptional level36. Transcription factors (TFs) are 
sequence-specific DNA-binding proteins which are induced in response to particular 
external and internal stimuli arising from environmental needs of cells, controlling the 
expression of specific genes. TFs exhibit a pivotal role in regulating either positively or 
negatively gene transcription and deciding whether the primary gene transcript will result 
in the synthesis of the corresponding protein36b. Some TFs are constitutively and 
ubiquitously expressed over the lifespan of an organism. However, the expression of a 
number of TFs varies dramatically between characteristic tissues and corresponds with 
their regulatory requirements36a. Advances in human genome sequencing revealed the 
presence of 2,000-3,000 proteins that are presumed to contain specific DNA-binding 
domains.  
 
1.2.2 Role of transcription factors in cancer 
 
Given the pivotal role of TFs in a wide range of biological cellular processes, it has 
become increasingly clear that transcriptional misregulation is highly likely to be 
associated with human diseases37. Incorrect regulation and aberrant activity of regulatory 
TFs due to mutations are strongly linked with disorders, including inflammation, viral 
infections, autoimmune diseases and human malignancies. Uncontrolled TF activation 
continuously drives cell division, proliferation and survival through enhanced expression 
of growth stimulating gene products, thereby crucially contributing to tumour 
development and progression. Accordingly, TFs represent a valuable target for the design 
and the development of anti-tumour strategies which include inhibition of their functional 
domains or their post-translational modification with the goal to terminate their 





1.2.3 Transcription factors used in this study 
 
1.2.3.1 Nuclear Factor-κB (NF-κB) 
 
The NF-κB proteins belong to a family of structurally related, rapidly acting TFs that play 
a fundamental role in regulating a diverse range of physiological processes, including the 
innate-adaptive immune responses, inflammation, cell differentiation and proliferation as 
well as apoptosis38.  
 
The NF-κB TFs exist as dimers composed of two of five possible subunits. These subunits 
may be divided into two subclasses; the Rel proteins RelA (p65), RelB and c-Rel (which 
contain the transcription activation domain, TAD), and the p50/105 and p52/100 
members (which lack the TAD required for transcriptional activity)39. In order to exhibit 
transcriptional ability members of this second class require association with Rel proteins. 
The NF-κB proteins bind as homodimers or heterodimers to 9-10 base pair DNA sites 
(κB sites) in the promoters or enhancer regions of target genes recognising 
GGGRNYYYCC sequences (R = purine; Y = pyrimidine; N = any base), hence 






Figure 1.6: Molecular model of the NF-κB p50-p65 heterodimer (p50 in yellow and p65 in red) 
interacting with its DNA consensus sequence 5'-GGGGACTTTCC-3' (grey) (PDB ID: 1VKX)41. 
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The NF-κB TFs are not synthesised de novo. They are present in the cytosol in a latent 
and inactive state bound to inhibitory IκB proteins (e.g., IκBα, IκBβ, IκBγ or IκBε)42. 
They are activated via two distinct signalling pathways, namely the canonical (classical) 






Figure 1.7: Canonical and non-canonical pathway of NF-κB activation. Adapted from E. 
Viennois, F. Chen, D. Merlin; NF-κB pathway in colitis-associated cancers; Transl Gastrointest 
Cancer 2012;2(1); DOI:10.3978/j.issn.2224-4778.2012.11.01. 
 
Extracellular stimuli, such as viruses, bacterial lipopolysaccharide (LPS), oxidative 
stress, chemical and pharmacological agents, pro-inflammatory cytokines, tumour 
necrosis factor α (TNF-α) and UV radiation induce activation of the IκB kinase complex 
(IKK) comprising of IKKα, IKKβ and IKKγ (NEMO) members44 which in turn 
phosphorylate the inhibitory IκB proteins leading to their ubiquitination and proteasomal 
degradation. As a consequence, the unmasked NF-κB proteins are able to translocate to 
the nucleus where they influence the expression of specific target genes either alone or in 




Furthermore, via the canonical pathway, NF-κB encodes genes for IκB de novo synthesis. 
That creates a negative feedback loop. Newly synthesised IκB proteins migrate to the 
nucleus, remove associated NF-κB from the DNA and export it back to the cytoplasm in 
order to restore the original inactive state. 
 
The canonical pathway is responsible for the control of the innate immunity and 
inflammation43, whereas the non-canonical pathway occurs mainly during the 
development, organisation and function of secondary lymphoid organs and in B cell 
differentiation and survival43. 
 
Recent studies have provided strong evidence for aberrant activation of the NF-κB 
signalling cascade in both solid tumours (e.g., breast, cervical, prostate, renal, lung, colon, 
liver and pancreatic tumours) and haematological malignancies (i.e., leukaemias and 
lymphomas)45. Genetic alterations, including gene mutations or amplifications in key 
components of the NF-κB signalling pathway (e.g., RelA, RelB, c-Rel, IKKs and IκBs), 
over-expression of target genes and their products (i.e., anti-apoptotic members of the 
Bcl-2 family, survivin, cyclin D1) and chromosomal translocations are presumed to 
contribute to cancer cell proliferation, growth, angiogenesis, metastasis and resistance to 
apoptosis46.  
 
When viewed from this perspective, the inhibition of major components of the NF-κB 
pathway is a considerable and powerful strategy for the treatment of neoplastic diseases.  
 
1.2.3.2 Early Growth Response-1 (EGR-1) 
 
EGR-1 (Figure 1.8) belongs to the EGR family of TFs which are implicated in a wide 
range of normal cellular processes, such as cell growth, proliferation, differentiation, 
survival and apoptosis47. The EGR family is composed of four members, EGR-1, EGR-
2, EGR-3 and EGR-4 of which all are characterised by a highly conserved DNA-binding 
domain containing three zinc-finger motifs (Figure 1.8)48. These fingers recognise 
consensus DNA target sequences of 5'-GCG GGG GCG-3' with each finger spanning 
three bases (Figure 1.8)49. EGR-1 is rapidly and transiently expressed in response to a 
variety of stimuli, including growth factors, cytokines, environmental and mechanical 
stress50. Bound to promoter and enhancer regions in proximity to specific target genes, 
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Figure 1.8: The EGR TF family and its cognate response element. (A) The four EGR-family 
members containing the three zinc-finger DNA-binding domains (black). R1 represents the 
repression domain. (B) An EGR-family member is binding to the consensus EGR sequence 
located in close proximity to the target gene. Each zinc finger (black circle) binds to a three-
nucleotide segment. Adapted from K. J. O'Donovan, W. G. Tourtellotte, J. Millbrandt, J. M. 
Baraban; Trends in Neurosiences; Vol 22, Issue 4, 1 April 1999, Pages 167–173; 
doi:10.1016/S0166-2236(98)01343-5. 
 
In the context of human malignancies, EGR-1 is considered as a tumour suppressor by 
promoting the expression of the major tumour suppressor genes p53, Rb and PTEN and 
the pro-apoptotic gene c-Jun51. Decreased levels of EGR-1 expression were observed in 
various human tumour types (e.g., glioblastomas, lymphomas, non-small cell lung 
tumours, breast and colon cancers), therefore strongly linked with disease development 
and progression52.  
 
However, sufficient evidence has emerged of a role for EGR-1 in proto-oncogene 
function, contributing to malignancy. EGR-1 over-activity has been shown to underpin 
the pathophysiology of various human tumours, including prostate, gastric cancers and 
diffuse large B-cell lymphoma51. Hence, inhibition of EGR-1 may be a possible anti-
tumour target for human neoplastic diseases owing aberrant EGR-1 expression.   
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1.2.3.3 Activating Protein-1 (AP-1) 
 
The activating protein-1 (AP-1) proteins are a family of dimeric regulatory TFs, 
comprising four subfamilies; the Jun (c-Jun, JunB and JunD), the Fos (c-Fos, FosB, Fra1 
and Fra2), the activating TFs (ATF) proteins (ATF2, ATF3/LRF1 and B-ATF) and lastly, 
the Maf subfamily members (c-Maf, MafA, MafB, MafG/F/K and Nrl)53. The proteins of 
the AP-1 family possess two common peculiarities; the leucine-zipper (bZIP) domains 
which are essential for dimerisation and the basic sequence which is required for the 
DNA-binding to AP-1 consensus motifs in the promoter and enhancer segments of 
numerous mammalian genes54.  
 
Jun and ATF proteins can homodimerise and heterodimerise, whereas members of the 
Fos subfamily can only exhibit transcriptional activity by forming heterodimers with the 
Jun proteins55. Jun-Jun and Jun-Fos dimers associate with the highest affinity to the 
response element 5'-TGA (C/G) TCA-3' (Figure 1.9)56. Jun-ATF heterodimers 
demonstrated a preference for the cognate 5'-TGA CG TCA-3' sequence57. However, due 
to the immense number of AP-1 proteins and consequently the broad combinatorial 
possibilities, they may bind to many other 'AP-1-like' sequences, depending on the AP-1 
dimer composition. This huge combinatorial diversity also envisions the wide spectrum 
of genes which are regulated by AP-1 TFs58. 
 
 
Figure 1.9: The structure of the heterodimer Fos-Jun AP-1 complex bound to its consensus target 
sequence on DNA. Taken from http://www.web-books.com/MoBio/Free/Ch4F5.htm.  
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The AP-1 proteins are implicated in the regulation of diverse biological processes, 
including inflammation, cell proliferation, differentiation and survival, apoptosis, cellular 
migration and wound healing (Figure 1.10)58-59. The activation of AP-1 members is 
initiated by growth factors, hormones, cytokines, stress, reactive oxygen species as well 
UV radiation and subsequently transmitted down-stream via the mitogen-activated 





Figure 1.10: Activation of the TF AP-1 by various stimuli. Stimulation of different mitogen-
activated protein kinase (MAPK) signalling pathways activates AP-1 resulting in the expression 
of a wide variety of genes participating in essential physiological processes. Adapted from S.P.M. 
Reddy, B.T. Mossman; American Journal of Physiology - Lung Cellular and Molecular 
Physiology Published 1 December 2002 Vol. 283 no. 6, L1161-L1178 
DOI:10.1152/ajplung.00140.2002. 
 
Elevated protein expression levels of c-Jun, JunB and Fos members, observed in a 
subgroup of human neoplasms, such as colorectal carcinomas and Hodgkin’s lymphomas 
are strongly linked with tumour development and promotion54, 60. The importance of AP-
1 TFs in human malignancies leads to the deduction that AP-1 may be a promising 




1.2.3.4 Signal Transducer and Activator of Transcription 3 (STAT3) 
 
The signal transducer and activator of transcription 3 (STAT3) (Figure 1.11) belongs to 
the STAT family of cytoplasmatic proteins. Seven mammalian STAT proteins have been 
identified (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6) which all 
relay extracellular signals to the nucleus, thereby regulating the transcription of specific 




Figure 1.11: Molecular model of STAT3 homodimer (blue) interacting with the DNA sequence 
5'-TGCATTTCCCGTAAATCT-3' (grey) (PDB ID: 1BG1)62. 
 
The STAT3 protein contains several substantial domains that are critical for its 
transcriptional activity. The DNA-binding domain is essential for the recognition of 
STAT3 consensus binding sequences on DNA. The SH-2 (Src homology-2) domain is 
required for the recognition of cell-surface receptor binding sites and lastly the C-terminal 
transactivation domain, necessary for transcription induction63.    
 
STAT3 is present in a latent and inactive state in the cytoplasm until it receives 
extracellular signals for activation. Growth factors (e.g., EGF, PDGF, FGF or G-CSF) 
and cytokines (i.e., IL-6, IL-10, IL-11 or oncostatin M) bind to their cognate cell-surface 
receptors and induce autophosphorylation and the activation of the Janus kinase (JAK) 
family (Figure 1.12). Following this, monomeric STAT3 molecules dock to the 
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phosphorylated tyrosine kinase complex through their SH-2 domain resulting in 
phosphorylation of STAT3 proteins in their C-terminal domain. This activation step 
allows STAT3 monomers to dimerise and translocate to the nucleus, where they bind to 
specific DNA response elements in the promoter regions of responsive target genes 
(Figure 1.12)61, 63. Alternatively, the mTOR (mammalian target of rapamycin) and 





Figure 1.12: The JAK-STAT signal transduction pathway. Ligands activate JAKs that 
subsequently phosphorylates inactive STAT monomers. The STAT molecules dimerise and 
migrate to the nucleus, where they bind to specific response elements and induce gene 
transcription. Taken from M. Benekli, M. R. Baer, H. Baumann and M. Wetzler; Signal transducer 
and activator of transcription proteins in leukaemias; Volume: 101 (8) p 2940 – 2954; DOI: 
http://dx.doi.org/10.1182/blood-2002-04-1204. 
 
Under normal conditions, the activity of STAT3 is endogenously controlled by specific 
regulatory proteins61a, 61b, 63b. For example, proteins of the SOCS (suppressors of cytokine 
signalling) family prevent STAT3 activation through directly binding to the 
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phosphorylated JAK. However, an increasing body of evidence suggests that elevated 
levels of STAT3 promote tumour cell proliferation, differentiation, angiogenesis and 
metastasis and protect neoplastic cells from apoptosis by regulating responsible genes, 
such as Bcl-2, Bcl-xL, Fos, cyclin D, c-myc, VEGF, survivin and fascin61b, 63a, 65. Increased 
STAT3 expression or activity is frequently observed in a wide range of human neoplasms, 
including leukaemias, lymphomas, multiple myelomas, breast, prostate, lung and ovarian 
cancers61b, 65a, 66. Interestingly, to date no naturally occurring mutations that lead to 
constitutive STAT3 activation have been detected indicating aberrant regulation or 
activation of key up-stream elements61, 63b. With this knowledge in hand, inhibition of the 
JAK/STAT3 signalling cascade may offer a novel strategy for the treatment of human 
malignancies.  
 
1.3 DNA as a target for anti-tumour therapy 
 
DNA is a valuable and attractive target for the development of anti-tumour therapies. Due 
to its inevitable presence in all living organisms, damage or disruption in DNA function 
results in destruction and/or death of cellular organisms.  
 
DNA is composed of two anti-parallel arranged sugar-phosphate strands to which four 
different bases adenine (A), guanine (G), cytosine (C) and thymine (T) are linked, 
forming a double-stranded helix (Figure 1.14a). The two opposite running strands are 
stabilised through hydrogen bonds and base-stacking between the aromatic 
nucleobases67. Adenine pairs with thymine by forming two hydrogen bonds and guanine 
associates with cytosine by forming three hydrogen bonds (Figure 1.14b). The right-
handed B-form is the most frequently observed conformation of DNA in which the base 









Figure 1.14: The structure of DNA. (a) B-form of DNA; (b) Base pairing between two DNA 
strands. T = thymine, A = adenine, C = cytosine, G = guanine. Taken from Molecular Cell 
Biology, Sixth Edition © W.H. Freeman and Company.  
 
The adoption of the double helical conformation results in the formation of two grooves 
within the DNA helix, the major and the minor groove (Figure 1.14a). The major groove 
is wide and deep (22 Å) compared to the minor groove which is narrower and shallower 
(12 Å)68. This unique structure of the DNA double helix allows the appearance of 
additional hydrogen-bond donating and accepting groups located within the major and 
minor groove69. The major groove offers hydrogen bond donor groups at the C6-amino 
of adenine or the C4-amino of cytosine and hydrogen bond acceptor groups at the 
adenine-N7, thymine-O4, guanine-N7 and O6. The minor groove has hydrogen acceptor 
groups at adenine-N3, thymine-O2, guanine-N3 and cytosine-O2 and a hydrogen donor 
group at the 2-amino group of guanine.  
 
For example, anti-tumour therapies can target DNA at the specific bases in order to 
interrupt crucial replication mechanisms or intercalate between the DNA strands and 
make them inoperable70. Moreover, inhibition of DNA-associated processes has gained 
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increased importance in anti-cancer drug development. For example, the transcription of 
specific genes which play a crucial role in the development and progression of human 
malignancies can be inhibited by small-molecule ligands71 which block cognate 
sequences in double-stranded DNA, thereby preventing TFs to bind to their DNA target 
sequences29, 31.  
 
1.3.1 DNA-interactive agents 
 
The vast majority of DNA-interactive agents directly target the DNA, such as alkylating 
agents and topoisomerase inhibitors, or interfere with the DNA synthesis 
(antimetabolites) (see also section 1.1.4.2.1)69. 
 
1.3.1.1 Topoisomerase inhibitors 
 
Topoisomerases (topoisomerase I and topoisomerase II) are reversible nucleases that 
cleave super coiled DNA strands in order to ensure availability of DNA bases for DNA 
synthesis. Inhibition of topoisomerases through cytostatic drugs leads to the formation of 
irreparable DNA strand breaks forcing the cell to induce apoptosis. The activity of 
topoisomerases is elevated in many human tumours, therefore making it an attractive 
target for topoisomerase inhibitors. 
 
Mitoxantrone (Figure 1.15) represents a powerful topoisomerase inhibitor in the 





Figure 1.15: Chemical structures of the topoisomerase inhibitors mitoxantrone and doxorubicin.  
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The naturally occurring anthracycline doxorubicin (Figure 1.15) inhibits topoisomerase 
and is used in a wide range of human malignancies. In addition to the topoisomerase 
inhibiting potential, doxorubicin also has the ability to intercalate in the DNA, thereby 
blocking the DNA replication and to transform to free radicals resulting in double-strand 




Intercalating agents are polyaromatic planar molecules. Due to their flat shape they insert 
themselves between the DNA base pairs, thereby inhibiting essential processes, including 
transcription, DNA replication and repair73-74. 
 
The anthracyclines doxorubicin and daunorubicin (Figure 1.16) represent the best 
studied and widely used family of intercalating agents in the treatment of haematological 
malignancies, such as leukaemia, Hodgkin’s diseases and lymphomas as well as solid 
tumours, including breast, ovarian and lung cancers73. These natural products, isolated 
from Streptomyces species exert their anti-tumour activity through a wide range of 
mechanisms, including DNA intercalation, inhibition of topoisomerase and formation of 
free radicals73. They are composed of a planar anthraquinone ring system linked to an 
amino-sugar through a glycoside bond. However, their toxicity (e.g., cardiotoxicity) 









1.3.1.3 Alkylating agents 
 
Alkylating agents exhibit their anti-tumour activity through the attachment of alkyl 
groups to guanine bases in DNA leading to DNA damage which cells cannot repair and, 
therefore, induce apoptosis74, 76. These DNA modifications trigger the DNA repair 
machinery77. Moreover, alkylating agents can bind to two guanines located either on the 
same or opposite DNA strand, thereby forming cross-linked adducts. This mechanism 
prevents separation of the DNA strands during replication and transcription24, 77. 
 
1.3.1.3.1 Cross-linking agents 
 
In addition to mono-adduct formation, cross-linking agents also react through their 
electrophilic moieties with DNA bases that are present on the same or opposite DNA 
strand, thereby generating the formation of cross-linked adducts within the DNA. Tumour 
cells lack the ability to repair the DNA damage and consequently induce apoptosis78.  
 
A) Nitrogen mustard analogues 
 
The most important examples of this group are cyclophosphamide, melphalan and 
chlorambucil (Figure 1.17). These anti-tumour agents are established standard 





Figure 1.17: Chemical structures of the nitrogen mustard analogues cyclophosphamide, 





B) Cisplatin and carboplatin  
 
Cisplatin and carboplatin are also members of the group of cross-linking agents (Figure 
1.18). By forming intrastrand cross-links within the DNA they induce covalent DNA 
modifications that are not easy to repair for the tumour-repair machinery. They are used 
for the treatment of breast, ovarian and testicular cancers with 90-95% successful tumour 
eradication1. Cisplatin induces an intrastrand cross-link between the N7-N7 positions of 




Figure 1.18: Chemical structures of cisplatin and carboplatin. 
 
1.3.1.3.2 Minor groove binders 
 
The traditional major groove binders such as the nitrogen mustards have long been used 
in the treatment for human malignancies. However, they demonstrate poor sequence 
specificity due to random adduct formation throughout the entire human genome. This 
unspecific binding is responsible for their cytotoxicity as they also kill rapidly dividing 
healthy cells, particularly of the bone marrow and gut epithelium81. Furthermore, studies 
have demonstrated that the N7 guanine adducts can easily be repaired by intracellular 
enzymes, resulting in resistance to chemotherapy76. Therefore, extensive effort has been 
made in order to design anti-cancer drugs that specifically bind within the DNA minor 
groove74.  
 
Minor groove binding agents are both naturally occurring and synthetic small-molecules 
that perfectly fit within the DNA minor groove because of their size and curvature82. They 
are composed of aromatic heterocycles and various linkers83. Studies have shown that the 
crescent shape of ligands significantly influences sequence specific ligand 
accommodation within the minor groove84. The interaction with DNA is mainly based on 
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non-covalent association caused through electrostatic forces, such as hydrogen bonding 
and van der Waals interactions. The majority of the minor groove binding agents exists 
in a positively charged form in vivo85, therefore highly attracted to the electronegative 
potential of A/T sequences. The formed ligand/DNA adducts do not significantly alter 
the structure of DNA which makes them difficult to be recognised by intracellular DNA 
repair enzymes and eliminated. Moreover, agents that bind to the minor groove of DNA 
generally influence gene transcription by interfering with consensus sequences of many 
transcription factors. In biological studies, minor groove binding agents have 
demonstrated antibacterial, antiviral, antiprotozoal and anti-tumour activity85.  
 
Distamycin, Berenil and Hoechst 33258 
 
Distamycin (Figure 1.19) is a natural product extracted from Streptomyces species86. It 
has a polyamide structure consisting of five-membered planar rings. The ligand shows a 
preference for AT regions by binding to four or five successive A-T base pairs within the 
minor groove. Hydrogen bonds are formed between the ligand and the O2 atoms of 
thymine and N3 atoms of adenines which help the molecule to accommodate within the 




Figure 1.19: Chemical structures of the minor groove binding agents distamycin, berenil and 
Hoechst 33258.  
 
Berenil (Figure 1.19) is a bis-phenylamidinium minor groove binding agent composed 
of two linked phenyl rings. The ligand binds preferentially to 5'-AAT-3' motifs where the 




Another AT selective minor groove binder is Hoechst 33258 (Figure 1.19). Footprinting 
studies have shown that the benzimidazole-based ligand preferably binds to 5'-AATT-3' 




The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are sequence-selective DNA minor 
groove binding agents based on the naturally occurring anthramycin family of anti-
tumour antibiotics83, 88, the best known member of which is anthramycin itself (1, Figure 
1.20).  The skeletal structure of the PBDs contains a substituted aromatic A-ring, a 
diazepine B-ring and a pyrrolidine C-ring89, with an S-chiral centre at the C11a-position 
between the B and C rings. This provides a 3-dimensional shape perfectly crafted for the 
molecules to fit within the DNA minor groove90 (Figure 1.21). They also possess an 
electrophilic imine moiety at the N10-C11 position within their B-ring which can form a 
covalent aminal linkage between their C11-carbon and the C2-NH2 group of a guanine 







Figure 1.20: Structures of the naturally occurring anthramycin (1), the PBD C8-conjugates GWL-
78 (2) and KMR-28-39 (3), and examples of C7/C7'-linked (4) and C8/C8'-linked (e.g., DSB-120, 
5a, n = 3 and SJG-136, 6a, n = 3) PBD dimers.  
 
Since the discovery of anthramycin in 196592 a range of synthetic PBDs has been 
developed. For example, non-covalent minor groove binding components have been 
appended to the C8-position of the PBD A-ring (e.g., GWL-7889b, 2, and KMR-28-3990, 
3, Figure 1.20), and monomeric PBD units have been joined through their C7/C7' 93 (4) 
and C8/C8'-positions (e.g., 5a-d and 6a,b) to afford PBD dimers (e.g., SJG-13694, 6a, 
Figure 1.20). PBD units have also been joined through their C2/C2' and C8/C2' positions 
but the resulting dimers do not have the appropriate shape to fit into the DNA minor 




Figure 1.21: The mechanism of covalent binding of a PBD to DNA once it has located in a low 
energy position within the minor groove. 
 
The unique structure of PBD dimers allows them to form interstrand or intrastrand DNA 
cross-links in addition to mono-alkylated adducts96, thus resulting in greater DNA 
stabilisation94, 97 compared to the monomeric PBDs. Due to the additional types of DNA 
adducts possible and the greater adduct stability, the PBD dimers generally have 
significantly greater cytotoxicity, anti-tumour activity and antibacterial activity compared 
to the natural, unsubstituted PBD monomers. One such agent, SJG-136, has reached 
Phase II clinical trials in ovarian cancer and leukaemia98. In addition, related PBD dimers 





The covalent binding of both monomeric and dimeric PBDs to DNA is thought to be a 
two-step process, the first involving recognition of a favoured low-energy binding site by 
a fast, reversible non-covalent association of the molecules in the minor groove through 
interactions including hydrogen bonding, van der Waals and electrostatic interactions90. 
If these non-covalent intermolecular interactions are weak, the PBD presumably 
dissociates and re-associates at another site, with the process repeating itself until a 
suitable low-energy triplet with the C2-NH2 of the central guanine aligned for 
nucleophilic attack at the PBD C11-position is found. In the second step, the PBD forms 
a covalent bond with the guanine base, and the molecule is then locked into position. 
Whereas the initial non-covalent association is a fast reaction, the covalent attachment 
step is much slower and can take up to 24 hours to complete89b (Figure 1.21).  
 
Once covalently bonded to DNA, PBD monomers and dimers have been shown to 
mediate a number of biological effects in cells including DNA strand breakage94, 
inhibition of endonucleases100 and RNA polymerase89b, 101, and transcription factor 
inhibition. For example, some PBDs can prevent the transcription of genes crucial for cell 
survival such as NF-Y102 and NF-κB90. 
 
1.4.1 Structure Activity Relationships (SARs) 
 
A large body of Structure Activity Relationship (SAR) data has been generated based on 
both the known natural products and a large number of synthetic compounds that have 
become available. A summary of the key SAR features of the PBD monomers (Figure 







Figure 1.22: Summary of the Structure Activity Relationships (SARs) for the PBD monomers 
(A), the PBD dimers (B), and the indolinobenzodiazepine analogues (C). Modifications which 
enhance activity are shown in blue, and those which reduce activity are in red.   
 
N10-C11 imine (or equivalent) 
 
The presence of an imine, carbinolamine or carbinolamine methyl ether group at the N10-
C11 position is essential for the covalent interaction of a PBD molecule with DNA. Early 
studies by Kohn103 and Hurley104 demonstrated that the PBDs covalently bond to guanine-
containing sequences, and also established that they do not interact through an 
intercalation mechanism105 (Figure 1.21). 
 
Crucially, replacement of the N10-C11 imine with amide or secondary amine 
functionalities (Figure 1.23A, B) results in a dramatic fall in DNA-binding ability106 and 
cytotoxicity. For example, it has been demonstrated that DNA-binding affinity upon 
replacing the two N10-C11 imines of the PBD dimer SJG-136 (6a) with amide 
functionalities is lost94. Similarly, didehydroanthramycin107 (Figure 1.23C) which has 
extended N10–C11/C11a–C1/C2–C3 conjugation is biologically inactive, as the N10-
C11 imine is too stable to react with a guanine base. Although PBD dilactams (e.g., 4a) 
cannot bind covalently to DNA, they are still isohelical with the DNA minor groove due 
to their chiral C11a-position, and so can possess weak DNA-binding properties through 
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non-covalent hydrogen bonding and other interactions such as van der Waals. For 
example, a series of dilactams synthesised by Lown and co-workers108 provided a ΔTm of 
up to approximately 3 °C with calf thymus DNA, although this compares unfavourably 
with a simple PBD monomer such as anthramycin which gives a ΔTm of 13.1 °C under 
the same conditions, and PBD dimers produce significantly higher ΔTm values due to 
their length (and hence greater number of non-covalent contacts in the minor groove) and 
cross-linking ability100. Libraries of PBD dilactams synthesised by Thurston and co-
workers have shown similar ΔTm value ranges (e.g., up to approximately 2.4 °C for C2-




Figure 1.23: Structures of PBD analogues in which the electrophilic N10-C11 imine moiety has 
been replaced with an amide (i.e., dilactam, A) or a secondary amine (B), or in which the imine 
has been rendered non-electrophilic by conjugation with double bonds in the C-ring to create a 
fully aromatised system (i.e., didehydroanthramycin, C). All molecules of types A, B and C 
cannot bond covalently with DNA, and so have negligible cytotoxicity. Some examples (e.g., the 
dilactams) can still bind to DNA, albeit weakly, through non-covalent interactions because they 




It has been shown through NMR109 and X-ray crystallography110 studies that all PBDs 
exist in a single stereochemical form (S) at the C11a-position which provides a right-
handed twist that allows the molecule to follow the curvature of the minor groove within 
the right-handed B-DNA helix. Molecules with the (R)-stereochemistry at C11a are not 
isohelical with the DNA minor groove, causing them to sterically interact with the groove 
wall110-111. Examples of PBDs with (R)-stereochemistry at C11 have been synthesised 




Conflicting data exists in the literature as to the stereochemistry at the C11-position of 
the PBD/guanine adduct. Although the anthramycin crystal structure110 and a number of 
NMR studies of both PBD monomers109, 111 and PBD dimers113 have shown that the 
adduct formed is in the C11-S configuration, molecular mechanics calculations 114 and an 
NMR structure115 have suggested that in some situations, both R and S configurations are 
equally preferred. It is now thought that PBD monomers can form either R or S adducts 
at C11, and this is likely to relate to the substitution pattern of a particular PBD (e.g., C8-
substitution may be partially influential) and the sequence to which it is covalently 
bound114c.   
 
Functionalization of the A-ring 
 
The number and pattern of substituents in the A-ring of the PBD skeleton can affect the 
DNA-binding ability and cytotoxicity. The presence of electron-donating substituents, 
particularly at the C7- and C8-positions, can enhance DNA interactivity by increasing the 
electrophilicity and alkylating potential of the N10-C11 imine moiety116. Furthermore, 
extensive molecular modelling studies have shown that substituents at the C8-position 
position themselves along the floor of the minor groove which can lead to significant 
additional stabilisation of the adduct90. Thus, polyheterocyclic fragments (e.g., pyrroles, 
furans, imidazoles, thiophenes, indoles, benzofurans and biaryl units) have been added to 
this position to create PBD C8-conjugates (e.g., GWL-78, KMR-28-39, Figure 1.20). 
Similarly, two PBD units have been joined through their C8-positions to create C8/C8'-
linked PBD dimers94, 113a, 117, and this approach led to the design and synthesis of the 
C8/C8'-linked PBD dimer SJG-136118 (Figure 1.20). The C7-position has also been used 
as a potential linker point for PBD dimers93a, but molecules joined in this way have 
significantly less DNA cross-linking ability and cytotoxicity, as the two PBD units are 
not properly aligned for alkylation of guanine bases93b.  
 
The presence of a hydroxyl group at C9 renders the molecule cardiotoxic119, which is 
thought to be due to free radical production in cardiac tissue120. Other studies on PBDs 
such as anthramycin110 have shown that a C9-OH has the potential to hydrogen bond to 
bases within the minor groove of DNA, thus increasing binding affinity and sequence 
selectivity110. The presence of a larger group (e.g., a methoxy group) at C9 renders the 
PBD biologically inactive, as the steric hindrance between this substituent and functional 
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groups on the minor groove floor inhibits alkylation as can be demonstrated through 
molecular dynamics simulations (Jackson and Thurston, unpublished data).  
 
C-ring unsaturation  
 
The degree of saturation/unsaturation within the C-ring can also influence DNA-binding 
ability and cytotoxicity. In general, PBD monomers with C2-exo or C2-endo unsaturation 
(e.g., anthramycin104, tomaymycin121 and sibiromycin122) have enhanced DNA-binding 
ability relative to PBD monomers with fully saturated C-rings (e.g., neothramycin A123, 
chicamycin124 and DC-81125). This feature has been adopted in the rational design of PBD 
dimers (Figure 1.22B), where the introduction of exo-unsaturation at the C2/C2'-
positions of the PBD dimer DSB-120113a (5a, Figure 1.20) led to SJG-136 (6a, Figure 
1.20). DSB-120 has poor activity in vivo, attributed partly to its high reactivity with 
cellular thiol-containing molecules such as glutathione126. However, the introduction of 
C2-exo unsaturation as in SJG-136 led to a decrease in electrophilicity of the N10-C11 
imines and an overall increase in DNA-binding affinity and cellular cytotoxicity, thought 
to be due to a lower reactivity toward cellular nucleophiles with more of the agent 
reaching its target DNA. In addition, modeling studies have shown that C2/C2' 
unsaturation causes a flattening of the C-ring which may lead to superior van der Waals 
contacts within the minor groove94 and enhanced DNA-binding affinity114a. Interestingly, 
complete unsaturation of the C-ring significantly reduces the electrophilicity of the N10-
C11 imine by producing a fully aromatic system across N10-C11/C11a-C1/C2-C3 which 
ablates DNA-binding ability and cytotoxicity completely (e.g., didehydroanthramycin107, 
Figure 1.22C). 
 
C2-C3 substitution  
 
In a similar manner to C9-substitution, a substituent at C3 can affect the DNA-binding of 
a PBD in the minor groove. For example, methylation or butylation of the C3-hydroxyl 
substituent of neothramycin A blocks interaction in the DNA minor groove127. However, 
extended C2-substituents (e.g., the polyacrylamide side chain of anthramycin110) 
significantly enhances DNA interactivity because they locate along the minor groove and 
stabilise the adduct through van der Waals interactions and sequence-specific hydrogen 
bonds with side chain and functional groups on the minor groove floor. For example, 
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early studies on anthramycin suggested that removal of the C2-acrylamide tail can 
significantly reduce its DNA interactivity128. This feature has been used in the design of 
novel C2-substituted PBD monomers with enhanced DNA-binding and cytotoxicity106a. 
For example, some C2-substitutents such as -phenyl-CH3 moieties can lead to 
cytotoxicities in the low nanomolar range106a. Studies have also shown that replacement 
of the C1-atom itself with an oxygen provides analogues (e.g., oxazolbenzodiazepines) 
with similar activity to the parent PBDs89a, 127, 129. 
 
Many of the modifications outlined above have been incorporated into the PBD dimers 
that are now being used as chemical payloads for Antibody-Drug Conjugates (ADCs) 
(Figure 1.22B and C). For example, the ADC SGN-CD33A contains a C2-C3 endo-
unsaturated C2-aryl-substituted PBD with a C8/C8'-propylenedioxy linker99. The A-ring 
contains oxygen substituents in both the C7- and C8-positions which enhance its 
interactivity with DNA, and the C3-, C6- and C9-positions remain unsubstituted, thereby 
minimising any steric hindrance within the DNA minor groove. In addition, researchers 
at the company ImmunoGen Inc. have added a fourth D-ring to the C-ring of the PBD 
skeleton to produce indolinobenzodiazepines (Figure 1.22C)130. They have also 
introduced an aromatic ring into the centre of the C8/C8'-linker which does not affect 
DNA-binding affinity but provides an antibody attachment point (Figure 1.22C)131. 
 
1.4.2 Evolution of the PBD dimers 
 
The first PBD dimers were synthesised by Suggs and co-workers in 198893b with the two 
PBD units joined through linkers attached at the C7/C7'-positions of the aromatic A-rings 
(4a-c, Figure 1.20). Although modest DNA cross-linking activity was reported, no 
cytotoxicity data was provided. Based on a rational approach to the way in which a PBD 
dimer might best fit into the DNA minor groove, in 1992 Thurston and co-workers132 
reported the PBD dimer DSB-120 (5a, Figure 1.20) which consists of two unsubstituted 
PBD units coupled through their C8/C8'-positions via a 1,3-dioxypropyl linker. This 
molecule, which was designed to more closely follow the curvature of the DNA minor 
groove, had very high DNA-stabilising (i.e., ΔTm = > 15.1 °C) and interstrand cross-
linking (i.e., CL = > 90%) properties, and significant cellular cytotoxicity132. SAR 
studies133 demonstrated that changing the central methylene linker from 3 (5a, Figure 
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1.20) to 4, 5 or 6 methylene units (5b-d, Figure 1.20) still allowed DNA-binding but 
significant differences were observed. Increasing the linker length to n = 5 (5c, Figure 
1.20) afforded a molecule with similar cross-linking efficacy to DSB-120 (n = 3) but with 
approximately half of the DNA-stabilising ability, while the cellular cytotoxicity was 
significantly enhanced. Conversely, increasing the linker length to n = 4 or 6 afforded a 
reduction in all three parameters, and led to the conclusion that linkers with an odd 
number of methylenes are preferred for maximum activity. This was later explained 
through molecular modeling studies133, as only dimers with odd numbers of methylenes 
in their linkers allow the two PBD units to arrange themselves in the correct orientations 
for their N10-C11 imine moieties to alkylate guanine C2-NH2 groups. Although DSB-
120 had potent activity in biophysical and cellular assays, it proved to be inactive in 
human tumour xenograft studies in mouse models. This was thought to be due to the N10-
C11 imine moieties being too electrophilic due to the fully saturated state of the C-rings, 
with the molecule reacting with extra- and intra-cellular thiol-containing nucleophiles 
before it could reach its DNA target134. To reduce the electrophilicity of the N10-C11 
imine moieties and increase the chances of the molecule reaching the target DNA in the 
nucleus of cells, methylene substituents were added at the C2/C2'-positions to afford SJG-
136 (6a, Figure 1.20)90, 96, 135. This analogue was equally potent in biophysical and 
cellular assays but was also active in in vivo assays. This was attributed to the flattening 
of the C-rings due to the presence of the C2/C2'-substituents which modifies the 
electrophilicity of the N10-C11 imines through an, as yet, unidentified mechanism, but 
which also provides a better fit of the molecule in the minor groove.  
 
Due to the presence of two electrophilic imine moieties, SJG-136 (6a, Figure 1.20) can 
form interstrand and intrastrand cross-links in addition to mono-alkylated adducts94 
(Figure 1.24). The type of adducts that form appears to depend on the precise DNA 
sequence and the distance between reacting guanines96, 136. Studies have shown that SJG-
136 (6a, Figure 1.20) has a preference for forming Pu-GATC-Py interstrand cross-linked 








Figure 1.24: Diagram of the various possible adduct types that can be formed between SJG-136 
(6a, Figure 1.20) and DNA (i.e., interstrand and intrastrand cross-links, and mono-adducts). 
 
Examples also exist in the literature of PBD dimers linked through the C8/C2'-95a or 
C2/C2'- positions rather than the C8-C8'-positions (Figure 1.25), but these molecules are 
at least 103-fold less cytotoxic than the most potent C8-linked dimers. For example, 
Thurston and co-workers95a synthesised a C8/C2'-linked PBD dimer (Figure 1.25A) 
containing C2'/C3'-endo unsaturation at the C2-linkage, which had an IC50 of > 25 μM in 
A2780 cells (human ovarian carcinoma cell line). This is less cytotoxic than the core PBD 
monomer DC-81, suggesting that the second PBD unit was impeding rather than 
enhancing DNA-interaction. Kamal and co-workers138 synthesised a similar C8/C2'-
linked dimer consisting of a C8'-phenyl-PBD linked via its C2'-position to the C8 of a 
second PBD unit (Figure 1.25B). This dimer also had cytotoxicity in the micromolar 
range (e.g., 2.6 μM in MCF-7 cell lines, human breast cancer), and in DNA thermal 
denaturation studies provided a ΔTm of 5.7 °C after incubation with calf thymus DNA for 
18 hours, which compares unfavourably with the ΔTm for the C8/C8'-linked dimer DSB-
120 under similar conditions (15.1 °C), again suggesting a poor fit in the DNA minor 
groove. In the same study, Kamal and co-workers synthesised an analogue which had one 
of its N10-C11 imine functionalities converted to an amide (Figure 1.25C). Interestingly, 
this molecule produced a level of cytotoxicity approximately 40-fold less than the bis-
imine parent molecule (Figure 1.25B) suggesting that, although the molecule could no 
longer cross-link DNA, some form of DNA interaction (presumably mono-alkylation) 
could still occur. Molecular dynamics studies have since confirmed that the 3-
dimensional shape of C8/C2'-linked PBD dimers is not conducive to a good fit within the 







Figure 1.25:  Examples of C8/C2'- and C2/C2'-linked PBD dimers synthesised by the Thurston95a, 
Kamal95b and Lown95b groups. Dimer 1.25C differs from the others in that it possesses only one 
electrophilic N10-C11 imine moiety, and so cannot cross-link DNA.   
 
A library of C2/C2'-linked dimers has also been synthesised by Lown and co-workers95b 
(Figure 1.25D). Cytotoxicity studies indicated that one member of the series (where n = 
3) had an average LC50 of approximately 50 μM across 60 cancer cell lines. Molecular 
dynamics simulations have since confirmed that PBD dimers linked in a C2/C2' manner 
do not have the appropriate 3-dimensional for effective interaction in the DNA minor 
groove139. 
 
1.4.3 The PBD dimer SJG-136 
 
The best known PBD dimer, SJG-136 (Figure 1.26) (also known as NSC 694501 or 
BN2629), was synthesised in the 1990s and is currently being investigated in Phase II 
clinical trials in ovarian cancer and leukaemia patients98b, 140. More recently, PBD dimer 
analogues are being attached to tumour-targeting antibodies to create Antibody-Drug 
Conjugates (ADCs), a number of which are now in early clinical trials, with many others 












Figure 1.26: Chemical structure of the PBD dimer SJG-136.  
 
SJG-136 is composed of two PBD monomer units connected through a C8-O-(CH2)3-O-
C8' linker90, 96, 135. Both of the PBD monomers contain an electrophilic imine moiety at 
the N10-C11 position which allows SJG-136 to form interstrand crosslinks in addition to 
intrastrand, and mono-alkylated adducts94. This adduct type preference is depending on 
the DNA sequence and the distance between reacting guanines. Studies with SJG-136 
have shown that the agent has a preference for the Pu-GATC-Py interstrand cross-linked 
adduct96, 137. 
 
An increasing body of evidence suggests that PBD monomers exert their pharmacological 
effect through transcription factor (TF) inhibition. The PBD monomer GWL-78 has been 
shown to inhibit the TF NF-Y102 and KMR-28-39 has recently been reported to interact 
with one or more consensus DNA sites of the TF NF-B90. These findings led to the 
proposal that TF inhibition may contribute to the overall anti-tumour activity of SJG-136 
within the biological system and also may explain the observed differences in its activity 




1.5 Biophysical methods used to study DNA-binding agents 
 
Newly discovered DNA-binding agents are initially evaluated in simple in vitro 
experiments, including UV spectroscopy141, fluorescence141, Raman spectroscopy, 
circular dichroism142 and DNA thermal denaturation studies143 in order to determine their 
ability to bind to DNA. However, these techniques are useful for the initial assessment of 
the DNA-binding capability of those ligands and do not provide any additional 
information regarding the sequence specificity.  
 
The DNase footprinting assay is the most widely used technique to identify the sequence 
selectivity of novel anti-tumour agents144. In this assay, a DNA fragment of known 
sequence is labelled with 32P and incubated with DNaseI in the presence of the ligand. By 
binding to specific sequences on the DNA, the ligand protects those from enzymatic 
digestion by DNaseI resulting in a differential cleavage pattern which is subsequently 
visualised using agarose gel electrophoresis. This technique has been applied to study the 
sequence preference of netropsin145 and chlorambucil146. 
 
Furthermore, the single cell electrophoresis assay (COMET) has become established as 
an uncomplicated and highly sensitive technique for the measurement of DNA strand 
breaks at the level of the individual eukaryotic cell147. Cells are suspended in agarose and 
casted on a microscope slide and lysed with detergents and high salt. During this process, 
undamaged DNA forms highly organised structures with the matrix proteins in the 
nucleus, whereas damaged DNA loses this property. During electrophoresis at high pH, 
the undamaged DNA is not able to migrate through the agarose gel towards the positively 
charged anode due to the supercoiled loop structure. DNA strand breaks, however, are 
capable of leaving the cavity and migrating towards the anode as they are composed of 
smaller fragments. Therefore, the amount of DNA that migrated during electrophoresis 
is representative for the amount of DNA damage in the cell. Image analysis compares the 






1.6 The evaluation of SJG-136 
 
Extensive pre-clinical and clinical evaluation has been carried out on SJG-136. The most 
relevant methods and results are described in the following section. 
 
1.6.1 Biophysical evaluation of SJG-136 
 
The DNA binding affinity of SJG-136 was investigated in DNA thermal denaturation 
studies using calf thymus DNA at SJG-136/DNA ratios of 1:100, 1:50 and 1:594. The ΔTm 
values obtained (Table 1) demonstrated an increase in the DNA melting temperature for 
each ratio after 0, 4 and 18 hour of incubation at 37 °C, clearly indicating the ability of 
SJG-136 to stabilise double-stranded calf thymus DNA. The data show a significant 
elevation of helix melting temperature by 33.6 °C after 18 h incubation at a 1:5 ratio 
(SJG-136/DNA), with a significant stabilisation effect already evident at t = 0, suggesting 
a strong kinetic component to the interaction. After 72 h incubation at a 1:5 ratio, the ΔTm 
increased still further to a value of 34.4 °C, providing a plateau saturation level for 
covalent DNA interaction. It is noteworthy that the ΔTm values obtained were 
significantly higher than for the PBD monomers tomaymycin and sibiromycin, with 





Induced ΔTm (°C) after incubation at 37 
 °C for: 
  0 h 4 h 18 h 
SJG-136 1:100 7.1 8.0 9.1 
SJG-136 1:50 11.3 12.3 15.0 
SJG-136 1:5 25.7 31.9 33.6 
Tomaymycin 1:5 0.97 2.38 2.56 
Sibiromycin 1:5 - - 16.3 
 
Table 1:  Thermal denaturation data for the interaction of SJG-136 with calf thymus DNA after 




The extent of interstrand cross-link formation produced by SJG-136 was investigated 
using a gel electrophoresis assay developed by Hartley and co-workers94, 148. It was 
evaluated at concentrations between 0.001 to 10 µM, and demonstrated highly efficient 
DNA cross-linking (Figure 1.27a). After 2 h incubation of DNA with SJG-136, cross-
links were visible starting from a concentration as low as 0.01 µM, with single-stranded 
DNA disappearing completely at 0.3 µM. The degree of cross-linking was quantitated 
using laser densitometry as shown in Figure 1.27b. Overall, these results demonstrated 




Figure 1.27: (a) Autoradiograph of a neutral agarose gel showing DNA interstrand cross-linking 
of linear 32P-end-labeled pBR322 DNA by SJG-136 following a 2 h incubation at 37 °C. The 
lanes are: C, double-stranded DNA control; 0, single-stranded DNA control; and 0.001, 0.003, 
0.01, 0.03, 0.1, 0.3, 1.0, 3.0, 10.0 μM SJG-136. DS and SS are double- and single-stranded DNA, 
respectively; (b) Quantification of the gel in Figure 1.27a to show the concentration dependence 
of DNA cross-linking for SJG-136 in linear 32P-end-labeled pBR322 DNA94. "Reprinted with 
permission from Gregson, S. J., et al (2001) Design, synthesis, and evaluation of a novel 
pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and 
potent cytotoxicity, Journal of Medicinal Chemistry 44, 737-748. Copyright © 2001 American 
Chemical Society." 
 
Molecular modeling studies of cross-link formation were carried out to support the 
observations made in the thermal denaturation and DNA cross-linking studies94. Two 12-
mer DNA duplexes, 5'-CGCAGATCTGCG-3' and 5'-CGCTCTAGAGCG-3' (G-G cross-
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link sequences spanned underlined; alkylated guanine bases in bold), were designed for 
energy calculations. Each sequence offered optimal binding sites (i.e., 5'-AGA) on either 
strand for alkylation by a PBD but in either the 3'- or 5'-direction. The results suggested 
that either no (or insignificant) disruption to the DNA secondary structure occurred upon 
adduct formation and cross-linking, and that no induced distortion of base pairs within 
the helical structure occurred94. Furthermore, energy-minimised models demonstrated 
excellent accommodation of SJG-136 within the DNA minor groove, with no significant 
part of the molecule exposed beyond the periphery of the duplex. This feature may 
explain the observed resistance of SJG-136 adducts to DNA repair which is usually 
initiated after repair enzymes recognise distortion or helical perturbation of the DNA 
helix as occurs with the majority of DNA alkylating agents. The calculated binding 
energies also supported the observation that covalent interaction between SJG-136 and 
DNA stabilises the DNA structure to a greater extent than the related PBD monomers 
(i.e., the energy of binding values were twice as low as for the monomers). Moreover, the 
flexible C8/C8'-linker which connects the PBD monomeric units in SJG-136 was 
observed to enhance overall binding in the DNA minor groove through van der Waals 
interactions, with hydrogen bonds observed to form between the N10-protons of the PBD 
units and the N3-atoms of 3'-adenine bases adjacent to the covalently-modified guanines 
on either strand. These computational studies allowed models to be created for the 
interaction of SJG-136 with DNA as shown in Figure 1.28. Overall, these modelling 
results were consistent with the high ΔTm values observed for SJG-136 compared to the 




Figure 1.28:  A. Schematic diagram of the PBD dimer SJG-136 covalently binding to, and 
interstrand cross-linking with, the DNA sequence 5'-AGATCT-3'. Its sequence-selectivity is due 
in part to (a) covalent bonds forming between the C11/C11' positions of the PBD units and the 
A.                                                    B.                                                    
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exocyclic N2 groups of guanines on opposite strands (shown as ----), and (b) hydrogen bonds 
(shown as - - -) formed between the N10/N10' protons of the PBD units and the ring nitrogen N3 
acceptors of the 3'-adenines adjacent to the covalently modified guanines149;  B. Molecular model 
of SJG-136 forming an interstrand cross-link within the sequence 5'-TATAGATC(G)TATA-3' 
(covalently modified bases underlined, and bases on the opposing strand in brackets) between the 
guanines on each strand (both magenta). 
 
The sequence-selectivity of SJG-136 toward naked DNA was initially studied using a 
traditional DNA footprinting method based on a 262-bp duplex DNA sequence from the 
MS2 plasmid150. This DNA fragment contained the preferred cross-linking site for SJG-
136 (i.e., 5'-Pu-GATC-Py-3') in addition to less-favoured sites (i.e., 5'-GXXC-3'; X = any 
base)94. The sequence included two preferred binding sites at positions 5'-48GGATCC53-
3' and 5'-208GGATCC213-3', together with 17 other less-favoured potential binding sites 
containing the sequence 5'-GXXC-3'. As anticipated, the two predicted most-
energetically-favoured binding sites were 5'-48GGATCC53-3' and 5'-208GGATCC213-3', 
where the molecule was observed to bind with high affinity. It was also observed to bind 
to a number of lower affinity sites such as 5'-GXXC-3', where XX was TA, GC, CT, TT, 
GG, or GT. This result was surprising at the time of publication, given that a guanine 
residue should not be well-tolerated between the cross-linked guanines due to the bulky 
nature of the C2-exocyclic amino group which points into the minor groove. However, 
based on more recent studies that have demonstrated the formation of mono-adducts and 
intrastrand cross-links in addition to interstrand cross-links96, this observation can now 
be explained by the formation of these other adduct types. Interestingly, the gels also 
showed high molecular weight material appearing from 1 µM SJG-136 concentration and 
above at the top of the gel, which intensified with higher concentrations. This material 
was assumed to be duplex DNA that could not denature to single stranded DNA either 
before and/or during denaturing gel electrophoresis due to the interstrand cross-links 
formed by SJG-136. 
 
Apart from the effect of DNA interstrand cross-linking on DNA replication, it is also 
possible that the in vitro and in vivo biological activity151 of SJG-136 may be due to its 
sequence-selective interaction with DNA binding sites corresponding to key sequences 
in genes involved with the promotion of tumour growth. Therefore, an in vitro 
transcription stop assay was carried out on a 282-bp DNA sequence to investigate the 
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effect of SGJ-136 on T7 RNA polymerase and transcription termination101, 150. Significant 
transcriptional stop sites (T-stops) were observed which appeared to be mainly associated 
with 5'-GXXC-3' sequences. Although this assay cannot distinguish between mono-
alkylated and cross-linked adducts, at the time the T-stops produced were assumed to be 
mainly associated with interstrand cross-links, as high affinity adducts would be required 
to produce significant T-stops101. In accord with the DNA footprinting experiments, the 
most favourable sequence 5'-48GGATCC53-3' gave the strongest T-stop, suggesting that 
this sequence might be the principal cross-linking site for SJG-136. The kinetic behaviour 
of SJG-136 was also studied by time-dependent experiments, and the results showed that 
incubation with DNA for 15 minutes was sufficient to inhibit transcription with negligible 
changes up to 1 hour incubation. Intriguingly, the data also revealed that, once 
transcription was initiated, addition of SJG-136 had no effects on transcription inhibition, 
suggesting that adducts needed to be fully formed before they could block transcription. 
In addition, temperature-dependent experiments showed that the activation energy for 
covalent drug-DNA interaction must be very low at 5'-Pu-GATC-Py-3' sites, since 
footprints were clearly detectable on the gels at the same site at 4 °C. In contrast, the 
activation energy for the less preferred 5'-39GGTACC44-3' site must be higher, as the 
strongest footprint was observed at only 37 °C.   
 
A significant number of studies were also carried out in tumour cell lines (both human 
and canine) using the Single Cell Electrophoresis (COMET) and/or γ-H2AX Foci assays 
to correlate the extent of DNA cross-linking with cytotoxicity149. SJG-136 was initially 
evaluated in K562 (leukaemia), U266B1 (myeloma), U937 (lymphoma), PC-3 (prostate), 
OVCAR-5 (ovarian), MCF-7 (breast), CaCo2 (colon) and HCT-15 (colon) cell lines 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazol (MTT) growth inhibition 
assay, and an average GI50 (concentration for 50% maximal inhibition of cell 
proliferation) of 212 pM was established (range: 2.1 pM in A2780 to 2.3 nM in HCT-
15)149. The COMET and/or γ-H2AX Foci assays were then used to detect DNA 
interstrand cross-links in some of these cell lines following a one hour exposure to SJG-
136. Cross-linking was detectable at very low SJG-136 concentrations (i.e., 0.5 nM in the 
K562 cell line) with cross-links persisting over a 48 hours period. 
 
The γ-H2AX assay152 is more sensitive than the COMET assay153 in its ability to detect 
DNA damage caused by DNA cross-linking agents. γ-H2AX foci formation is rapidly 
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induced at DNA double-strand breaks and sites of replication fork collapse that are often 
induced by cross-linking agents154. They accumulate at the sites of DNA damage and 
serve to recruit DNA repair and cell cycle checkpoint enzymes in order to initiate repair 
of the damage. They can be visualised using immunostaining techniques, and the number 
of γ-H2AX foci present is proportionate to the DNA damage. Therefore, the γ-H2AX 
assay has become an important and useful biomarker assay for measuring the DNA 
damage caused by DNA cross-linking agents such as SJG-136155. The assay was initially 
used to establish whether it could detect a correlation between the rate of interstrand 
cross-link formation and the appearance of γ-H2AX foci in HCT-116 cells156. The cells 
were exposed to either 50 nmol/L SJG-136 for 1 hour, or 1 nmol/L for 24 hours, and 
significant foci formation was detected for both conditions after 4 hours or 8 hours post 
treatment, respectively.  Despite these exposure differences, the levels of γ-H2AX foci 
formed in both cases were comparable after 24 hours, demonstrating that interstrand 
cross-links (ICLs) are formed earlier (i.e., maximum reached after 1 hour SJG-136 
treatment) than γ-H2AX foci are detected (i.e., visible after 4 hours exposure to the agent) 
when the cells were exposed for 1 hour to a higher concentration of SJG-136. This delay 
was even more pronounced in cells treated with a lower concentration of SJG-136 for 24 
hours. In this case, H2AX foci were visible at 8 hours post incubation whereas cross-link 
formation could be observed 1 hour after a one hour exposure, with maximum ICL 
formation after 24 hours. These results were consistent with the need for DNA adducts to 
form prior to γ-H2AX foci appearing. 
 
A reversed phase HPLC/MS methodology has also been developed to study the sequence 
selectivity of SJG-136157. This technique requires only small quantities of short 
inexpensive oligonucleotides, and does not require the use of radioactivity compared to 
traditional methods, such as DNA footprinting. Furthermore, the adducts formed can be 
rapidly visualised (i.e., < 30 min), and so both thermodynamic and kinetic data can be 
obtained, along with sequence selectivity information if different oligonucleotides are 
used. Initial studies of SJG-136 using this methodology involved self-complementary 12-
mer oligonucleotides containing Pu-GATC-Py (Seq-1), Pu-GTAC-Py (Seq-2), Py-
GATC-Pu (Seq-3) and Pu-IATC-Py (Seq-4) sequences (I = Inosine). This assay was also 
used to investigate the extent of cross-link formation at different molar ratios after 24 
hours. The data obtained clearly showed that optimal cross-linking (i.e., ~100%) occurred 
at a 4:1 (SJG-136/DNA) ratio157. The fastest reaction was observed with Seq-1, followed 
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by Seq-2 and Seq-3, with Seq-4 not reacting. These results confirmed that SJG-136 
preferred the sequence Pu-GATC-Py (Seq-1), consistent with the previous gel-
electrophoresis studies88b, 94. Seq-4, which had its guanines replaced with non-
nucleophilic inosines, failed to react as anticipated, thereby acting as a negative control. 
 
The biological activity of SJG-136 was thought to be entirely due to the Pu-GATC-Py 
interstrand cross-links formed in the DNA minor groove94, 150, 158. However, based on the 
results of further HPLC/MS studies, it became clear that SJG-136 is capable of forming 
longer interstrand cross-links at Pu-GAATC-Py sequences, intrastrand cross-links at both 
shorter (e.g., Pu-GATG-Py) and longer (e.g., Pu-GAATG-Py) sequences, and mono-
alkylated adducts at guanine residues where cross-linking is not possible because of the 
distance of the next potentially reacting guanine96. Furthermore, a direct competition 
experiment was then carried out between the interstrand Pu-GATC-Py and Pu-GAATC-
Py sequences, and the intrastrand Pu-GATG-Py and Pu-GAATG-Py sequences. The 
results indicated a rank order of reactivity of Pu-GAATG-Py > Pu-GATC-Py »Pu-
GATG-Py > Pu-GAATC-Py. 
 
Molecular dynamics simulations were undertaken to gain insight into these 
observations96. It was clear from energy minimised models that the two electrophilic N10-
C11 imine moieties of SJG-136 were well-positioned to react covalently with the 
guanines in the Pu-GATC-Py (i.e., favoured interstrand cross-link) and Pu-GATG-Py 
(i.e., intrastrand cross-link) sequences with little distortion of the DNA helix. However, 
for the extended Pu-GAATC-Py and Pu-GAATG-Py sequences, the model predicted that 
bis-alkylation could only occur at the expense of some distortion of the DNA at the points 
of covalent attachment, and with SJG-136 adopting a slightly lower position in the DNA 
minor groove in order to span the necessary distance between reactive guanines.   
 
1.6.2 Biological evaluation of SJG-136 
 
In the late 1990s, SJG-136 was evaluated in the National Cancer Institute's (NCI's) 60-
cell line panel in which it showed considerable promise in terms of potency and 
selectivity82, 90. This screen, which comprised sub-panels of leukaemia, melanoma, lung, 
colon, kidney, ovary and central nervous system tumour cells was, in its original form, 
capable of evaluating more than 10,000 new chemical agents per year, and was used as 
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the basis to select both compounds and cell lines for follow-up Hollow Fibre and in vivo 
xenograft studies. The results indicated a LC50 (i.e., median lethal concentration) of 7.4 
nmol/L with a range of 0.14 to 320 nmol/L. In particular, the significant differences 
between the LC50, TGI (i.e., tumour growth inhibition) and GI50 (i.e., concentration for 
50% maximal inhibition of cell proliferation) values across the different cell lines 
suggested that SJG-136 had selective cytotoxicity toward certain panels of cell lines and 
individual cell lines. For example, the leukaemia and melanoma cell panels were 
particularly sensitive. Furthermore, it was possible to compare the overall cytotoxicity 
profile of SJG-136 with those of approximately 60,000 compounds in the NCI’s database 
using a molecular target analysis program known as COMPARE159. Although this 
analysis indicated an activity pattern for SJG-136 similar to some known DNA-binding 
agents (e.g., melphalan, cyclophosphamide, chlorambucil), its overall profile was not a 
perfect match with cluster patterns associated with any specific chemotherapeutic agents, 
thus reflecting its unique mechanism of action. 
 
Based on the results from the NCI’s 60-cell line screen, SJG-136 was next evaluated in 
the Hollow Fibre assay158 to guide the selection of tumour cell types for use in xenograft 
studies. This assay involves cultivation of sensitive tumour cells in porous hollow fibre 
tubes which were then implanted into the intraperitoneal (i.p.) and subcutaneous (s.c.) 
compartments of host immunocompromised mice. These cells were then exposed to SJG-
136 by systemic administration followed by retrieval of the hollow fibres after a suitable 
time period, and quantitation of the viability of the cells within using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazol) assay160. In the NCI Standard Hollow Fibre 
assay158, 160, SJG-136 was evaluated against 12 different tumour cell lines, and achieved 
> 50% growth inhibition in 83% of the cell lines growing in fibres in the i.p. cavity, and 
in 29% in the s.c. location. Overall, SJG-136 produced cell kill in 5 of the 12 cell lines 
used in the study (i.e., NCI-H522 lung adenocarcinoma, 13% kill; LOX IMVI melanoma, 
10% kill; UACC-62 melanoma, 10% kill; MDA-MB-435 breast carcinoma, 29% kill; 
OVCAR-3 ovarian adenocarcinoma, 47% kill). During the course of the experiment, the 
average body weight loss in mice treated systemically with SJG-136 was ≤ 9% with no 
drug-related deaths, indicating that the agent was well tolerated. 
 
Based on these results, the NCI evaluated the in vivo efficacy of SJG-136 in 10 human 
tumour xenograft models151, 161 using tumour cell lines selected from the 60 cell line 
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screen and Hollow Fibre assay data158, 160, 162. These included LOX IMVI and UACC-62 
(melanomas), OVCAR-3 and OVCAR-5 (ovarian carcinomas), MDA-MB-435 (breast 
carcinoma), SF-295 and C-6 (gliomas), LS-174T (colon carcinoma), HL-60 TB 
(promyelocytic leukaemia) and NCI-H522 (lung carcinoma). SJG-136 showed time-and 
dose-dependent anti-tumour activity in all of these tumour models, although the NCI-
H522 and HL-60 tumours were particularly sensitive. Activity was demonstrated in all 
mouse models with the best efficacy observed with it being dosed once daily for 5 days, 
and similar results were obtained in rat xenograft models.  
 
SF-295 and LOX IMVI were selected for assessment of maximum-tolerated dose (MTD) 
and minimum effective dose (MED) values in the mouse model, which were established 
as 120 µg/kg/day and 16 µg/kg/day, respectively. Additionally, HL-60 TB and NCI-H522 
were selected for evaluation of alternative dosing schedules, such as a single dose every 
seven days for 3 treatments. The results showed that SJG-136 was well tolerated and 
highly efficacious in both models, with HL-60 TB found to be the most sensitive, and the 
once daily for five days schedule providing the best anti-tumour activity in both models. 
In addition, a single intravenous (i.v.) bolus regimen was compared with multiple daily 
i.v. administrations in the SF-295 and LOX IMVI tumour xenograft mouse models. 
Interestingly, an immediate tumour mass reduction was observed after the single dose 
administration (MTD for single bolus = 400 µg/kg/day), although tumour re-growth 
occurred within the next four days. In contrast, multiple daily administration of SJG-136 
appeared to be more effective in maintaining growth suppression and/or tumour 
regression. Lastly, continuous infusion of SJG-136 was explored in the SF-295 and LOX 
IMVI xenograft mouse models but did not provide any greater efficacy compared to bolus 
administration. 
 
Next, the early-stage LOX IMVI tumour xenograft model was adopted for an in-depth 
evaluation of the in vivo anti-tumour activity of SJG-136. After a single i.v. 
administration of 75 µg/kg, 5 out of 8 animals became tumour free by the end of the 
experiment (68 days), and the other three animals had a mean tumour growth delay of 
26.5 days. Additional tumour growth delay experiments were carried out in the SKOV-3 
ovarian model using different dose schedules including daily for five days, and every 
fourth day for three treatments, at SJG-136 concentrations between 25 to 120 µg/kg. In 
these studies, four mice experienced a partial response (PR) and three a complete 
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response (CR), demonstrating cumulative dose-dependent activity with all treatment 
schedules tolerated.  SJG-136 was also evaluated in an advanced LS 174T xenograft 
model administered as a single-dose, daily for five days, or daily for four days for three 
treatments, to study dose accumulation. As for the previous models, all treatment 
schedules were well tolerated, and SJG-136 exhibited significant anti-tumour activity 
with a correlation between efficacy and cumulative dose, as well as substantial tumour 
growth delay and survival benefit after multiple daily administrations. A leukaemia 
xenograft model (HL-60) was also used to evaluate SJG-136, in which it showed dose-
dependent efficacy at concentrations between 25-60 µg/kg. Therefore, SJG-136 was 
found to be significantly active in all four in vivo tumour xenograft models studied (i.e., 
melanoma, ovarian, colon and leukaemia), and with dose-dependency after multiple daily 
i.v. administrations, and with greater efficacy following drug accumulation.  
 
Finally, the efficacy of SJG-136 in the cisplatin-sensitive human ovarian cancer parental 
cell line CH1 was studied158. It was found to have significant anti-tumour activity in this 
model, providing tumour growth delays at a dose of 0.2 mg/kg given i.v. on days 0, 4 and 
8 comparable to cisplatin at 4 mg/kg using the same schedule. More importantly, SJG-
136 provided significant growth delay in the related cisplatin-resistant CH1cisR tumour 
model at 0.2 mg/kg, whereas cisplatin was inactive at 4 mg/kg158. 
 
In order to measure the pharmacokinetics of SJG-136 in the animal models, and to 
develop methodology that could potentially be used in clinical trials, a sensitive, selective 
and reproducible reversed phase LC/MS assay was initially developed to assess 
pharmacokinetic parameters in the mouse models163. Using this assay, it was determined 
that SJG-136 was detectable in plasma up to 4 hours after a single administration with a 
peak plasma concentration of 336 nM and a Cmax of 30 minutes. The measured half-life 
(t1/2) was 0.98 h, with a total clearance of 17.72 mL min
-1 kg-1. Overall, SJG-136 was 
shown to be stable in blood and plasma over a 6 hour period with no significant loss due 
to degradation over this time. The plasma protein binding capacity was found to be 
moderate at 65 ± 11% and 76 ± 5% for initial concentrations of 100 and 1,000 nM, 
respectively. Similar pharmacokinetic studies were carried out in a rat model following 
single-dose (15 and 50 µg/kg) or multiple-dose (25 µg/kg/day for 5 days) administration 
using a similar LC/MS/MS method164. In these studies, no plasma accumulation of SJG-
136 was observed after administration of 25 µg/kg/day for 5 days. Another direct liquid 
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chromatography assay was developed to quantify the reactive imine form of SJG-136, 
which proved to be reproducible, linear and accurate135. The metabolism of SJG-136 was 
also evaluated using a rat liver microsome assay in which the agent was found to be 
metabolised by CYP3A isoforms, to have a half-life of 9 min, clearance of 190 
mL/min/m2, and a volume of distribution of 1780 mL/m2 164. 
 
To study the pharmacodynamic (PD) endpoint of the mechanism of action of SJG-136 in 
the in vivo xenograft experiments, the COMET assay was used to evaluate tumour 
biopsies taken from the s.c.-growing LS 174T human colon cancer xenograft model in 
MF1 nude mice165. SJG-136 caused a significant growth delay in this tumour model when 
delivered i.v. at 0.30 or 0.45 mg/kg, and tumour samples were removed at 1, 3 and 24 
hours, and then subjected to COMET analysis. A small but significant level of DNA 
cross-linking was observed at 1 hour which remained constant over 24 hours. However, 
the extent of cross-linking increased with the higher dose of 0.45 mg/kg which also 
remained constant over 24 hours158. 
 
Finally, an ex vivo bone marrow (CFU-GM) colony formation assay was used to assess 
the toxicity of SJG-136 toward the hematopoietic system158, 166. The results demonstrated 
that the concentrations of SJG-136 required to achieve cytostatic and/or cytocidal effects 
in HL-60 TB and Molt-4 human leukaemia tumour cells in cell culture or in a soft agar 
colony formation assay (i.e., the IC50, IC75, and IC90 values) were much lower than the 
concentrations required for similar effects in an ex vivo bone marrow assay158, thus 
suggesting a significant selective cytotoxicity toward the tumour cells. 
 
In summary, SJG-136 showed significant activity in most of the in vivo models examined 
after short exposure times at nanomolar concentrations, or for longer exposure times at 
sub-nanomolar concentrations. For example, in the early-stage NCI xenograft studies, 
significant tumour growth delays were observed in seven of the eight models after i.v. 
administration, with multilog cell kill in four of the eight models. It was also found to be 
markedly efficacious in two advanced-stage xenograft models (LOX IMVI melanoma 
and HL-60 TB promyelocytic leukaemia) with similar results to those obtained in the 
early-stage models. Overall, it was established that SJG-136 is significantly active after 
a single bolus administration but provides the best efficacy after administration multiple 
times over a five-day period151. 
64 
 
1.6.3 Clinical evaluation of SJG-136 
 
The first clinical evaluation of SJG-136 as a single agent in a Phase I setting was carried 
out in patients with advanced and/or metastatic solid tumours refractory to conventional 
anticancer therapies, or for whom no conventional treatment was available98b. The 
purpose of the study was to establish the Maximum Tolerated Dose (MTD) along with 
pharmacokinetic and pharmacodynamic profiles using COMET153 and γ-H2AX155 foci 
assays. SJG-136 was administered i.v. every 21 days at different doses. An MTD of 45 
µg/m2 was established for this 21-day schedule. The major observed drug-related adverse 
events were reversible liver toxicity (i.e., transaminitis), fatigue and a delayed lower-limb 
oedema. Out of twelve evaluable patients, stable disease (SD) was observed in ten 
patients, but no partial (PRs) or complete responses (CRs) were reported.  
 
A second Phase I clinical trial with a different dosing schedule was carried out in patients 
with refractory solid tumours using a starting dose of 10 µg/m2 per day. In this case, SJG-
136 was administered as a bolus infusion over 20 minutes on days 1, 8 and 15 of a 28-
day cycle. The MTD was assigned as 40 µg/m2 per day.  
 
The third Phase I clinical trial was carried based on the previous Phase I clinical study 
conducted by Hochhauser and co-workers98b. This study evaluated two different dose 
schedules. Sixteen patients were enroled, and a MTD of 30 µg/m² was determined. The 
DLTs observed were similar to those documented in the previous Phase I clinical trials 
(i.e., oedema, fatigue, dyspnoea and elevations in liver transaminases and alkaline 
phosphatase). In this trial, one patient experienced a confirmed partial response (PR), and 
one an unconfirmed PR.  Furthermore, two patients achieved stable disease (SD) lasting 
more than 12 weeks. 
 
On the basis of these encouraging Phase I results, SJG-136 progressed to a multicentre 
Phase II clinical evaluation in patients with epithelial ovarian cancer who had not 
responded to prior treatment with cisplatin or carboplatin. Nineteen patients were enroled 
with SJG-136 administered i.v. over 20 minutes on days 1-3 every 21 days. The goals of 
the study were to evaluate the overall response rate to SJG-136, and to assess toxicity. 
Furthermore, for each patient the extent of adduct formation was determined in peripheral 
blood mononuclear cells (PBMCs) and tumour biopsies using the COMET and γ-H2AX 
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assays. However, patient recruitment to this trial was poor, and no clinical results have 
been reported to date. 
 
A second Phase II clinical evaluation of SJG-136 in patients with advanced chronic 
lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) has been terminated 
in November 2015. In this trial patients received SJG-136 intravenously at a dose level 
of 15 µg/m2/day (Cohort I) or 30 µg/m2/day (Cohort II) on days 1, 2 and 3 every 21 days 
for six cycles. The maximum tolerated dose (MTD) was assessed based on the DLTs 
observed and, for secondary outcome measures the safety profile of SJG-136 was 
evaluated based on pharmacokinetic parameters such as maximum plasma concentration 






1.7 Methods used in this study to study the interaction of small-molecule 
binding ligands with oligonucleotides  
 
This section will focus on the principles and background of the methods and techniques 
used in this study. The biophysical study applied reversed phase high performance liquid 
chromatography (RP-HPLC), matrix-assisted laser desorption/ionisation time of flight 
mass spectrometry (MALDI-TOF-MS), circular dichroism (CD), fluorescence resonance 
energy transfer (FRET) and molecular modeling (MM) studies. Moreover, the traditional 
polymerase chain reaction (PCR), quantitative polymerase chain reaction (qPCR) and 
Western blotting (WB) were used during the biological analysis of SJG-136.  
 
1.7.1 Reversed Phase High Performance Liquid Chromatography (RP-HPLC) 
 
RP-HPLC is a very powerful and widely-used technique for the separation, purification 
and analysis of complex mixtures comprising large and small biomolecules, such as 
proteins, peptides and nucleic acids167. In particular, it is a useful analytic technique to 
study the interaction of small-molecules with specific DNA target sequences of 
oncogenic transcription factors. Preliminary data can easily and rapidly be obtained on 
the ability of ligands to bind to consensus transcription factor sequences. In the case of 
ligand/DNA interaction, additional peaks appear in the chromatographic profile due to a 
change in the polarity of the ligand/DNA complex compared to the DNA alone.   
 
The principle of RP-HPLC is an adsorption mechanism which depends on hydrophobic 
interactions between solubilised molecules (solutes) in a mobile phase and specifically 
modified ligands chemically fixed to a non-polar chromatography matrix (sorbent, 
stationary phase). The sample to be analysed is introduced into the mobile phase solution 
with a high pressure pump by injection and subsequently forced through the column 
(HPLC tube, stationary phase) (Figure 1.29). The solute separation occurs within the 
column based on hydrophobicity. Non-polar molecules contained in the mixture form 
strong attractions with the stationary phase through van der Waals interactions, and 
therefore will distribute on the surface of the stationary matrix. In contrast to this, polar 
components lack the hydrophobic association with the stationary phase and consequently, 
will remain in the mobile phase and migrate through the column more rapidly. The 
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absorbance of eluted components is monitored using a UV detector which is placed 
directly after the column. The intensity of the UV signal depends on the amount of a 
particular compound in the mixture passing the HPLC tube and absorbing light. The UV 
signals are converted into electrical signals appearing as peaks in the chromatographic 
profiles. By measuring the area under the peak (AUC) precise quantification is possible 




Figure 1.29: Reversed phase HPLC separation: Overview. Adapted from 
www.chemguide.co.uk/analysis/chromatography/hplc.html. 
 
The stationary phase of RP-HPLC consists of hydrophobic ligands which are 
incorporated into a porous, insoluble beaded matrix. Silica is the most commonly used 
support material in RP-HPLC168. The surface active sites on the silica gel, the silanol 
groups (Si-OH) are modified by attaching long non-polar linear hydrocarbon chains (C1, 
C4, C6, C8, C18, etc.) or phenyl and cyanopropyl ligands in order to increase the 
hydrophobicity of the stationary phase (Figure 1.30). The matrix plays a fundamental 
role during the separation process as the interaction of the solutes with the stationary 
phase occurs on its surface and is highly dependent on the type of bonded phase, particle 
size, pore size and alkylchain density as well as its length169. The precise mechanism of 
retention is still an on-going debate170. It is presumed to be governed by a combination 
of adsorption and a partitioning type mechanism where the solute molecules embed fully 






Figure 1.30: The surface of reversed phase stationary phases.  
 
The mobile phases used in RP-HPLC are mixtures of water and organic solvents 
(modifiers), typically acetonitrile or methanol. The role of the organic modifiers is to 
compete against the ligands of the stationary phase for the attraction of the solute 
molecules. Initially, the analysed mixture is introduced into the system with the mobile 
phase containing low concentrations of organic modifiers with the aim to allow non-polar 
solutes to adsorb to the hydrophobic matrix. During the RP-HPLC process, the 
concentration of the organic modifier is gradually increased to favour desorption of the 
solutes from the reversed phase medium back into the mobile phase. Consequently, very 
polar components require low concentrations of organic modifiers, migrate through the 
stationary phase more quickly, and hence elute from the column prior to less-polar 
molecules. Hydrophobic solutes will form strong attractions with the matrix ligands 
through van der Waals interactions, and thus spend more time in the column.  
 
The solutes separation can proceed either by an isocratic (concentration of organic 
modifier is constant during the HPLC process) or gradient elution where the 
concentration of the organic solvent is gradually increased from high to low polarity.  
Ion pair RP-HPLC is the predominant chromatography mode applied for the study of 
nucleic acids, including DNA and RNA172. The aqueous mobile phase often contains 
ionic additives, referred as ion pair agents. The ion pairing reagents are cationic amines, 
typically triethylammonium acetate (TEAA) or triethylammonium bicarbonate (TEAB), 
which form ion pairs with the negatively charged phosphate groups of the nucleic acids 
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making them electrically neutral. This process increases the hydrophobic character of the 
nucleic acids and allows the separation of ionic and highly polar molecules on a reversed 
phase column, such as DNA, RNA as well as hydrophilic peptides.  
 
1.7.2 Matrix-Assisted Laser Desorption/Ionisation Time of Flight Mass 
Spectrometry (MALDI-TOF-MS) 
 
MALDI is the most popular analytical technique for analysing low and high molecular 
weight compounds, particularly oligonucleotides, peptides, proteins and 
oligosaccharides(198-200). MALDI-TOF is widely used in the analysis of drug-DNA 
interactions. It precisely determines the mass of formed ligand-DNA complexes173. This 
analytical application allows rapid and accurate mass identification with detection 
sensitivity in the picomolar concentration range174.  
 
A typical MALDI instrument consists of three essential components (Figure 1.30): ion 
source, mass analyser and detector. The analysed mixture is embedded in a particular 
matrix which is exposed to a focused laser beam, commonly nitrogen laser pulse at 337 
nm. The crystallised matrix components absorb the laser energy, followed by an 
ionisation process which in turn results in charge transfer from the matrix molecules to 
the analysed compounds. Subsequently, the charged molecules pass an electric field of 
known strength and are separated in the mass analyser according to their molecular 
weight (time of flight). Molecules with higher molecular weight fly slowly through the 
mass tube compared to compounds with low molecular mass, thus reaching the detector 
at a later time point. The flying speeds of the produced ions are proportional to their mass-
to-charge ratio. The detector counts the numbers of different ions and generates the mass 







Figure 1.30: Principle of MALDI-TOF. Adapted from www.studyblue.com.   
 
Two different types of analyser are available for MALDI-TOF-MS: the linear mode and 
the reflectron mode analyser. The linear mode analyser simply measures the required time 
for an ionised compound to fly from one end of the mass analyser to the detector. During 
the reflectron mode, the charged molecules initially pass a linear mass analyser and are 
then reflected, followed by passage through a second linear mass analyser before they 
reach the detector. The main advantage of the reflectron mode is the fact that the charged 
molecules spend more time flying, allowing an improved separation of molecules with 
very similar mass-to-charge ratios yielding a higher resolution.  
 
The choice of matrix plays a fundamental role in MALDI-TOF-MS, affecting sensitivity 
and reproducibility of mass spectrometry analysis. Benzoic acid, cinnamic acid and 
related aromatic compounds are commonly used for the analysis of proteins175. 3-
Hydroxypicolinic acid176 and succinic acid177 demonstrated to be suitable matrices for 
oligonucleotides. The appropriate matrix is combined with the analyte of interest by 
solubilisation in a mixture of water and an organic solvent in order to ensure that 
hydrophobic as well as hydrophilic components completely dissolve. The matrix mix is 
then spotted onto a MALDI target plate and dried naturally for crystallisation. Finally, 
the laser pulse is applied resulting in matrix ionisation and charge transfer to the analysed 






Figure 1.31: Principle of ionisation process during MALDI. Adapted from fr.wikipedia.org. 
 
1.7.3 Circular Dichroism (CD) 
 
CD is a powerful spectroscopic method used to study conformational changes in the 
secondary structure of oligonucleotides178. It is an indispensable technique for the 
investigation of the various conformational forms of nucleic acids, such as A-form, B-
form, Z-form, quadruplexes and other structures178, hence a valuable tool for mapping 
conformational features of specific oligonucleotide sequences. More importantly, CD can 
be applied to evaluate conformational changes in the secondary structure of DNA upon 
binding of specific DNA-interacting ligands. Therefore, in context to this project, CD is 
a useful tool that may provide important data on anti-tumour agents that specifically target 
and regulate fundamental elements crucial for gene expression which is also the focus of 
current anti-cancer drug development178c.   
 
CD originates from the interaction of chiral molecules (vast majority of biological 
molecules) with circularly polarised light which is the sum of left-handed and right-
handed linearly polarised light179. Chiral molecules absorb left-handed and right-handed 
light differently and the resulting difference is simply the CD signal, called ellipticity θ 
and expressed in degrees. Ligands bound to biological compounds alter its secondary 
structure leading to a change in characteristic CD signals of the native molecules 
providing information about binding constants, kinetics of binding as well as 
conformational changes in the ligand/molecule complex.    
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A monochromator produces linearly polarised light which subsequently converted to 
circularly polarised light by a photoelastic modulator (PEM) (Figure 1.32). Following 
this, the circularly polarised light beam passes through the optically active sample where 
it is absorbed differently. The photomultiplier detects the difference in the absorbed 
transmitted light and measures the exhibited CD signal. CD studies of oligonucleotides 
mainly employ UV within 180-300 nm where the DNA bases absorb light. π→π* 
transitions in purines and pyrimidines have been shown to be responsible for the 
characteristic CD bands of nucleic acids180. Of utmost importance is that the position and 
amplitude of CD signals of various DNA conformations, such as A-form, B-form, Z-





Figure 1.32: The principle behind CD spectroscopy. The light from UV is passed into a Photo 
Elastic Modulator (PEM) which converts the linearly polarized light into alternating left and right 
handed polarized light. The two polarizations are differently absorbed, and the difference in 
absorption is detected with a Photo Multiplier Tube (PMT). Taken from www.isa.au.dk.  
 
CD spectroscopy is a fast and relatively inexpensive technique. It exhibits high sensitivity 
at low DNA concentrations (20 µg/mL). Furthermore, short oligonucleotides as well as 
longer DNA fragments up to 8,000 base pairs can be easily analysed using CD182. And 
lastly, CD is capable of examining solutions and films183. However, CD cannot provide 
any structural information of the analysed molecules on the atomic level in contrast to X-
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ray diffraction and NMR spectroscopy, hence CD is primarily utilised for preliminary 
studies.  
 
1.7.4 Fluorescence Resonance Energy Transfer (FRET) assay 
 
FRET is a distance-dependent physical phenomenon in which energy from an excited 
donor molecule is transferred to a suitable acceptor molecule in the absence of 
radiation184. FRET is widely applied to investigate molecular interactions in biomedical 
research and drug discovery. FRET data can provide useful information about structure 
and conformation of proteins185 and nucleic acids186. Small-molecules stabilise the 
secondary structure of DNA upon binding which results in an increase in the melting 
temperature of the ligand/DNA complex. The differences in the melting temperature of 
the DNA/ligand complex are compared with the melting temperature of the DNA alone 
and expressed as ΔTm and can provide useful data about the reactivity of ligands toward 
specific DNA sequences.   
  
The donor probe, which is always a fluorescent molecule, absorbs energy resulting in 
excitation from its ground state to an excited state within picoseconds187. If an acceptor 
molecule is located in close proximity, the emitted energy from the excited donor 
molecule is subsequently transferred to the acceptor molecule through long-range dipole-
dipole interactions (Figure 1.33)184. This process leads to a decrease of the fluorescence 
intensity of the donor molecule and an increase in the emitted fluorescence of the acceptor 








The process of energy transfer occurring in our study is an inversion of the FRET 
principle described above. The hairpin oligonucleotides were tagged on the 5'-end with 
the fluorescent donor molecule 6-carboxyfluorescein (FAM) and on the 3'-end with the 
acceptor probe 6-carboxytetramethylrhodamine (TAMRA) (Figure 1.34). TAMRA owns 
a quencher role and neutralises the emitted fluorescence of the donor probe due to the 
close proximity of both molecules. An increase in the melting temperature results in 
destabilisation of the hairpin leading to a conversion to linear single-strand. 
Consequently, this reaction removes the proximity of donor and acceptor and allows the 




Figure 1.34: The principle of the FRET assay used in this study.  
 
1.7.5 Molecular modeling 
 
Molecular modelling techniques allow for the atomic-level evaluation of a molecule’s 
shape-fit and binding affinity with a receptor. These techniques find use in establishing 
structure-activity relationships of libraries of ligands, thereby playing a role in the drug 
discovery process. The vast majority of molecular modelling techniques involve the use 
of static structures derived through crystal or NMR studies. Molecular dynamics (MD) 
simulations, on the other hand, consist of the calculation of the time-dependent behaviour 
of molecular systems, and, therefore, involve simulation of protein or DNA.  MD 
simulations are far more robust and reliable than modelling analysis alone, and have 
provided valuable information on the changes in conformations of biomolecules (for 
example proteins or nucleic acids) as predicted over a certain time-course.  
 
The field of molecular dynamics simulations has progressed rapidly through 
technological advancement. The speed of computers has doubled every two years 
('Moore’s Law'188) for the past few decades, and the use of specialised GPUs (Graphics 
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Processing Unit) and super-computers has allowed the simulation of large 
macromolecules. This has culminated in the 1 ms all-atom molecular dynamics 
simulations of BPTI (Bovine Pancreatic Trypsin Inhibitor)189 using a specially built, 
massively parallel super computer capable of simulating in orders of magnitude greater 
than standard computer systems190. Statistical mechanics is central to the concept of 
molecular dynamics simulations and it is the study of microscopic systems to produce 
macroscopic conclusions. In MD simulations, individual atoms within systems are 
simulated in order to determine features of the system. Ensembles are defined as systems 
which have different microscopic states, but identical macroscopic ones, and in order to 
simulate whole systems, averages corresponding to experimental observables are defined 
in terms of 'ensemble averages'. The central hypothesis to this is that over the course of a 
simulation, all possible macroscopic states should be simulated by different microscopic 
states, and, therefore, at the end of a simulation, the system will have passed through all 
states. From a drug discovery perspective, the simulation of a ligand with a receptor 
should result in the determination of the lowest energy conformation (and thus, most 
biologically likely) combined drug:receptor complex structure.    
 
In the case of this study, a molecular dynamics-driven approach was undertaken, as an 
MD protocol has been developed and extensively validated in this lab for use with 
pyrrolobenzodiazepine-based DNA-drug adducts139, 191. The protocol involves the 
simulation of each PBD (i.e., SJG-136, GWL-78 and anthramycin) both covalently and 
non-covalently bound to DNA over a 10ns time-course in implicit solvent. Non-
covalently bound simulations are used to visually examine the shape-fit of the molecule 
in DNA and to calculate affinity of the molecule for a particular sequence. This is 
accomplished through free energy of binding calculations. Covalently bound simulations 
are then used to both investigate degree of DNA disorder once the PBD is bound to DNA, 
and also to ascertain the most preferred guanine for alkylation through potential energy 
calculations. Using this combined approach, it has been possible to fully rationalise 
results of biophysical assays undertaken in this study.   
 
1.7.6 Polymerase Chain Reaction (PCR) 
 
PCR is a quick, inexpensive and simple tool that allows the production and detection of 
a specific DNA segment more than billion-fold from a complex pool of DNA. This 
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scientific technique is routinely used in the clinic for diagnostic purposes and in the field 
of molecular biology for a variety of applications192. Popular applications for PCR are the 
detection of hereditary diseases, identification of genetic fingerprints in forensic science, 
diagnosis of infectious diseases (e.g., HIV, hepatitis, mycoplasma or pneumonia), DNA 
cloning Southern blotting, DNA sequencing and recombinant DNA technology. PCR is 
also a valuable tool for gene sequencing, particularly those implicated in the development 
and progression of human neoplasms and this has relevance to this body of work. In 
context to the body of this work PCR was used to analyse the changes in gene expression 
profiles before and after treatment with the ligand.  
 
Four primary components are essential for PCR: a DNA sample, gene-specific primers, 
DNA building blocks and the DNA polymerase. The DNA sample serves as the template 
and contains the DNA sequence of interest to be amplified, obtained from a variety of 
tissues and organisms, such as in vitro cultivated cells or peripheral blood. Even trace 
amounts of DNA samples are sufficient to generate enough copies. Primers are short 
(typically 18-25 base pairs), sequence-specific oligonucleotides generated via chemical 
synthesis. They are sequence-specific and complementary to the DNA region of interest. 
The DNA building blocks are composed of the nucleotides adenine, guanine, thymine 
and cytosine that are crucial for the DNA polymerase in order to create the new DNA 
strand. Lastly, the DNA polymerase is the key element of the PCR. The thermostable Taq 
polymerase can withstand high temperatures required for the PCR process193. It 
assembles the single bases to a concise DNA strand on the basis of the DNA template.  
 
The PCR process consists of three consecutive steps (Figure 1.35). In the first step, also 
referred to as denaturing, the DNA sample is heated to temperatures between 90 and 97ᵒC 
leading to breakage of the hydrogen bonds between the double-stranded DNA and 
separation into two single strands (Figure 1.35). The second step, the 
annealing/hybridisation, involves sample cooling to usually 50 ᵒC which enables the 
specific primers to associate with the complementary DNA sequences (Figure 1.35). 
During the last step (the extension) the Taq polymerase adds the single nucleotides to the 
ends of the primers at 72 ᵒC, thus generating a sequence specific complementary DNA 
strand (Figure 1.35). Repetition of these three steps results in doubled copy number with 
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each cycle. However, increasing the cycle number above 35 has a little positive effect 




Figure 1.35: Principle of the polymerase chain reaction. Adapted from 
http://users.ugent.be/~avierstr/principles/pcr.html. 
 
The traditional method applied for PCR product visualization and analysis is agarose gel 
electrophoresis. The products are stained with DNA-intercalating chemicals, such as 
ethidium bromide followed by separation on an agarose gel. Smaller DNA fragments 
migrate through the gel toward the anode faster than larger strands. A DNA ladder which 
represents a predetermined set of DNA products with known sizes is injected onto the 
agarose gel simultaneously allowing size comparison with the PCR products.   
 
1.7.7 Quantitative Polymerase Chain Reaction (qPCR) 
 
Despite the significant benefits and advantages, the traditional PCR, often termed as end-
point PCR, has some limitations. The term 'End-point' simply means that the detection 
and quantification of the amplified DNA sequence are undertaken once the reaction is 
complete after the last PCR cycle using agarose gel electrophoresis and image analysis. 
The DNA-intercalating dye ethidium bromide lacks sensitivity and consequently binds to 
any double-stranded DNA present in the sample194. Moreover, the resulting end-point 
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levels of PCR products vary strongly from PCR run to run leading to inconsistent 
results195. Additionally, image analysis is dependent on the brightness of the produced 
bands which also differ from experiment to experiment. These drawbacks led to a 
refinement of the traditional PCR by Higuchi and co-workers in 1992192. The 
development of quantitative PCR (often referred to as real-time PCR) allows 
simultaneous amplification and detection of specific DNA sequences while the 
amplification is occurring, in 'real-time', utilising fluorescent technology (fluorescent 
reporters). The main advantage of qPCR is its ability to precisely and accurately 
determine the initial amount of target DNA contained in a complex mixture even if only 
a few DNA copies are present. The most common applications for qPCR are pathogen 
detection, gene expression profiling, single nucleotide polymorphism analysis, analysis 
of chromosome aberrations and also recently protein detection by real-time immune 
PCR196.  
 
The basic principle of qPCR is the introduction of fluorescent reports into the sample that 
bind to the target DNA resulting in the generation of a fluorescence signal. The 
fluorescence intensity is directly proportional to the amount of double-stranded and 
increases during the amplification progress as the DNA sequence of interest accumulates. 
Hence, the changes in fluorescence signal are monitored over the course of the reaction 
by an instrument that combines thermal cycling with fluorescence measurement.    
 
SYBR green I, an asymmetric cyanine dye, emits 1,000-fold greater fluorescence when 
it binds to the minor groove of DNA compared to its free from in solution197. Similar to 
ethidium bromide, SYBR green I lacks selectivity as it interacts with any present double-
stranded DNA.  
 
An alternative approach is the use of hydrolysis probes that are sequence-specific dually 
fluorophore-labelled short oligonucleotides198. Hydrolysis probes contain a fluorescent 
reporter molecule at the 5' end and a quencher molecule at the 3' end of the molecule, 
thereby forming a donor-acceptor pair199. In case of close proximity of the reporter and 
the quencher molecule, the quencher absorbs the fluorescence emission of the reporter 
based on the FRET principle as described in Section 1.7.4. Following attachment of the 
hydrolysis probe to the target DNA, it is cleaved from the DNA strand by the Taq 
polymerase due to its 5'-exonuclease activity during the amplification (Figure 1.36). As 
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a result, the reporter and the quencher get separated allowing the reporter’s energy and 
fluorescence to be liberated (Figure 1.36). Hydrolysis probes offer greater specificity 
because they bind specifically to the DNA segment of interest, thus only sequence-




Figure 1.36: Hydrolysis probe detection during qPCR. Adapted from 
http://eng.bioneer.com/products/geneexpression/qPCRArrayService-detection.aspx.  
 
1.7.8 Western blotting 
 
Western blotting, also known as immunoblotting, is a well-established and widely 
accepted analytical technique used in molecular biology, biochemistry and 
immunogenetics to separate and identify specific proteins from a complex protein 
mixture. Proteins can be detected in ng-range due to the high resolution of the 
electrophoresis and the high specificity and sensitivity of the immunoassay. This 
technique is of utmost importance for the investigation of ligands that specifically inhibit 
gene expression. As protein synthesis is the final process from transcription to translation, 
examination of protein profiles before and after treatment with ligands enables to 
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determine whether the DNA-binding agents indeed bind to the targeted sequences alter 
the gene expression into a favourable direction.  
 
The Western blotting procedure is composed of four major steps: SDS-PAGE, transfer 
onto the membrane, probing with antibody and detection. The complex protein samples 
originate typically from cell or tissue homogenates that first have to undergo preliminary 
treatment before continuing to separation by gel electrophoresis. Reducing agents, such 
as 6-mercaptoethanol are applied to the protein samples in order to disrupt the quaternary 
and tertiary protein structures by breaking any inter-and intra-chain disulfide and to 
linearise the proteins which is a crucial step for subsequent SDS-PAGE. Moreover, SDS, 
an anionic detergent is added to the protein samples with the aim to mask any inherent 
charge by negatively charged detergent micelles, also an essential process for SDS-
PAGE. Followed this, the protein samples are subjected to SDS-PAGE where they 
migrate toward the anode due to their negative charge and separate according to physical 
properties, including size, charge and structure. After electrophoresis the proteins are 
transferred onto a membrane, usually nitrocellulose or polyvinylidene difluoride (PVDF). 
A gel-membrane-filter sandwich is assembled with the membrane facing the gel surface 
and the anode so that the negatively charged proteins located on the gel travel through 
the membrane toward the anode when an electric current is applied. Subsequently, the 
membrane is probed with a primary antibody that specifically recognises and binds to 
proteins or epitopes on proteins. The unbound primary antibody is washed off the 
membrane and an enzyme labelled secondary antibody (e.g., horseradish peroxidase, 
HRP) is incubated with the membrane that in turn precisely interacts with the bound 
primary antibody (Figure 1.37). Addition of substrate molecules results in a reaction 
between the enzyme bound to the secondary antibody and the substrate generating 
coloured bands (Figure 1.37). Detected signals represent proteins bound to the membrane 






Figure 1.37: Graphical representation of detection during Western blotting. Adapted from 
http://employees.csbsju.edu/hjakubowski/classes/ch331/Techniques/TechElectrophoresis.htm.  
 
1.8 The aims of the project 
 
The main objective of this study was to investigate whether PBD dimers like SJG-136 
also interact with transcription factor binding sequences and exert their anti-tumour 
activity through transcription factor inhibition in addition to previously reported 
mechanisms. The aim was to develop an ion pair reversed phase HPLC/MS analytical 
methodology in order to obtain both kinetic and thermodynamic data about the adduct 
formation between the PBD dimer SJG-136 and the consensus sequences of the 
oncogenic transcription factors NF-κB, EGR-1, AP-1 and STAT3. In addition, circular 
dichroism, fluorescence resonance energy transfer DNA binding assay and molecular 
modeling simulations were used to support the HPLC/MS observations. The biological 
study utilised the traditional polymerase chain reaction, quantitative polymerase chain 




Chapter 2: Development of an ion pair reversed phase HPLC/MS 
based methodology to study the interaction between PBD monomers 





The pyrrolobenzodiazepine (PBD) dimer SJG-136 has been recently used for the 
development of a combined HPLC/MS assay to study the interaction of DNA minor-
groove binding agents with short oligonucleotides157. Traditional methods applied to date 
for evaluating the interaction between anti-cancer agents and naked DNA are mainly gel 
electrophoresis-based148. In this method, radiolabeled, drug-treated duplex DNA is 
denatured by heat, and electrophoresed on a neutral agarose gel. This process allows re-
annealing of the cross-link to duplex DNA induced by the cross-linking agent. The 
resulting adducts are then quantitated by densitometry. However, this robust and 
reproducible technique has many disadvantages, e.g. it is labour-intensive as 
radiolabelling, gel electrophoresis, imaging and densitometry steps are required. Also, no 
data relating to the rate and extent of adduct formation can be obtained from using this 
technique. In addition, a further drawback is the use of expensive and potentially harmful 
radioactivity which is necessary to label the DNA. Therefore, the main aim of this study 
was to develop a novel ion pair reversed phase HPLC (RP-HPLC) and MS based method 
which would allow the characterisation and quantitation of adducts formed between 
cognate sequences of oncogenic transcription factors and covalent DNA minor groove 
binding agents such as the PBD monomers and dimers. In contrast to the traditional 
method, this analytical technique would require only small quantities of short, 
inexpensive oligonucleotides without any use of radioactivity. Furthermore, formed 
adducts would be rapidly visualised (< 30 min) by HPLC and positively identified by 
MS. A major advantage of this newly developed technique is that both thermodynamic 
and kinetic data can be obtained relating to the rate of reaction for any given DNA 
sequence. Materials and methods used in the previously reported method are described 






Based on the above reported HPLC/MS analytical method (see Section 2.1), the aim of 
the study was to further modify this methodology so that it can be applied to study the 
interaction of PBD dimers such as SJG-136 with cognate sequences of oncogenic 
transcription factors (TFs) (Figure 2.1). For NF-B, two possible consensus sequences 
were investigated (NF-B-1 and NF-B-2).  
 
Figure 2.1: Hairpin oligonucleotides used in this study with the cognate sequences of the TFs 
NF-B-1, NF-B-2, EGR-1, AP-1 and STAT3 highlighted in red.  
 
2.3 Methodology approach 
 
The flow chart shown in Figure 2.2 summarises the overall approach. Initially, it was 
aimed to develop an ion pair reversed phase HPLC method and validate it by investigating 
the interaction of the PBD monomers GWL-78 (2, Figure 1.20) and KMR-28-39 (3, 
Figure 1.20) with the cognate sequences of the oncogenic TFs NF-B, EGR-1, AP-1 and 
STAT3 (Figure 2.1). Similarly, a MALDI-TOF-MS method was aimed to be developed 
in order to identify ligand/DNA adducts. Upon successful validation, the RP-HPLC 
method will be used to study the interaction of SJG-136 with the oncogenic transcription 
factor cognate sequences, NF-B, EGR-1, AP-1 and STAT3, followed by identification 





Figure 2.2: Flow chart of methodology approach. 
 
2.4 Method development 
 
In order to examine the reaction between PBD monomers GWL-78 (2, Figure 1.20) and 
KMR-28-39 (3, Figure 1.20) with NF-B, EGR-1, AP-1 and STAT3 consensus sequences 
(Figure 2.1), an ion pair RP-HPLC method was developed as described below. 
  
2.4.1 RP-HPLC method development 
 
Chromatography was performed on a Dionex UltiMate 3000 system from Thermo 
Scientific. The instrument was equipped with a 2.1 x 50 mm XBridge™ OST C18 column 
packed with 2.5 µm particles. The general settings used are listed in Table 2.1. The 
mobile phase consisted of 100 mM triethylammonium bicarbonate (TEAB) as buffer A 
and 40% acetonitrile in water as buffer B. The pump gradients used for HPLC analysis 

































Table 2.1: Generals setting used for the RP-HPLC study. 
 
Parameter Setting 
Run time 25 min 
Column  20 °C 
Sampler 15 °C 
UV 254 nm 





Initially, Method I was designed using the mobile phase composition listed in Table 2.2 
and Figure 2.3, and the instrument settings described in Table 2.3. The preparation 
procedure of hairpin DNA working solutions is described in Section 7.2.1.2. Following 
this, the DNA samples were subjected to ion pair RP-HPLC as described below. Based 
on previous studies with PBDs and 10-30 mer oligonucleotides157 the DNA was expected 
to elute between 7 and 18 min corresponding to 30-45% mobile phase B. 
 
Table 2.2: Mobile phase composition used for Method I. Phase A: 100 mM TEAB; Phase B: 40 
% acetonitrile. 
 
Time [min] A [%] B [%] 
0 90 10 
5 80 20 
7 70 30 
18 55 45 
20 30 70 
22 20 80 
23.5 10 90 
24 10 10 



















Figure 2.3: Graphical representation of the flow gradient used for Method I. B = 40% acetonitrile.  
 
 
Table 2.3: Parameters including their settings used for Method I. 
 
Parameter Setting 
Run time 25 min 
Column  20 °C 
Sampler 15 °C 
UV 254 nm 
Flow rate 0.5 mL/min 
Loop 200 µL 
Injection volume 50 µL 
Injection type Partial 
 
  
As anticipated, injection of the DNA sequences alone onto the HPLC column resulted in 
the chromatograms shown in Figure 2.4. The oligonucleotides were detected at the 
following retention times (RT): NF-κB-1 RT 7.505 min, NF-κB-2 RT 7.468 min, EGR-
1 RT 7.921 min, AP-1 RT 8.003 and STAT3 RT 8.533 min. Using the flow gradient 
shown in Figure 2.3, satisfactory results were achieved in terms of DNA retention times 
since all sequences eluted between 7 and 9 min. However, as visible on the individual 
chromatographic profiles (Figure 2.4), the UV intensities of the peaks were very high 
(between ca. 1600 mAU and ca. 5000 mAU) suggesting that either high concentrations 
































Figure 2.4: HPLC chromatograms of annealed NF-κB-1 (A), NF-κB-2 (B), EGR-1 (C), AP-1 
(D) and STAT3 (E) sequences using Method A. 
 
To address the high UV absorbances which were observed for Method I, two possible 
solutions were discussed: i) to reduce the concentration of the oligonucleotides by 




Previous RP-HPLC studies carried out on PBDs and short oligonucleotides have 
demonstrated that best results were achieved when a 4:1 ratio of PBD/DNA was used96, 
136, 157. Therefore, the sample injection volume was reduced in order to decrease the UV 




To reduce the sample injection volume, the previous 200 µL injection loop was changed 
to a 20 µL loop. The injected sample volume was reduced from 50 µL to 20 µL. The flow 
gradient and instrument settings were kept as shown in Table 2.2 and Figure 2.3. The 
instrument settings are listed in Table 2.4. The hairpin DNA was then subjected to HPLC 
analysis using this method. The chromatographic profiles are shown in Figure 2.5. The 
hairpin oligonucleotides were detected at the following retention times: NF-κB-1 RT 
7.318 min, NF-κB-2 RT 7.279 min, EGR-1 RT 7.654 min, AP-1 RT 7.837 and STAT3 
RT 8.339 min. The loop change and the reduction of the injection volume slightly shifted 
the DNA retention times. Similar to Method I, the retention times were satisfactory 
(between 7 min and 9 min), however, the loop change and the reduced injection volumes 
resulted in a significant decrease in the UV absorbance of each oligonucleotide (from ca. 
12.5 mAU to ca. 70 mAU) (Figure 2.5), making a precise detection and subsequent 
quantification difficult.  
 
 
Table 2.4: Parameters including their settings used for optimised Method Ia. 
 
Parameter Setting 
Run time 25 min 
Column  20 °C 
Sampler 15 °C 
UV 254 nm 
Flow rate 0.5 mL/min 
Loop 20 µL 
Injection volume 20 µL 


































Figure 2.5: HPLC chromatograms of annealed NF-κB-1 (A), NF-κB-2 (B), EGR-1 (C), AP-1 









To overcome the problem described for Method Ia, the 20 µL injection loop was changed 
back to the previous 200 µL loop and the injection volume was increased to 30 µL. The 
instrument settings used for Method Ib are described in Table 2.5. The flow gradient 
applied for Method Ib is listed in Table 2.2. Similar to the procedure carried out for 
Method I and Ia, the hairpin oligonucleotides were subjected to RP-HPLC analysis. The 
obtained chromatographic profiles are shown in Figure 2.6. The DNA hairpins were 
observed at the following retention times: NF-κB-1 RT 7.456 min, NF-κB-2 RT 7.468 
min, EGR-1 RT 7.921 min, AP-1 RT 8.026 and STAT3 RT 8.548 min. The loop change 
and the increase of the injection volume had an effect on the DNA elution times. The 
obtained retention times (between 7 and 9 min) and the UV absorbance (ca. 1000 mAU 
to ca. 1800 mAU) (Figure 2.6) for the hairpin oligonucleotides were considered as being 
satisfactory. Following this, Method Ib was used to investigate the interaction of GWL-
78 and the NF-κB-1, NF-κB-2, EGR-1, AP-1 and STAT3 sequences (Figure 2.1) as 
described in the following Section 2.4.1.1. 
 
 
Table 2.5: Parameters including their settings used for Method Ib. 
 
Parameter Setting 
Run time 25 min 
Column  20 °C 
Sampler 15 °C 
UV 254 nm 
Flow rate 0.5 mL/min 
Loop 200 µL 
Injection volume 30 µL 




































Figure 2.6: HPLC chromatograms of annealed NF-κB-1 (A), NF-κB-2 (B), EGR-1 (C), AP-1 










2.4.1.1 Interaction of GWL-78 with the cognate sequences of the oncogenic 
transcription factors NF-κB, EGR-1, AP-1 and STAT3 using Method Ib 
 
The preparation procedure of hairpin DNA working solutions is described in detail in 
Section 7.2.1.2. Working solutions of GWL-78 were prepared according to the protocol 
described in Section 7.2.1.7. GWL-78/DNA complexes were prepared as described in 
Section 7.2.1.10. Briefly, a GWL-78 working solution of 100 µM was added to a DNA 
working solution of 25 µM in a 4:1 ratio (GWL-78/DNA). The mixture was mixed and 
incubated for various time intervals at 25 °C. A time-course study was carried out from 
5 min to 24 hours by withdrawing samples at particular time points and immediate 
subjection to RP-HPLC analysis. The amount of adduct formed was calculated by 
measuring the Area Under the Curve (AUC) of the chromatographic peaks and plotted 
against the time.  
 
The results obtained from the time-course experiment conducted on GWL-78 and NF-
κB-1, NF-κB-2, EGR-1, AP-1 and STAT3 sequences are summarised in Table 2.6 and 
Figure 2.7. For NF-κB, two possible consensus sequences were studied referred to as 
NF-κB-1 and NF-κB-2. It was expected that longer incubation time would result in 
greater adduct formation unless the reaction has reached saturation and the % adduct 
formed would remain at a constant value. However, significant variations in the extent of 
adduct formation were observed for all the sequences. This inconsistency in adduct 
formation was more pronounced for the EGR-1 sequence (Table 2.6, Figure 2.7). For 
example, 1.4% adduct were formed after 5 min incubation which increased to 47.5% after 
15 min. However, the amount of adduct formed decreased to 37.4% after the 30 min 
incubation and increased again to 47.4% after the 3 hours incubation. More drastically, 
only 8% of adducts were formed after the 6 hours incubation which increased again to 










Table 2.6: Extent of adduct formation (in %) during the time-course study (5 min to 24 hours) 
carried out on the interaction of GWL-78 and NF-κB-1, NF-κB-2, EGR-1, AP-1 and STAT3 
sequences using Method Ib. 
 
Time [min] NF-κB-1 NF-κB-2 EGR-1 AP-1 STAT3 
0 0.0 0.0 0.0 0.0 0.0 
5 18.7 1.8 1.4 100.0 25.5 
10 18.0 2.6 23.6 99.8 44.5 
15 19.2 39.6 47.5 98.2 46.4 
30 16.6 30.6 37.4 73.0 45.7 
60 37.3 43.7 40.1 80.5 55.0 
120 33.7 53.4 33.4 80.2 54.9 
180 34.2 53.0 47.4 77.3 45.6 
360 45.3 62.0 8.0 81.5 45.1 
720 35.0 61.3 28.5 87.0 46.7 




























Figure 2.7:  Graphical representation showing variability in adduct formation between GWL-78 







These differences in the extent of adduct formation suggest a loss of sample during the 
injection process within the sample loop. The question was raised whether the observed 
discrepancies in the extent of adduct formation may be due to the partial-loop injection 
mode used for Method Ib. 
 
The sample loop is used to precisely measure the volume of sample to be injected. During 
HPLC two different injection modes can be applied to deliver the sample to the column, 
the partial-loop and the full-loop injection mode. The injection volume necessary for the 
partial-loop injection is less than the loop volume and should be ideally less than half the 
loop volume. The autosampler withdraws the injection volume plus 2x the cut volume 
which is specified and dependent on the desired sample volume to be injected (usually 1-
30 µL). The cut volume is positioned before and after the sample but is not injected as it 
is “cut” from the sample by the injection valve. The sample needle aspirates the specified 
injection volume plus the cut volume and transfers it to the sample loop. Following this, 
the initial mobile phase, sample and the wash solvent which is necessary for the needle 
wash are co-injected onto the HPLC column. This co-injection may lead to sample 
dilution and loss. The full-loop injection mode is more accurate and precise than the 
partial-loop injection mode as the injection volume is equal to the loop volume and the 
sample manager injects 100% of the sample loop volume. To flush the sample loop, the 
autosampler withdraws, at least, four times the volume of the sample loop from the vial 
and injects the centre of the larger sample volume. Full-loop injections deliver the best 





To investigate whether the inconsistency in the extent of adduct formation was due the 
injection mode, the previous 200 µL loop was changed to a 50 µL loop applying a full-
loop injection of 50 µL sample. The loop change was carried out to reduce the sample 
volume that is being injected as the full-loop injection mode for the 200 µL loop would 
imply a sample injection volume of 200 µL. The instrument settings used for Method Ic 
are listed in Table 2.7. The flow gradient used for Method Ic is shown in Table 2.2 and 
Figure 2.3. Following this, the hairpin oligonucleotides were subjected to RP-HPLC 
analysis according to the procedure described for Method I (see also Section 2.4.1). The 
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obtained chromatographic profiles are shown in Figure 2.8. The DNA hairpins were 
detected at the following retention times: NF-κB-1 RT 7.041 min, NF-κB-2 RT 6.948 
min, EGR-1 RT 7.450 min, AP-1 RT 7.156 and STAT3 RT 8.491 min. Similarly, the 
loop and injection mode change affected the DNA elution times compared to Method Ib. 
Using Method Ic, satisfactory results were achieved in terms of DNA retention times (7 
to 9 min) and UV absorbance (ca. 1000 mAU to ca. 1800 mAU) (Figure 2.8). Method Ic 
was then used to evaluate the interaction of GWL-78 and the NF-κB-1, NF-κB-2, EGR-
1, AP-1 and STAT3 sequences (Figure 2.1) as described in the following Section 2.4.1.2. 
 
 
Table 2.7: Parameters including their settings used for Method Ic. 
 
Parameter Setting 
Run time 25 min 
Column  20 °C 
Sampler 15 °C 
UV 254 nm 
Flow rate 0.5 mL/min 
Loop 50 µL 
Injection volume 50 µL 












































Figure 2.8: HPLC chromatograms of annealed NF-κB-1 (A), NF-κB-2 (B), EGR-1 (C), AP-1 









2.4.1.2 Interaction of GWL-78 with the cognate sequences of the oncogenic 
Transcription factors NF-κB, EGR-1, AP-1 and STAT3 using Method Ic 
 
The preparation procedure of hairpin DNA working solutions is described in Section 
7.2.1.2 in detail. Working solutions of GWL-78 were prepared according to the protocol 
described in Section 7.2.1.7. GWL-78/DNA complexes were prepared according to the 
procedure described in Section 7.2.1.10. The results obtained from the RP-HPLC study 
are summarised in Tables 2.8, 2.9, 2.10 and Figure 2.9. The time-course experiment 
showed no variations in the extent of reaction when Method Ic was applied (Figure 2.9). 
This result confirmed that the full-loop injection produced better results in terms of 
reproducibility and linearity compared to the partial-loop injection mode as discussed in 
Section 2.4.1.1 in detail.  
 
Initially, using Method Ic, each hairpin oligonucleotide (25 µM) was injected three times 
onto the HPLC in order to obtain the experimental error and investigate whether Method 
1c provides consistent retention times for each hairpin oligonucleotide. Table 2.8 shows 
the obtained RT for each oligonucleotide after three injections and the average RT in 
correspondence with their standard deviation (SD). The corresponding HPLC 
chromatograms are shown in the Appendix (Figure A2.1 Appendix). Based on these 
retention times, new peaks that appeared in the chromatographic profiles after incubation 
with SJG-136 and were also not within the SD were assumed to be SJG-136/DNA 
adducts. 
 





Sequence RT [min] Average RT [min] ± SD [min] 
NF-κB-1 7.178, 7.041, 7.006 7.075 ± 0.091 
NF-κB-2 7.198, 7.072, 6.904 7.058 ± 0.147 
EGR-1 7.673, 7.369, 7.402 7.481 ± 0.167 
AP-1 7.267, 7.278, 7.325 7.290 ± 0.031 
STAT3 8.535, 8.474, 8.328 8.446 ± 0.106 
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The data from the RP-HPLC experiments have shown that GWL-78 may interact with 
the cognate sequences of the oncogenic transcription factors NF-κB, EGR-1, AP-1 and 
STAT3 as adduct formation was observed for all studied sequences (Table 2.9, Table 
2.10 and Figure 2.9). The differences in RT between some of the DNA sequences (e.g., 
NF-κB-1, NF-κB-2 and AP-1) and the corresponding adducts are not statistically 
significant. However, subsequent MALDI-TOF analysis (after 5 min, 3 hours and 24 
hours incubation, all MALDI-TOF spectra included in the Appendix) has clearly 
confirmed that adducts had been formed. The study showed differences in extent and rate 
of reaction between GWL-78 and the DNA hairpins. For example, GWL-78 reacted 
rapidly with sequences NF-κB-1 (~42% adduct formed) (Figure A2.2B Appendix), AP-
1 (~100% adduct formed) (Figure A2.8B Appendix) and STAT3 (~42% adduct formed) 
(Figure A2.10B Appendix) after 5 min. However, as the incubation proceeded, GWL-
78 showed greater reactivity with the NF-κB-2 (~100% adduct formed after 3 hours) 
(Figure A2.4C Appendix) and AP-1 (~100% adduct formed after 3 hours) (Figure 
A2.8C Appendix) sequences whereas moderate adduct formation was observed for the 
NF-κB-1 (~51% adduct formed after 3 hours (Figure A2.2C Appendix) , ~77% adduct 
formed after 24 hours (Figure A2.2D Appendix)), EGR-1 (~10% adduct formed after 3 
hours (Figure A2.6C Appendix), ~32% adduct formed after 24 hours (Figure A2.6D 
Appendix),) and STAT3 (~43% adduct formed after 3 hours (Figure A2.10C Appendix), 
~49% adduct formed (Figure A2.10D Appendix)) sequences (Table 2.9 and Figure 
2.9). Moreover, GWL-78 formed one type of adduct with NF-κB-2 and AP-1 sequences. 
Multiple adducts were observed for NF-κB-1, EGR-1 and STAT3 sequences (Figures 
A2.2, A2.4, A2.6, A2.8, A2.10 and Table 2.10). These observations suggest a preference 
of GWL-78 toward the NF-κB-1 and AP-1 sequences. However, the differences in the 
RTs between NF-κB-1, NF-κB-2 and AP-1 sequences and the corresponding adducts 
were very small (NF-κB-1 RT 7.069 min, GWL-78/NF-κB-1 adduct mean RT 7.296 min; 
NF-κB-2 RT 7.097 min, GWL-78/NF-κB-2 adduct mean RT 7.219 min; AP-1 RT 7.206 
min, GWL-78/AP-1 adduct mean RT 7.477 min) (Figures A2.2, A2.4 and A2.8 
Appendix). This was assumed to be due to the high GC content of the hairpin 
oligonucleotides used in this study. GC-rich (more polar than AT-rich) sequences are 
very similar in polarity as their corresponding PBD/DNA adducts. As a consequence, the 
parent DNA sequences and the corresponding adducts elute at very close retention times. 
These observations were in broad agreement with previous studies where similar small 
differences (<1 min) between GC-rich DNA sequences and their corresponding 
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PBD/DNA adducts have been reported96, 200. In contrast to this, the retention time 
differences between AT-rich DNA sequences (less polar than GC-rich) and their 
corresponding adducts are bigger as the non-polar character of the PBD/DNA complex is 
increased after drug binding136. This was also the case in the current thesis when the 
reactive guanines within sequence AP-1 were consecutively replaced with the less polar 
inosine bases during the DNA-binding site analysis on the AP-1 sequence (see Chapter 
5). During this study it was observed that sequences bearing less guanine bases have 
significant differences in the retention times compared to the corresponding adducts201. 
For example, when the parent AP-1 hairpin sequence has two guanine bases replaced with 
two inosine bases (AP-1 1, 17I, Figure 5.3), the corresponding adducts show much bigger 
differences in the retention times (adduct 1 RT 12.50 min; adduct 2 RT 14.38 min) 
compared to the AP-1 1, 17I sequence alone (RT 6.50 min) (Figure 5.4). Furthermore, it 
was not conclusive whether the observed adduct peaks were only the adducts or a mixture 
of the parent DNA and the corresponding adducts. Limitations of the developed technique 
may also be an explanation for this observation. It is possible that multiple adducts had 
been formed but using the developed methodology the parent DNA and the adduct peaks 
could not accordingly be resolved. Therefore, whether the reaction between NF-κB-2 and 
AP-1 sequences and GWL-78 proceed to full extent with 100% adduct formed after 5 
min cannot be confirmed by utilising this method. Optimisation of the developed method 
has to be carried out in future studies in order to resolve those peaks. In summary, 
although no significant differences in the retention times of some DNA and their 
corresponding adducts have been observed, an indication that no adduct had been formed, 
adduct formation was positively confirmed by MALDI-TOF-MS for all studied 
sequences. Due to space limitations, as an example, only the chromatographic profiles 
obtained for the interaction of GWL-78 with the NF-κB-2 sequence using Method Ic are 
shown below (Figure 2.10). All obtained HPLC chromatograms are shown in the 
Appendix. In the chromatographic profiles for the interaction between GWL-78 and the 
EGR-1, AP-1 and STAT3 sequences, the peak area for GWL-78 is present for all studied 
sequences. However, they also show variabilities in the peak associated to the compound 
(Figures A2.6, A2.8 and A2.10 Appendix). As the reaction proceeds and more adduct is 
formed, the peak area corresponding to the compound is expected to decrease. The HPLC 
data show that in the cases for EGR-1, AP-1 and STAT3 the peak area for GWL-78 
increases, although more adduct is formed after 3 hours and 24 hours, respectively 
(Figures A2.6, A2.8 and A2.10 Appendix). This can be explained through the overall 
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detected absorbance. For example, in Figure A2.6B (Appendix) the maximum 
absorbance measured is ~1600 mAU (after 5 min incubation of GWL-78 with EGR-1 
sequence. However, in Figure A2.6D (Appendix) the maximum detected absorbance is 
only ~500 mAU (after 24 hours incubation). Hence, the peak associated to GWL-78 in 
Figure A2.6D appears much higher than in Figure A2.6D despite more adduct being 
formed. For example, the calculated AUC for GWL-78 in the HPLC chromatogram 
Figure A2.6B, C and D (Appendix) are 101.15 mAU*min (after 5 min incubation), 
80.69 mAU*min (3 hours incubation) and 72.35 mAU*min (after 24 hours). This clearly 
demonstrated that more adduct had been formed and the drug was used up despite this 
not being visible on the chromatographic profiles. If the chromatographic profiles would 
be presented in the same way (fixed maximum absorbance) then the peak corresponding 
to the compound in Figure A2.6D would appear much smaller. These data were also 
supported by the literature where the same observation was made for PBD monomers and 
dimers96, 136. 
 
Table 2.9: The extent of adduct formation between GWL-78 and the TF sequences used in this 
study (adduct formed in %) at different time points. 
 
Time [min] NF-κB-1 NF-κB-2 EGR-1 AP-1 STAT3 
5 42 6 0 100 42 
180 51 100 10 100 43 
1440 77 100 32 100 49 
 
 
Table 2.10: The number of adducts formed between GWL-78 and the TF sequences used in this 
study (adduct formed in %) after 24 hours of incubation (Figures A2.2, A2.4, A2.6, A2.8, A2.10 
Appendix). 
 
 NF-κB-1 NF-κB-2 EGR-1 AP-1 STAT3 




























Figure 2.9:  Graphical representation showing variability in adduct formation after 5 min, 3 hours 













Figure 2.10: Time-course HPLC chromatograms; (A) Annealed NF-κB-2 sequence; (B) 
Annealed NF-κB-2 sequence after incubating with GWL-78 for 5 min showing the appearance of 
one new minor peak at RT 7.183 min; (C) Annealed NF-κB-2 sequence after incubating with 
GWL-78 for 24 hours showing conversion to one main adduct at RT 7.265 min.  
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2.4.1.3 Interaction of KMR-28-39 with the cognate sequences of the oncogenic 
transcription factors NF-κB, EGR-1, AP-1 and STAT3 using Method Ic 
 
Method Ic was then applied to study the interaction of the PBD monomer KMR-28-39 
and the hairpin sequences shown in Figure 2.1. The preparation procedure of hairpin 
DNA working solutions is described in Section 7.2.1.2. Working solutions of KMR-28-
39 were prepared as described in Section 7.2.1.8. KMR-28-39/DNA complexes were 
prepared according to the procedure described in Section 7.2.1.10. The results obtained 
from the RP-HPLC study are summarised in Table 2.11 and Table 2.12. Similar to the 
results for GWL-78, the time-course study showed no fluctuations in the extent of 
reaction when Method Ic was applied, again confirming that the full-loop injection mode 
yields reproducible and linear results compared to partial-loop injection. 
 
The results from the RP-HPLC study have shown that KMR-28-39 may also be able to 
bind to the cognate sequences of the oncogenic transcription factors NF-κB, EGR-1, AP-
1 and STAT3. Adduct formation was observed for all studied sequences. In contrast to the 
study conducted on GWL-78, a similar extent of reaction was observed for all sequences 
(Table 2.11 and Table 2.12). According to the obtained chromatographic profiles 
(Figures A2.12, A2.14, A2.16, A2.18 and A2.20 Appendix), KMR-28-39 reacted the full 
extent (100% adduct formation already after 5 min incubation (Figures A2.12B, A2.14B, 
A2.16B, A2.18B and A2.20B Appendix)) and formed one main adduct with the NF-κB-
1, NF-κB-2, AP-1 and STAT3 sequences (Figures A2.12B, A2.14B, A2.18B and A2.20B 
Appendix). One major and one minor adduct was observed for the EGR-1 sequence 
(Figure A2.16B Appendix). Based on these data, KMR-28-39 demonstrated to be highly 
selective for the hairpin sequences used in this study. However, these results do not 
confirm that KMR-28-39 immediately (after 5 min) formed one adduct with the NF-κB-
1, NF-κB-2, AP-1 and STAT3 sequences, and one major and one minor adduct with the 
EGR-1 sequence as these observations were assumed to be a consequence of the 
insufficient resolution of the DNA and KMR-28-39/DNA peaks, resulting in a 
simultaneous elution of the DNA and ligand/DNA complexes from the column. 
Therefore, KMR-28-39 may form multiple adducts with the hairpin sequences used in 
this study which elute from the HPLC column at the same time due to similar polarity of 
the DNA and KMR-28-39/DNA adducts. This results in the appearance of one major peak 
and is not conclusive enough to state that KMR-28-39 has reacted to full extent with those 
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sequences after 5 min. With this consideration in mind, the HPLC data from the 
interaction of KMR-28-39 and the NF-κB-1, NF-κB-2, EGR-1, AP-1 and STAT3 need to 
be analysed with caution. As an example, only the chromatographic profiles obtained for 
the interaction of KMR-28-39 with the NF-κB-1 sequence using Method Ic are shown 
below (Figure 2.11). All obtained HPLC chromatograms are shown in the Appendix. 
Additionally, all chromatographic profiles (except for EGR-1) lack the appearance of the 
peak associated to KMR-28-39 after 5 min, 3 hours and 24 hours (Figures A2.12, A2.14, 
A2.18 and A2.20 Appendix). This was explained through the previously reported high 
reactivity of KMR-28-39 towards GC-rich DNA sequences90. Based on these data, it was 
assumed that KMR-28-39 reacted rapidly. This observation was investigated using 
MALDI-TOF mass spectrometry method. The results from this study have positively 
confirmed adduct formation after 5 min, 3 hours and 24 hours as the correct masses for 
the 1:1 KMR-28-39/DNA adducts were detected (see Section 2.4.2.1). As discussed in 
Section 2.4.1.2 in detail, the lack of the KMR-28-39 peak may also be due to the high 
detected absorbance of minimum 1000 mAU, which affects the intensity of the KMR-28-
39 peaks. 
 
Table 2.11: The extent of adduct formation between KMR-28-39 and the TF sequences used in 
this study (adduct formed in %) after a 24 hours incubation. 
 
 
 NF-κB-1 NF-κB-2 EGR-1 AP-1 STAT3 
KMR-28-39 100 100 100 100 100 
 
 
Table 2.12: The number of adducts formed between KMR-28-39 and the TF sequences used in 
this study (adduct formed in %) after 24 hours of incubation (Figures A2.12, A2.14, A2.16, A2.18 
and A2.20 Appendix). 
 
 NF-κB-1 NF-κB-2 EGR-1 AP-1 STAT3 








Figure 2.11: Time-course HPLC chromatograms; (A) Annealed NF-κB-1 sequence; (B) 
Annealed NF-κB-1 sequence after incubating with KMR-28-39 for 5 min showing the appearance 
of one new major peak at RT 7.555 min; (C) Annealed NF-κB-1 sequence after incubating with 
KMR-28-39 for 24 hours showing no further changes in the chromatographic profile with one 






2.4.2 MALDI-TOF-MS method development 
 
After completing the RP-HPLC experiments using the PBD monomers GWL-78 and 
KMR-28-39 applying Method Ic, the goal was to develop a MALDI-TOF-MS method to 
confirm the stoichiometry of the adducts formed during the HPLC study.  
 
The MALDI-TOF experiments were carried out on a Bruker Daltonics Autoflex™ 
(Bruker Daltonik) with an automated high-throughput Matrix-Assisted Laser 
Desorption/Ionisation Time of Flight (MALDI-TOF) system. A nitrogen laser in positive 
linear mode with a delayed extraction of 500 ns and an accelerating voltage of 25000 V 
was applied during this study. Acquisition was undertaken between 1000-10000 Dalton 
with 100 shots per spectrum. The instrument was calibrated prior to sample analysis using 
insulin as standard. Briefly, 1 µL insulin was spotted onto the MALDI-TOF target plate 
and naturally dried, followed by addition of 1 µL α-Cyano-4-hydroxycinnamic acid 
(CHCA) matrix. All data were processed using AutoFlex software (Bruker Daltonik). 
 
Working solutions of the hairpin oligonucleotides, ligands and ligand/DNA complexes 
were prepared according to the procedure described in Section 7.2.3.2. After incubation 
of the ligands with the DNA, the samples were diluted in 1:1, 1:4 and 1:10 ratios with 0.1 
M triethylammonium acetate buffer (TEAA). The ZipTipC18™ reversed phase sample 
preparation method shown Figure 2.12 was applied. The aim of this procedure was to 
purify and concentrate the oligonucleotide samples (femtomoles to picomoles) prior to 
MALDI-TOF analysis which yields better data quality. The samples were diluted with 
TEAA due to optimal binding and recovery of the DNA from C18 is performed in the 
presence of this ion-pairing agent. 
 
In the first step, the ZipTipC18™ was equilibrated for sample binding by aspirating and 
dispensing the equilibration solution composed of 50% acetonitrile and 0.1 M TEAA in 
a 1:1 ratio, followed by subsequent washing with a wash solution of 0.1 M TEAA. The 
equilibration and wash steps were repeated 3 to 4 times. The binding and washing of the 
oligonucleotides were carried out by aspirating the same ZipTipC18™ into the sample 
solution. In order to achieve maximum binding, this step was repeated 10 times. 
Following this, the ZipTipC18™ was washed for 3 cycles by aspirating and dispensing of 
the wash solution (0.1 M TEAA) and HPLC grade water for 3 cycles. The matrix used 
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for MALDI-TOF analysis was prepared according to the procedure described in Section 
7.2.3.1. The ligand/DNA complexes were eluted from the ZipTipC18™ and mixed with 
0.5 µL of the matrix. 0.2 µL of sample/matrix mix was spotted onto the MALDI-TOF 
target plate (MTP AnchorChip 384TF, Bruker Daltonik) and naturally allowed to dry 





























2.4.2.1 MALDI-TOF-MS study of GWL-78 and KMR-28-39 with the cognate 
sequences of oncogenic transcription factors NF-κB-1, EGR-1, AP-1 and STAT3 
 
The MALDI-TOF method (described in Section 2.4.2) was then used to confirm the 
adduct formation between GWL-78 and KMR-28-39 and the NF-κB-1, NF-κB-2, EGR-
1, AP-1 and STAT3, which was observed during the RP-HPLC study. The MALDI-TOF 
results for GWL-78 and KMR-28-39 are summarised in Table 2.13. All MALDI-TOF 
spectra are shown in the Appendix. The MALDI-TOF spectra obtained showed for both 
ligands and all studied sequences the correct molecular weight for the 1:1 ligand/DNA 
adducts (Table 2.13). For all studied DNA sequences adduct formation was observed 
after 5 min, 3 hours and 24 hours incubation with both ligands, GWL-78 (Figures A2.3, 
A2.5, A2.7, A2.9 and A2.11) and KMR-28-39 (Figures A2.13, A2.15, A2.17, A2.19 and 
A2.21). Based on the detected masses, the adducts formed between the ligands and the 
hairpin oligonucleotide were assumed to be the 1:1 ligand/DNA adducts, since the 
binding of the ligands to one guanine prevents further ligand association to the DNA 
sequence. Two examples of the obtained MS spectra are shown in Figure 2.13. Based on 
the chromatographic profiles it was anticipated that the SJG-136/DNA adduct peaks 
would have higher intensities compared to the parent DNA as more adduct is formed 
while the reaction proceeded. Interestingly, the MALDI-TOF results contrasted to this 
anticipation as higher intensity peaks were observed for the parent hairpins whereas the 
SJG-136/adduct peaks were of lower intensity. This indicated the presence of higher 
DNA content in the sample than the formed SJG-136/DNA adduct. Previous studies 
carried out on the interaction of SJG-136 with short oligonucleotides have shown that 
during the MALDI-TOF process the formed adduct separates into the parent DNA and 
SJG-136 resulting in a higher peak for the DNA and a smaller peak for the formed SJG-
136/DNA adduct136, 157, 202. Figure 2.14 demonstrates that although the reaction between 
the 12 bp dsDNA and SJG-136 had nearly gone to completion in the HPLC study (~95.5% 
adduct formed after 24 hours), only a small peak for the 1:1 SJG-136/DNA adduct (m/z 
7844.5) was detectable in the MALDI-TOF spectra157. This previous observation was in 
broad agreement with the MALDI-TOF results obtained in this study. Moreover, past 
studies have demonstrated that PBD molecules do not bind to single stranded DNA, as 
they require a minor groove environment for covalent attachment125. Consequently, it 
possible that not annealed, linear DNA is still present in the sample that is detected by 
MALDI-TOF, therefore contributing to the peak intensity of the detected DNA peak157. 
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All of the aspects mentioned in the discussion above may enhance the MALDI-TOF 
signals for the parent DNA and therefore, explain the appearance of MALDI-TOF DNA 
peaks of high intensities compared to SJG-136/DNA formed adducts. 
  
Table 2.13: Theoretical and observed masses [Da] of single-stranded hairpin oligonucleotides 
















Figure 2.13: A, MALDI-TOF spectrum of GWL-78/NF-κB-2 (after a 24 hours incubation) 
confirming the stoichiometry of the 1:1 adduct formed (NF-κB-2 observed mass: 7034.3 m/z, 
theoretical mass: 7033.6 m/z, NF-κB-2 adduct observed mass: 7625.1 m/z, theoretical mass: 
7624.2 m/z); B, MALDI-TOF spectrum of KMR-28-39/ NF-κB-1 (after a 24 hours incubation) 









Figure 2.14: MALDI-TOF spectra confirming the identity of SJG-136 forming adduct with 12 
bp long dsDNA. (A) MALDI–TOF MS spectrum of dsDNA alone showing that dsDNA separates 
into the corresponding single stranded DNA under the MALDI-TOF conditions. (B) MALDI–
TOF MS spectrum of the 1:1 SJG-136/dsDNA adduct. The ion at m/z 7844.5 corresponds to the 
[M+H]+ ion of the SJG-136/dsDNA adduct, and the ions at 7284.3 and 3644.8 correspond to 
[M+H]+ ions of dsDNA and ssDNA, respectively, formed by in source fragmentation. 
 
2.5 Summary of RP-HPLC/MS method development 
 
In summary, after the development of a suitable RP-HPLC/MALDI-TOF method, it was 
applied to study the interaction of the PBD monomers GWL-78 and KMR-28-39 with the 
cognate sequences of the oncogenic transcription factors NF-κB, EGR-1, AP-1 and 
STAT3, which have recently been demonstrated to interact with consensus transcription 
factor sequences90, 102. The results obtained indicated that both ligands may bind to the 
NF-κB, EGR-1, AP-1 and STAT3 sequences. In all experiments adduct formation was 
observed during the RP-HPLC study and their 1:1 stoichiometry subsequently confirmed 
by MALDI-TOF-MS. These data validated the developed method and demonstrated that 
it may be suitable for its application in future studies. Following method validation, it 
was used to investigate the interaction of the PBD dimer SJG-136 with the same hairpin 
sequences. The results obtained from this study are presented in the following chapter 
(Chapter 3).   
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Chapter 3: Evaluation of the interaction of the PBD dimer SJG-136 





The main aim of this study was to investigate the interaction of the PBD dimer SJG-136 
with the cognate sequences of the oncogenic transcription factors NF-κB, EGR-1, AP-1 
and STAT3 (Figure 3.1) using the HPLC/MS analytical method developed in Chapter 2. 
These particular consensus transcription factor sequences were selected for the study as 
they are known to play a crucial role in the development of human malignancies and to 
be over-expressed in human cancer types in which SJG-136 has demonstrated to be highly 
efficient158. For example, NF-κB is over-expressed in most leukaemias, STAT3 in breast 
cancer and EGR-1 and AP-1 in ovarian cancer. Extensive studies have been carried out 
to evaluate the cytotoxicity of SJG-136 on a panel of human tumour cell lines158. The 
agent exhibited LC50 (median lethal concentration) values ranging from 0.14 to 320 
nmol/L158. The results clearly demonstrated selectivity of SJG-136 toward particular cell 
lines and could not be explained through the previously reported mechanism of action, 
including DNA strand breakage94, inhibition of enzymes101, 203 and arrest of the 
replication fork. Moreover, the NCI cell line screen has revealed an activity pattern for 
SJG-136 similar to some reported DNA-binding agents (e.g., melphalan, 
cyclophosphamide, chlorambucil). However, its overall profile did not exactly match 
with cluster patterns associated with any specific chemotherapeutic agents, hence 
assuming a unique mechanism of action of SJG-136.  
 
Therefore, new data relating to any potentially additional mechanism of action of SJG-
136 could help to understand and explain the previously observed differences in activity 
between various human cancer types (e.g., in vitro 60 Cell Line Screen158). To address 
this issue, in our study, SJG-136 was incubated with the hairpin forming oligonucleotides 
depicted in Figure 3.1 at 25 ºC for various time intervals, followed by subjection to ion 
pair reversed phase HPLC analysis. The extent and rate of adduct formation were 
calculated by measuring the area under the curve (AUC). The stoichiometry of adducts 
formed was confirmed by MALDI-TOF-MS analysis based on the molecular weight. The 
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fluorescence resonance energy transfer (FRET) DNA melting assay, circular dichroism 
(CD) experiments and molecular dynamics simulations were used to gain insight into 
adduct formation and support HPLC/MS observations. 
 
Figure 3.1: Hairpin oligonucleotides used in this study with the cognate sequences of the 
transcription factors NF-κB (two possible sequences were studied, in this study referred to as NF-
κB-1 and NF-κB-2), EGR-1, AP-1 and STAT3 highlighted in red. 
 
3.2 HPLC/MS study 
 
Reversed phase HPLC has been used to study the extent and rate of adduct formation 
between SJG-136 and the DNA sequences depicted in Figure 3.1. According to the 
method developed in Chapter 2 (Method Ic), first each hairpin sequence was injected onto 
the HPLC to obtain reference peaks. SJG-136 was then incubated with each hairpin DNA 
and subjected to HPLC analysis. In the case of adduct formation new peaks emerge in the 
chromatographic profiles in addition to the parent DNA sequence which differ in their 
RTs compared to the DNA reference peaks (see error analysis in Section 2.4.1.2. In a 
similar fashion, each hairpin sequence was subjected to MALDI-TOF analysis to obtain 
reference peaks. The SJG-136/DNA mixture was subsequently subjected to MALDI-
TOF-MS for stoichiometry identification. Similar to the MS spectra obtained in Chapter 
2, the parent DNA appears with high intensity in the MS spectra of the incubation 
mixture. This is discussed in Section 2.4.1.2 in detail. Additional HPLC chromatograms 
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(5min incubation) and MALDI-TOF spectra (5 min and 3 hours incubation) are shown in 
the Appendix. 
 
3.2.1 Results and discussion 
 
NF-κB-1 sequence (Figure 3.1) was annealed according to the procedure described in 
Section 7.2.1.2. NF-κB-1 sequence alone gave a single peak at RT 7.069 min (Figure 
3.2A) and a m/z of 7033.1 m/z (theoretical mass: 7032.6 m/z). After incubation with SJG-
136 at 25 ºC in a 4:1 ratio (SJG-136/DNA) for various time intervals, two new minor 
peaks gradually emerged after 3 hours at RT 7.436 min and RT 8.169 min with 
approximately 16.6% adduct formed (Figures 3.2B and C). The 1:1 stoichiometry of the 
two new peaks was confirmed by MALDI-TOF-MS (observed mass: 7590.6 m/z; 
theoretical mass: 7589.2 m/z) as the SJG-136/NF-κB-1 adduct (Figure 3.2D). Based on 
the detected mass, the formed adduct was assumed to be the 1:1 SJG-136/NF-κB-1 adduct 








Figure 3.2: A, HPLC chromatogram showing the annealed NF-κB-1 sequence at RT 7.069 min; 
B, Annealed NF-κB-1 sequence after incubating with SJG-136 for 3 hours; C, annealed NF-κB-
1 sequence after incubating with SJG-136 for 24 hours showing the appearance of two minor 
peaks at RT 7.436 min and RT 8.169 min with the reaction incomplete; D, MALDI-TOF spectrum 
of SJG-136/NF-κB-1 (after a 24 hours incubation) confirming the identity of adduct formation 
(NF-κB-1 observed mass: 7033.1 m/z, theoretical mass: 7032.6 m/z, NF-κB-1 adduct observed 
mass: 7590.6 m/z, theoretical mass: 7589.2 m/z). 
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Next, NF-κB-2 sequence (Figure 3.1) was annealed according to the procedure described 
in Section 7.2.1.2.  Injection onto the HPLC column of NF-κB-2 sequence alone resulted 
in the appearance of a single peak at RT 7.097 min (Figure 3.3A) which was identified 
by MALDI-TOF-MS (7033.1 m/z). Following incubation with SJG-136 at 25 ºC in a 4:1 
ratio (SJG-136/DNA) a new minor peak at RT 7.223 min emerged during the time-course 
study accounted for approximately 43% after the 24 hours incubation (Figures 3.3B and 
C). The 1:1 stoichiometry of the SJG-136/DNA adduct was confirmed by MALDI-TOF-
MS (observed mass: 7590.7 m/z, theoretical mass: 7590.2 m/z) (Figure 3.3D). Similar to 
NF-κB-1 sequence, the observed mass of the formed adduct suggested that the 1:1 SJG-
136/NF-κB-2 adduct was formed as the binding of the ligand prevents a further molecule 






Figure 3.3: A, HPLC chromatogram showing the annealed NF-κB-2 sequence at RT 7.097 min; 
B, Annealed NF-κB-2 sequence after incubating with SJG-136 for 3 hours; C annealed NF-κB-2 
sequence after incubating with SJG-136 for 24 hours showing the appearance of one minor adduct 
peak at RT 7.223 min with the reaction incomplete; D, MALDI-TOF spectrum of SJG-136/NF-
κB-2 (after a 24 hours incubation) confirming the identity of adduct formation (NF-κB-2 observed 
mass: 7033.1 m/z, theoretical mass: 7033.6 m/z, NF-κB-2 adduct observed mass: 7590.7 m/z, 
theoretical mass: 7590.2 m/z). 
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EGR-1 sequence was annealed according to the procedure described in Section 7.2.1.2. 
In a similar experiment EGR-1 (Figure 3.1) was incubated with SJG-136 at 25 ºC in a 
4:1 ratio (SJG-136/DNA) for different time points. Initially, EGR-1 sequence alone 
provided a single peak at RT 7.539 min (Figure 3.4A) with an observed mass of m/z 
6416.9 (theoretical mass: 6416.2 m/z). After 3 hours incubation, a new minor peak at RT 
8.469 min gradually emerged with approximately 28% adduct formation after 24 hours 
(Figures 3.4B and C). The 1:1 stoichiometry of the new peak was confirmed by MALDI-
TOF-MS (observed mass: 6973.3 m/z, theoretical mass: 6972.8 m/z) as the SJG-
136/EGR-1 adduct (Figure 3.4D). Analogous to NF-κB-1 and NF-κB-2 sequences, the 
detected mass of the formed adduct indicated that the ligand binds to the DNA and 






Figure 3.4: A, HPLC chromatogram showing the annealed EGR-1 sequence at RT 7.539  min; 
B, Annealed EGR-1 sequence after incubating with SJG-136 for 3 hours; C annealed EGR-1 
sequence after incubating with SJG-136 for 24 hours showing the appearance of one minor adduct 
peak at RT 8.469 min with the reaction incomplete; D, MALDI-TOF spectrum of SJG-136/EGR-
1 (after a 24 hours incubation) confirming the identity of adduct formation (EGR-1 observed 
mass: 6416.9 m/z, theoretical mass: 6416.2 m/z, EGR-1 adduct observed mass: 6973.3 m/z, 
theoretical mass: 6972.8 m/z). 
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AP-1 sequence was annealed according to the procedure described in Section 7.2.1.2. 
Annealed AP-1 sequence (Figure 3.1) gave a single peak in the HPLC chromatogram at 
RT 7.306 min (Figure 3.5A) identified by MALDI-TOF-MS. Incubation with SJG-136 
at 25 °C in a 4:1 ratio (SJG-136/DNA) resulted in a rapid appearance of a new major peak 
at RT 7.494 min after 3 hours with 100% adduct formation (Figure 3.5B). No further 
changes were observed in the chromatographic profiles following the 3 hours incubation 
indicating reaction had gone to completion (Figure 3.5C). The stoichiometry of the 
adduct was confirmed as 1:1 SJG-136/AP-1 by MALDI-TOF-MS with an observed mass 
of 6351.2 m/z (theoretical mass: 6350.4 m/z) (Figure 3.5D). Similar to the other 







Figure 3.5: A, HPLC chromatogram showing the annealed AP-1 sequence at RT 7.306  min; B, 
Annealed AP-1 sequence after incubating with SJG-136 for 3 hours showing the appearance of a 
new major peak at RT 7.494 min with the reaction complete; C annealed AP-1 sequence after 
incubating with SJG-136 for 24 hours showing no further changes with the adduct peak at RT 
7.532 min remaining; D, MALDI-TOF spectrum of SJG-136/AP-1 (after a 24 hours incubation) 
confirming the identity of adduct formation (AP-1 observed mass: 5794.8 m/z, theoretical mass: 
5793.8 m/z, AP-1 adduct observed mass: 6351.2 m/z, theoretical mass: 6350.4 m/z). 
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STAT3 sequence was annealed according to the procedure outlined in Section 7.2.1.2. 
HPLC analysis of the STAT3 sequence (Figure 3.1) gave a single peak at RT 8.452 min 
(Figure 3.6A) which provided the correct m/z (6413.7) for this oligonucleotide by 
MALDI-TOF-MS. Following incubation with SJG-136 at 25 °C in a 4:1 ratio (SJG-
136/DNA), three new minor peaks appeared in the HPLC chromatogram at RT 9.314 
min, 10.296 min and RT 11.985 with approximately 14% adduct formation after 24 hours 
(Figure 3.6B and C). The adduct stoichiometry was confirmed by MALDI-TOF-MS as 
1:1 SJG-136/STAT3 based on an observed mass of 6968.9 m/z (theoretical mass: 6968.8 
m/z) (Figure 3.6D). The observed mass of a 1:1 SJG-136/STAT3 adduct indicated that 







Figure 3.6: A, HPLC chromatogram showing the annealed STAT3 sequence at RT 8.452  min; 
B, Annealed STAT3 sequence after incubating with SJG-136 for 3 hours; C annealed STAT3 
sequence after incubating with SJG-136 for 24 hours showing the appearance of three minor 
adduct peaks at RT 9.314 min, RT 10.296 min and RT 11.985 with the reaction incomplete; D, 
MALDI-TOF spectrum of SJG-136/STAT3 (after a 24 hours incubation) confirming the identity 
of adduct formation (STAT3 observed mass: 6413.7 m/z, theoretical mass: 6412.2 m/z, STAT3 
adduct observed mass: 6968.9 m/z, theoretical mass: 6968.8 m/z). 
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The results obtained from the HPLC/MS study indicate that SJG-136 may be capable of 
binding to NF-κB, EGR-1, AP-1 and STAT3 consensus sequences. Based on the 
developed HPLC method, adduct formation was observed for all studied sequences, 
providing the correct molecular weight for the 1:1 SJG-136/DNA adducts by MALDI-
TOF-MS (Table 3.1). 
 
Table 3.1: Theoretical and observed masses [Da] of single-stranded hairpin oligonucleotides and 





Surprisingly, the data revealed significant differences in extent of adduct formation 
between the individual sequences although their guanine content is comparable (Table 
3.2). SJG-136 rapidly formed an adduct with NF-B-2 sequence (~43% adduct formed 
after 24 hours) and AP-1 sequence (~100% adduct formation after 5 min) while it reacted 
moderately with the EGR-1 sequence (~28% adduct formed after 24 hours), slowly with 
the NF-κB-1 sequence (~16% adduct formed after 24 hours) and STAT3 sequence (~14% 
adduct formation after 24 hours) (Figure 3.7In a similar fashion, the extent of adduct 
formation starkly contrasted between the NF-B-1 and NF-B-2 sequences although both 
sequences differ in only one guanine, eight and nine respectively. Interestingly, SJG-136 
appeared to be highly reactive towards the AP-1 sequence, containing four guanines while 
it has shown low reactivity towards the STAT3 sequence which comprises five guanines. 
However, similar to the observation made on the interaction between GWL-78 and KMR-
28-39 (see Sections 2.4.1.2 and 2.4.1.3) the difference in the RT for the AP-1 sequence 
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and the corresponding adduct was observed to be very small. This minimal difference 
makes it difficult to state that SJG-136 reacted with sequence AP-1 to full extent after 5 
min. This observation may be due to the insufficient resolution of the solvent system used 
in this method. Therefore, SJG-136 may have not reacted to the full extent with the AP-
1 sequence, but due to the similar polarities of the parent AP-1 sequence and SJG-
136/AP-1 adduct they elute simultaneously, resulting in one major peak. Furthermore, as 
for GWL-78 and KMR-28-39, very small differences in the RTs between DNA (e.g., NF-
B-1, NF-B-2 and AP-1) and SJG-136/DNA adducts were observed. This has been 
discussed in Section 2.4.1.2 in detail. As in the case of GWL-78 and KMR-28-39, all 
MALDI-TOF spectra showed the appearance of the parent DNA. This has been discussed 
in Section 2.4.2.1 in detail. 
 
Table 3.2: Extent of adduct formation after 24 hours SJG-136 with transcription factor sequences 
NF-κB-1, NF-κB-2, EGR-1, AP-1 and STAT3 (formed adduct in %). 
 
 
 NF-κB-1 NF-κB-2 EGR-1 AP-1 STAT3 










Figure 3.7:  Graphical representation showing variability in adduct formation between SJG-136 
and different transcription factor binding sequences NF-κB-1, NF-κB-2, EGR-1, AP-1 and 
STAT3.  
 
Equally important are the observed differences in the rate of adduct formation (Table 
3.3). Previous studies have demonstrated that SJG-136 can form interstrand crosslinks at 
Pu-GATC-Py, longer interstrand cross-links at Pu-GAATC-Py, intrastrand cross-linked 
adducts at Pu-GATG-Py, and longer intrastrand links at Pu-GAATG-Py sequences (rank 
order: Pu-GAAT > Pu-GATC-Py >> Pu-GATG-Py > Pu-GAATC). In addition, SJG-136 
is capable of forming mono-alkylated adducts with only one PBD unit covalently bound 
at sequences that contain suitable PBD binding sites but where neither inter- nor intra-
strand cross-links are feasible due to the unavailability of two appropriately positioned 
guanines96. Surprisingly, on the basis of our HPLC results SJG-136 formed three distinct 
adducts with the STAT3 sequence, two different adduct types with the NF-κB-1 sequence, 
while only single adducts were determined. In the case of NF-B-2, EGR-1 and AP-1 
sequences. These results suggest that SJG-136 favours one particular binding site within 
NF-κB-2, EGR-1 and AP-1 sequences as only one particular type of adduct had been 





Table 3.3: Number of adducts observed after 24 hours between SJG-136 and the transcription 
factor sequences NF-κB-1, NF-κB-2, EGR-1, AP-1 and STAT3 (number of adducts formed). 
 
 NF-κB-1 NF-κB-2 EGR-1 AP-1 STAT3 
SJG-136 2 1 1 1 3 
 
 
With the NF-κB-1 sequence, SJG-136 can form various types of adducts such as mono-
alkylated adducts, inter- and intrastand cross-links as this sequence contains multiple 
binding sites for SJG-136. Within NF-κB-1 sequence mono-adducts can be formed at G2, 
G3, G7, G15, G16 and G19. An interstrand cross-link is likely to appear between G7 and 
G19. Lastly, G3 and G7 are favourable for an intrastrand interaction between SJG-136 
and NF-κB-1 sequence. According to previous reports, guanines located at the 5'- or 3'-
end are not suitable binding sites for SJG-136 as the ligand would have to protrude 
beyond the 5'- or 3'-end of the hairpin with a loss of DNA/ligand stabilising interactions96, 
and therefore G1 is unfavourable for SJG-136 binding. Furthermore, the interaction 
between SJG-136 and the guanine at G14 are not expected to occur due to proximity of 
the guanine base to the TTT-loop which will result in steric interference. Although within 
the NF-κB-1 sequence various guanines are available for a covalent attachment of SJG-
136, we have observed that only two particular types of adducts had been formed 
suggesting two preferred binding sites of SJG-136. 
 
SJG-136 can bind to sequence NF-κB-2 and form mono-alkylated adducts at G2, G3, G4, 
G5, G8, G15 and G17. An interstrand cross-link is likely to appear between G5 and G15. 
G4, G17 and G5 and G8 are suitable binding sites for an intrastrand interaction between 
SJG-136 and NF-κB-2 sequence. Similarly, to NF-κB-1 sequence, within NF-κB-2 
sequence G1 is not a favourable binding position for SJG-136 due to its 5'-end location 
as well as G14 which resides next to the TTT-loop. It was surprising given that, although 
many different adduct types may be formed between SJG-136 and NF-κB-2 sequence 
only one particular adduct had been formed. Moreover, the data suggests that SJG-136 
has a higher affinity toward the NF-κB-2 sequence compared to NF-κB-1 sequence 




Analogous to NF-κB-1 and NF-κB-2 sequences, EGR-1 sequence is also guanine rich 
and contains several suitable binding sites for SJG-136. Mono-alkylation within EGR-1 
sequence may occur at G3, G4, G5, G6, G7, G14 and G20. An interstrand cross-linked 
adduct may be formed between G14 and G4 or G5, and G20 and G6 or G7. Finally, G3 
and G7 are favourable positions for an intrastrand cross-linked adduct. Presumably, SJG-
136 does not to bind to G1 located at the 5'-end of EGR-1 sequence as this would require 
the ligand to protrude beyond the sequence in a similar fashion to NF-κB-1 and NF-κB-
2 sequences. Furthermore, binding to G9 is not expected as steric interference may appear 
due to the proximate location of the guanine to the TTT-loop. In accordance with 
observations made for NF-κB-1 and NF-κB-2 sequences, SJG-136 formed only a single 
type of adduct with the EGR-1 sequence despite various favourable binding sites. This is 
again further support for the sequence selectivity and specific binding profile of SJG-136. 
 
The most striking results were obtained for AP-1 with 100% adduct formation after 5 min 
incubation with SJG-136 and one main adduct formed (Figure 3.5 and 3.7). This suggests 
that SJG-136 favours a specific binding site within AP-1 sequence due to the observed 
extent and rate of adduct formation compared to the NF-κB, EGR-1 and STAT3 
sequences (Figure 3.7). Similar to the other sequences, also with the AP-1 sequence SJG-
136 can form various adducts. Mono-alkylation within the AP-1 sequence may occur at 
G7 and G17. Interstrand cross-links can be formed at G7 and G17. It is not expected 
(based on previous literature results) that SJG-136 interacts with G1 at the 5'-end of AP-
1 sequence for the same reasons discussed for NF-κB and EGR-1 sequences. 
Additionally, G12 is not a favourable binding site for the ligand as steric interference may 
occur due to its nearby location to the TTT-loop.  
 
The rapid rate of adduct formation within AP-1 sequence led us to investigate in detail 
the binding site of SJG-136 in order to identify the guanine which is responsible for the 
binding behaviour of SJG-136. To address this issue, the guanines were subsequently 
replaced with inosine bases which lack the nucleophilic NH2 group and, therefore, prevent 
SJG-136 from binding to the sequence. The results obtained from this study are presented 
in Chapter 5. 
 
SJG-136 demonstrated low reactivity toward STAT3 sequence due to slow reaction 
(approximately 14% adduct formed after 24 hours incubation) and the appearance of 
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multiple adducts (Figure 3.6 and 3.7). Mono-alkylation within STAT3 sequence may 
occur at G5, G6, G7, G18 and G19ss. Interstand cross-linked adducts may be formed 
between G18 and G6 or G7 and G7 and G18.  
 
In order to rationalise the type of adducts formed with sequences NF-κB, EGR-1, AP-1 
and STAT3, molecular dynamics simulations and free energy binding calculations were 
undertaken, and these will be discussed in greater detail in Section 3.5.  
 
3.2.2 Summary of HPLC/MS study 
 
Taken together, the HPLC/MS study has indicated that SJG-136 may be capable of 
binding to the cognate sequences of the transcription factors NF-κB, EGR-1, AP-1 and 
STAT3. Adduct formation was observed during the HPLC study for all studied 
sequences. The stoichiometry of the adducts formed was subsequently confirmed by 
MALDI-TOF-MS. Interestingly, the data revealed significant differences in rate and 
extent of adduct formation Figure 3.7, Table 3.2 and 3.3. The ligand appeared to react 
rapidly with the AP-1 (~100% adduct formation after 24 hours), moderately with the NF-
κB-2 (~43% adduct formed after 24 hours) and EGR-1 (~28% adduct formation after 24 
hours) and slowly with the NF-κB-1 (~17% adduct formed after 24 hours) and STAT3 
(~14% adduct formation after 24 hours) (Figure 3.7). Limitations of the developed 
method and their effects on the results obtained for the AP-1 sequence have been 
discussed above. Moreover, multiple adducts have been detected for STAT3 and NF-κB-
1 sequences, three and two, respectively whereas only one type of adduct was formed 
with the NF-κB-2, EGR-1 and AP-1 sequences (Table 3.3) although multiple suitable 
binding sites for SJG-136 are available within these sequences. This result suggests a 
preferred binding site of SJG-136 within NF-κB-2, EGR-1 and AP-1 sequences.  
 
The observed differences in reactivity of SJG-136 toward the consensus sequences of the 
transcription factors NF-κB, EGR-1, AP-1 and STAT3 had previously not been reported 
and were assumed not to vary in this extent. The high reactivity of SJG-136 toward AP-
1 sequence was particularly surprising, as it means that the ligand must favour AP-1 
cognate sequence over NF-κB, EGR-1 and STAT3. From these results it was concluded 
that SJG-136 exhibits better sequence-selectivity than originally thought as it appeared to 
react to full extent with one adduct formed with the AP-1 consensus sequence. 
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Taken together, the HPLC/MS study has indicated that SJG-136 may be able to bind to 
the consensus sequences of NF-κB, EGR-1, AP-1 and STAT3 transcription factors. 
Remarkable differences in extent and rate of adduct formation have been observed for 
individual sequences. This surprising result is of utmost importance as it adds new data 
on the overall mechanism of action of SJG-136, and in addition can help to understand 
the previously reported differences in activity of SJG-136 in various human tumour cell 
lines.  
 
3.3 FRET study 
 
The DNA-binding affinity of SJG-136 toward the NF-κB-1, NF-κB-2, EGR-1, AP-1 and 
STAT3 sequences was examined using the FRET DNA melting assay. DNA binding 
agents stabilise the secondary structure of DNA upon binding which results in an increase 
in the melting temperature of the ligand-DNA complex. The differences in the melting 
temperature of the DNA/ligand complex are compared with the melting temperature of 
the DNA alone and expressed as ΔTm. During the FRET experiment the process of 











3.3.1 Results and discussion 
 
Working solutions of DNA, SJG-136 and SJG-136/DNA complexes were prepared 
according to the procedure described in Section 7.2.5. The melting temperatures of each 
sequence before treatment with SJG-136 are shown in Table 3.4. All FRET melting 
curves are shown in the Appendix. The melting temperatures of the NF-B-1, NF-B-2 
and EGR-1 sequences are very high (>75 °C). Therefore, it is difficult to interpret the 
FRET data for the NF-B-1, NF-B-2 and EGR-1 sequences. However, the melting 
temperatures of the AP-1 and STAT3 show appropriate melting values. 
 
Table 3.4: Average melting temperature [°C] of the hairpin sequences alone during the FRET 
study. 
 
NF-κB-1 NF-κB-2 EGR-1 AP-1 STAT3 
78.5 83.4 83.1 67.6 60.8 
 
 
For NF-κB-1 sequence, SJG-136 exhibited greater binding affinity at higher 
concentrations of 50 µM and 100 µM with an observed ΔTm of 17.6 °C and was less 
effective in stabilising NF-κB-1 sequence at lower concentrations of 0.1 µM, 1.0 µM and 
10 µM with an observed increase in ΔTm of < 1 °C) (Table 3.5). The similar ΔTm values 
at 50 µM and 100 µM suggest saturation of binding to NF-κB-1 at 50 µM.  
 
 
Table 3.5: ΔTm [°C] differences of NF-κB-1, NF-κB-2, EGR-1, AP-1 and STAT3 sequences after 






Similar stabilising effect of SJG-136 was observed for the NF-κB-2 sequence (Table 3.5). 
At ligand concentrations of 50 µM and 100 µM the ΔTm increased up to ~11 ºC with no 
stabilisation effect upon ligand binding at lower concentrations (Figure 3.9). Compared 
to NF-κB-1 sequence, SJG-136 demonstrated a lower stabilising effect on NF-κB-2 
sequence at higher concentrations of 50 µM and 100 µM (NF-κB-1 sequence ΔTm = 17 
ºC, NF-κB-2 sequence ΔTm = 11 ºC). Moderate stabilisation of NF-κB-2 sequence was 
achieved at 10 µM SJG-136 with ΔTm of 3.27 ºC compared to NF-κB-1 sequence with 





















Figure 3.9: Graphical representation of ΔTm [°C] differences of NF-κB-1, NF-κB-2, EGR-1, AP-
1 and STAT3 sequences after incubation with SJG-136 for 24 hours at various concentrations.  
 
Analogous to NF-κB-1 and NF-κB-2 sequences an increase in ΔTm of the formed SJG-
136/EGR-1 complex was observed at SJG-136 concentrations of 50 µM (ΔTm ~6.66 ºC) 
and 100 µM (ΔTm ~10.63 ºC) (Table 3.5). In contrast to NF-κB-1 and NF-κB-2 sequences 
no saturation of DNA binding appeared at 50 µM as the ΔTm of ~6.66 ºC at 50 µM 
elevated to ~10.63 ºC at 100 µM. Similar to NF-κB-1 sequence, at low concentrations of 
0.1 µM, 1.0 µM and 10 µM SJG-136 exhibited low DNA binding ability with no increase 
in ΔTm (Table 3.5 and Figure 3.9). 
 
The FRET results have demonstrated that SJG-136 exhibited the greatest stabilisation 
effect on AP-1 sequence (Table 3.5 and Figure 3.9). An increase in the melting 
temperature of the SJG-136/AP-1 complex of ~20 ºC was observed already at SJG-136 
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concentrations of 10 µM. This contrasted starkly with the ΔTm values obtained for NF-
κB-1, NF-κB-2, EGR-1 and STAT3 sequences where a ligand induced DNA stabilisation 
effect was achieved starting from 50 µM. The ΔTm values for AP-1 sequence at 10 µM, 
50 µM and 100 µM SJG-136 remained at a similar value of ~20 ºC indicating maximum 
binding of SJG-136 to AP-1 sequence at these concentrations. Similar to NF-κB-1, NF-
κB-2, EGR-1 and STAT3 sequences SJG-136 exhibited a very little stabilising effect on 
AP-1 sequence at low concentrations of 0.1 µM and 1.0 µM. The FRET results were in 
broad agreement with our observations made during the HPLC/MS study where SJG-136 
rapidly formed one main adduct with the AP-1 hairpin sequence. These data further 
support the observed preference of SJG-136 for the AP-1 consensus sequence. 
 
During the FRET study SJG-136 was demonstrated to have the lowest stabilising ability 
on STAT3 sequence compared to NF-κB-1, NF-κB-2, EGR-1 and AP-1 sequences 
(Table 3.5 and Figure 3.9). Moderate elevation of the SJG-136/STAT3 complex melting 
temperature was measured at 50 µM and 100 µM SJG-136 with ΔTm ~3.17 ºC and ~4.57 
ºC, respectively whereas for the other sequences the ΔTm values at 100 µM SJG-136 
increased at least up to 10 ºC (Table 3.5). As anticipated, no remarkable increase in ΔTm 
could be determined at 0.1 µM, 1.0 µM, and 10 µM SJG-136. These results correlated 
well with the HPLC/MS observations where the ligand was found to be less reactive and 
selective toward the STAT3 sequence.  
 
3.3.2 Summary of the FRET study 
 
In summary, from the FRET data listed above, SJG-136 appeared to stabilise NF-κB-1, 
NF-κB-2, EGR-1 and STAT3 sequences to some extent at higher concentrations of 50 
µM and 100 µM (Table 3.5 and Figure 3.9). No DNA stabilisation was achieved at lower 
ligand concentrations of 10 µM, 1 µM and 0.1 µM (Table 3.5 and Figure 3.9). Several 
questions remained however. It is difficult to analyse the FRET data as some hairpins 
(e.g., NF-κB-1, NF-κB-2 and EGR-1) melted at such high temperatures (>75 °C) that 
proper evaluation of DNA stabilisation couldn’t be achieved. Furthermore, at around 75 
°C, the degradation of some PBD-Guanine covalent bonds can occur which may result in 
false negative melting data. Therefore, the data obtained from the FRET study should be 
taken with caution as this experiment was used as a preliminary screen. Interestingly, 
SJG-136 has demonstrated a significant elevation in the melting temperature of AP-1 
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sequence already at 10 µM (ΔTm of ~ 20 °C) (Table 3.5 and Figure 3.9). This result 
suggests a greater stabilisation effect on the AP-1 sequence due to ligand binding 
compared to the other sequences that may be explained through the presence of a 
favourable binding site for SJG-136 within AP-1 sequence. The FRET results for the 
sequence AP-1 were in broad agreement with the HPLC/MS experiments, in which 
selectivity for the AP-1 sequence has been observed based on the fastest reaction with 
only one main adduct formed. Additionally, they further support the assumption that SJG-
136 may exhibit its anti-tumour activity also through TF inhibition. As discussed above, 
the data obtained for the NF-κB-1, NF-κB-2 and EGR-1 sequences should be analysed 
carefully for the reasons mentioned above.  
 
3.4 CD study 
 
CD spectroscopy was used to explore changes in the secondary structure of the DNA 
sequences upon SJG-136 binding. Working solutions of DNA (final concentration of 5 
µM), SJG-136 (final concentration of 20 µM) and SJG-136/DNA complexes were 
prepared according to the protocol described in Section 7.2.5. Initially, CD spectra of the 
DNA sequences (Figure 3.1) alone were recorded between 200 and 400 nm in order to 
obtain reference spectra for subsequent comparison after SJG-136 addition. Following 
this, the DNA sequences were incubated with SJG-136 in a 4:1 ratio (SJG-136/DNA) and 
either subjected immediately to CD measurements for t = 0 h experiments or incubated 
for 24 hours at 25 ºC followed by CD analysis as described in Section 7.2.6. 
 
3.4.1 Results and discussion 
 
The CD profiles of all sequences display a negative band at approximately 240 nm and a 
positive band at approximately 272 nm (Figure 3.10) and are typical CD profiles of the 
B-form hairpin DNA. It has been previously reported that the CD spectrum of pure B-
form DNA exhibits a negative band at about 245 nm and positive bands at about 260-280 
nm178c, 204. The negative band at about 245 nm appears due to the right-handed helicity of 
the DNA whereas the positive band at around 260-280 nm occurs due to the π-π base 
stacking. It should be stressed that the position and amplitudes of the CD bands may vary 
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with the sequence. This is due to differences in chromophores and also because of various 









Figure 3.10: CD spectra: A, NF-κB-1 sequence alone (black) and NF-κB-1/SJG-136 complex at 
t = 0 h; B, NF-κB-1 sequence alone (black) and NF-κB-1/SJG-136 complex at t = 24 h showing 
binding of SJG-136 to NF-κB-1sequence; C, NF-κB-2 sequence alone (black) and NF-κB-2/SJG-
136 complex at t = 0 h; D, NF-κB-2 sequence alone (black) and NF-κB-2/SJG-136 complex at t 
= 24 h confirming binding of SJG-136 to NF-κB-2 sequence; E, EGR-1 sequence alone (black) 
and EGR-1/SJG-136 complex at t = 0 h; F, EGR-1 sequence alone (black) and EGR-1/SJG-136 
complex at t = 24 h showing binding of SJG-136 to EGR-1 sequence; G, AP-1 sequence alone 
(black) and AP-1/SJG-136 complex at t = 0 h; H, AP-1 sequence alone (black) and AP-1/SJG-
136 complex at t = 24 h confirming binding of SJG-136 to AP-1 sequence; I, STAT3 sequence 
alone (black) and STAT3/SJG-136 complex at t = 0 h; J, STAT3 sequence alone (black) and 
STAT3/SJG-136 complex at t = 24 h showing binding of SJG-136 to STAT3 sequence.  
 
The CD profiles of all sequences showed an increase in the negative ellipticity at about 
240 nm and positive ellipticity at about 272 nm after addition of SJG-136 and immediate 
CD analysis (Figure 3.10A, C, E, G and I). These changes in the CD bands confirm 
alterations in the secondary structure of DNA upon SJG-136 binding.  
 
Similar results were obtained after 24 hours incubation. The CD profiles of all sequences 
displayed an enhancement of the negative band at about 240 nm and the positive band at 
about 270 nm (Figure 3.10B, D, F, H and J). Moreover, the positive CD band increased 
to a greater extent for all sequences after 24 hours incubation with SJG-136 compared to 
the t = 0 experiment. This result reflects the time-dependent extent of adduct formation 
showing that more adduct had been formed after 24 hours. 
 
Interestingly, after addition to AP-1 sequence, SJG-136 induced a significant increase of 
the positive CD band at about 263 nm from 4 mdeg up to 55 mdeg after 24 hours 
compared to t = 0 (Figure 3.10G and H). Furthermore, the AP-1/SJG-136 complex 
exhibited the biggest change in CD intensity of the positive band compared NF-κB-1, 
NF-κB-2, EGR-1 and STAT3 sequences indicating greater reactivity of SJG-136 toward 
AP-1 sequence. This result was consistent with our previous HPLC/MS and FRET data 





3.4.2 Summary of CD study 
 
Taken together, the CD study has confirmed the ability of SJG-136 to bind to the DNA 
target sequences of the TFs NF-κB, EGR-1, AP-1 and STAT3. All studied sequences 
displayed changes in their characteristic CD signals, demonstrating alterations in the 
secondary structure after SJG-136 binding which were particularly more pronounced 
after the 24 hours incubation. However, the results obtained from the t = 0 CD experiment 
carried out on AP-1 sequence does not support our HPLC/MS observation. During the 
HPLC/MS study, SJG-136 immediately formed an adduct with the AP-1 sequence 
(~100% adduct formation) after 5 minutes based on the presence of one main peak in the 
chromatographic profile. The HPLC chromatograms obtained during the time-course 
study did not change over time suggesting complete reaction after 5 minutes. However, 
from the observed differences in the CD spectra at t = 0 and 24 hours it becomes apparent 
that more adduct was formed after 24 hours indicating that the adduct formation was not 
complete after 5 minutes. These discrepancies in the HPLC and CD results after 5 min 
incubation are presumably due to the fact that the HPLC peak was not resolved and the 
parent AP-1 sequence and the formed adduct eluted from the column at the same time. 
Nevertheless, the CD study provided further support for the observations made on AP-1 
sequence during the HPLC/MS and FRET study. In accordance with HPLC results, the 
AP-1/SJG-136 complex displayed the biggest change in the positive CD band especially 
after the 24 hours incubation intensity, compared to NF-κB-1, NF-κB-2, EGR-1 and 





3.5 Molecular modeling study*  
 
Molecular dynamics simulations were used to study the reactivity of SJG-136 toward NF-
κB-1, NF-κB-2, EGR-1, AP-1 and STAT3 sequences in an effort to rationalise the results 
of HPLC/MS, FRET and CD studies. As SJG-136 is known to form mono-adducts and 
cross-links, both types of adduct were investigated, and in the case of mono-adducts, both 
loop-facing and non-loop-facing orientations were considered. Potential energy 
calculations (kcal/mol), averaged over the duration of a 10 ns simulation, were used to 
evaluate the binding potential of SJG-136 to each guanine in the DNA sequences. Based 
on publications to date three base-pairs were set as minimum criteria for adduct formation 
(based on the preference of the PBD for 5'-X-G-X-3' triplets). However, we have recently 
observed that SJG-136 is capable of binding to sequences while spanning only two base 
pairs. These results will be discussed in greater detail in Chapter 5.  
 
*Molecular modeling studies were undertaken by Dr Paul Jackson 
 
3.5.1 Results and discussion 
 
Potential energy calculations (kcal/mol) suggest that in mono-alkylated form, SJG-136 
should preferentially bind to G3 of the NF-κB-1 consensus sequence (Table 3.6). The 
lowest energy snapshot of a 10 ns molecular dynamics simulation illustrates SJG-136 
embedded in the minor groove of DNA, potentiated by non-covalent interactions between 
the central methylene linker of the dimer and the A4:T20 base-pair. Furthermore, as the 
second PBD of the dimer orientates over the A6:T18 base-pair, non-covalent interactions 
between the unreacted PBD and A:T assist in restraining the ligand in the minor groove 








Table 3.6: Potential Energy (kcal/mol) of SJG-136 covalently bound to every potential reacting 
guanine of NF-κB-1, NF-κB-2, EGR-1, AP-1 and STAT3 sequences.  
(F) indicates a forward adduct (i.e., towards the TTT-loop) and (R) indicates a reverse 
adduct (i.e., away from the DNA loop). 
 






NF-κB-1 Mono-adducts G3 (F) -4561.61 1 
  G2 (F) -4560.78 2 
  G7 (F) -4560.14 3 
 Cross-Links G2-G19 -4543.53 1 
  G1-G3 -4541.22 2 
  G3-G19 -4537.75 3 
 
NF-κB-2 Mono-adducts G5 (F) -4737.04 1 
  G17 (R) -4736.88 2 
  G4 (F) -4734.72 3 
 Cross-Links G1-G3 -4718.88 1 
  G4-G17 -4716.83 2 
  G2-G4 -4712.32 3 
 
EGR-1 Mono-adducts G6 (R) -4423.57 1 
  G19 (F) -4422.44 2 
  G7 (R) -4421.78 3 
 Cross-Links G5-G14 -4420.56 1 
  G3-G5 -4413.51 2 
  G5-G19 -4409.82 3 
 
AP-1 Mono-adducts G7 (R) -3230.85 1 
  G17 (F) -3229.70 2 
  G1 (F) -3227.69 3 
 Cross-Links G1-G17 -3212.85 1 
  G7-G17 -3200.44 2 
 
STAT3 Mono-adducts G7 (R) -3708.78 1 
  G7 (F) -3706.57 2 
  G19 (F) -3704.43 3 
 Cross-Links G6-G19 -3687.29 1 
  G6-G18 -3681.42 2 








Figure 3.10: Low energy snapshots: A, SJG-136 (blue) covalently bound to G3 (magenta) of NF-
κB-1. The central methylene linker of SJG-136 forms extensive van der Waals interactions with 
the A4:T20 base pair (yellow) and an unreacted PBD of the PBD dimer forms non-covalent 
interactions with the A6:T18 base-pair (cyan), allowing the molecule to bind snugly in the DNA 
minor groove. B, SJG-136 (blue) covalently bound to G2 and G19 (magenta) of NF-κB-1. The 
central methylene linker of SJG-136 forms extensive van der Waals interactions with the A4:T20 
base pair (yellow) with stabilising hydrogen bonds between the N10-proton of one PBD and the 
ring nitrogen (N3) of the adjacent G3, and between the N10-proton of the second PBD and O4 of 
the neighbouring T20. 
 
The most energetically preferred cross-linked adduct is the G2-G19 adduct, where SJG-
136 spans six base-pairs across the sequence 5'-Pu-GGAC-Pu-3' (Table 3.6). In a similar 
manner to results from NF-κB-2 sequence molecular dynamics simulations, the 5'-Pu-
GGAC-Pu-3' adduct is very similar to the most preferred adduct of SJG-136 5'-Pu-
GATC-Py-3'. Low energy snapshots of the simulation suggest that SJG-136 embeds in 
the minor groove due to the formation of non-covalent interactions between the central 
methylene linker and A4:T20 (Figure 3.11A). Hydrogen bonds between N10-H of the 
PBDs and adjoining bases (i.e., G3 and T20) also assist in restraining the DNA in the 
minor groove. Similarly, as both PBDs are in an ideal location for covalent attack of G2 
and G19, the DNA cross-link formed induces little distortion of the DNA base-pairing of 
the sequence, and the G2-G19 cross-link is therefore the most preferred adduct. Other 
potential cross-links in the NF-κB-1 sequence include three base-pair (e.g., G1-G3) and 
five base-pair (e.g., G3-G17) sequences, which are known to be less preferred than a 
central four base-pair sequence such as 5'-GATC-3'. As a result, these potential energy 





Figure 3.11: Low energy snapshots: A, SJG-136 (green) covalently bound to G5 (magenta) of 
NF-κB-2 sequence in reverse orientation (i.e., pointing away from the TTT-loop). B, SJG-136 
(blue) covalently bound to G4 and G17 (magenta) of NF-κB-2. G5 (which impedes ligand 
binding) is yellow and bases involved in non-covalent interactions are illustrated in orange sticks. 
 
Similar molecular dynamics simulations were undertaken on NF-κB-2 sequence to 
predict the most favoured reacting guanine. As SJG-136 is known to form mono-adducts 
and both inter- and intrastrand cross-links96, study design focused on the identification of 
sequences within the NF-κB-2 consensus site which could potentially form cross-linked 
or mono-alkylated SJG-136 adducts. Specific criteria were set in study design whereby 
cross-linked (both intra- and inter-) adducts were required to be a minimum of three base-
pairs in length, in line with the previous literature205. In the case of mono-alkylated 
adducts, a base-pair span of at least four base-pairs was considered necessary for 
reactions. As such, adducts such as the mono-alkylated G3 adduct in forward (i.e., loop-
facing) orientation were considered viable, whereas adducts such as G2 in reverse 
(pointing away from the loop) were not. Similarly, adducts such as a loop-facing G14 or 
G15 mono-adduct were not assessed due to steric hindrance introduced due to the 
presence of the TTT-loop206. In all, nine potential mono-alkylated adducts and fourteen 
potential cross-links were identified and the three most preferred are outlined in Table 
3.6.   
 
Potential energy calculations (kcal/mol) averaged over the duration of each simulation 
suggest the most likely mono-alkylated adduct is a G5 adduct where SJG-136 is in 
forward orientation (i.e., pointing towards the loop) (Table 3.6). In this instance, it is 
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likely that stabilising van der Waals interactions promote the interaction of the methylene 
chain of the ligand with the T6:A18 base-pair, assisting ligand accommodation in the 
minor groove of DNA (Figure 3.11B). 
 
Potential energy calculations (kcal/mol) suggest that the G1-G3 is the most stable cross-
link, and, therefore, most likely to occur. This observation is unusual, given prior 
evidence which suggests PBDs require a three base-pair site to bind (e.g., Pu-G-Pu)125. 
Visual analysis of the molecular dynamics simulation results show that although base-
pairing is maintained throughout the simulation, the ligand is highly distorted. As such, 
the G1-G3 adduct (and therefore alkylation of G1) is unlikely to preferentially occur. The 
second most-preferred adduct (based on potential energy calculations) is a G4-G17 
adduct (Figure 3.11A). SJG-136 is known to preferentially bind in an interstrand manner 
across a six base-pair sequence (Pu-GATC-Py) and as the G4-G17 adduct is remarkably 
similar in content, i.e., Pu-GGTC-Pu, it is likely that this is the preferred cross-linked 
adduct. This assumption is further supported by the fact that SJG-136 was shown through 
biophysical experiments to bind to examples of 5'-Pu-GXXC-Py-3' (where X is A, T, G 
or C)207. Moreover, although the exocyclic amine of G6 protrudes into the minor groove 
preventing the formation of adduct stabilising hydrogen bonds and full ligand 
accommodation, there is little ligand distortion evident in simulations of SJG-136 
covalently bound to 5'-GGTC(G)-3' (Figure 3.11A), and as such it is likely that a G4-
G17 adduct is most preferred.  
 
In the case of EGR-1 sequence, SJG-136 is known to form a potential G1-G3 cross-link 
across a three base-pair sequence (in this case 5'-GCG-3'), thus, this adduct was included 
in the analysis. Similarly, SJG-136 is known to be capable of forming an extended five 
base-pair cross-link, as such the G1-G5 cross-link was also investigated. Adducts such as 
a loop-facing G9 mono-adduct or a loop-facing G14 mono-adduct were not assessed due 
to steric hindrance introduced by the presence of the TTT-loop208. In all, eleven potential 
mono-alkylated adducts and ten potential cross-links were identified and the three most 
preferred are shown in Table 3.6.        
 
Potential energy calculations (kcal/mol) averaged over the duration of each simulation 
suggest that the most likely mono-alkylated adduct is a G6 adduct where SJG-136 is in 
reverse orientation (i.e., pointing away from the loop) (Figure 3.12A). The alkylation of 
142 
 
G6 by a single PBD of the dimer SJG-136 allows the molecule to maximise its interaction 
with DNA through van der Waals interactions with GC base-pairs (orange bases, Figure 
3.12A). The adduct is also stabilised by the formation of a hydrogen bond between the 
NH of the PBD and O2 of C17. Similarly, for the second and third most likely mono-
alkylated adducts (G19 in forward orientation and G7 in reverse orientation), the dimer 






Figure 3.12: Low energy snapshots: A, SJG-136 (green) covalently bound to G6 (magenta) of 
EGR-1 sequence in reverse orientation (i.e., pointing away from the TTT-loop). Bases involved 
in non-covalent interactions are illustrated in orange sticks. B, SJG-136 (green) covalently bound 
to G5 and G14 (magenta) of EGR-1 sequence in reverse orientation (i.e., pointing away from the 
TTT-loop). Bases involved in non-covalent interactions are illustrated in cyan sticks. 
 
The most likely cross-linked adduct (according to potential energy calculations) is the 
G5-G14 interstrand adduct (Table 3.6, Figure 3.12B). SJG-136 is known to be highly 
interactive with the sequence 5'-Pu-GATC-Py-3'94, and is also known to form other 
covalent attachments to DNA, including extended cross-links such as 5'-Pu-GAATC-Py-
3'205 and examples of 5'-Pu-GXXC-Py-3' (where X is A, T, G or C)207. As the G5-G14 
adduct 5'-Pu-GGGC-Pu-3' is an equivalent span and content to other preferred interacting 
sequences, the preference for formation of a G5-G14 adduct would be in accord with 
previous observations. Crucial to the strong interaction of SJG-136 with 5'-GGGC-3' is 
the accommodation of the molecule in the minor groove and the formation of two 
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hydrogen bonds; the first between the NH of the PBD bound to G5 and the N3 of G6 and 
the second between the NH of the PBD bound to G14 and O2 of C15 (Figure 3.12B).     
 
Molecular dynamics simulations were conducted on SJG-136 covalently bound to every 
potential reacting guanine in the AP-1 consensus sequence (i.e. G1, G7, G12, G17) in 
order to rationalise the formation of one adduct peak in HPLC studies. During study 
design, potential reaction sites were chosen based on the span of the molecule. For 
example in the case of G1, a terminal base, an adduct in reverse orientation (i.e., pointing 
away from the loop) was not selected for analysis due to the known preference of a PBD 
for a three base-pair motif for interaction. Similarly, for G7 and G12, a forward adduct 
(i.e., pointing towards the loop) was not analysed due to the potential steric hindrance 
associated with the TTT-loop, however G17 in both orientations was investigated due to 
the possibility of adduct formation in both orientations. 
 
Although SJG-136 is known to prefer to form adducts over a six or seven base-pair 
sequence (i.e., Pu-GATC-Py, Pu-GATG-Py, Pu-GAATG-Py or Pu-GAATC-Py205), 
potential energy calculations suggest that the adduct spanning 5'-GAC-3' (i.e., G1-G17) 
is preferred to the extended adduct (5'-CATTG-3'). Although surprising due to the fact 
that the extended 5'-ATT-3' base sequence in the centre of the DNA sequence should 
form extensive van der Waals interactions with the methylene linker of the ligand, this is 
in fact in accord with previous studies on PBD molecules, which suggest A-ring 3'-
orientation (as evident in 5'-GAC-3') is preferred to A-ring 5'-orientation (5'-CATTG-3'). 
It is also interesting to note that although 5'-GAC-3' (i.e., G1-G17, Figure 3.13A) is the 
most preferred cross-linked adduct, potential energy calculations suggest that a mono-
alkylated adduct in the same orientation (G17 facing away from the loop) may also form. 
In HPLC studies, a single adduct was observed to form and potential energy calculations 









Figure 3.13: Low energy snapshots: A, SJG-136 (green) covalently bound to G1 and G17 
(magenta) of AP-1 sequence forming an interstrand cross-link across the sequence 5'-GAC-3'. B, 
SJG-136 (green) covalently bound to G7 of AP-1 sequence. The NH group of the PBD forms a 
hydrogen bond with an adjacent adenine base, A14 (yellow). 
 
Potential energy calculations (kcal/mol) conducted on the STAT3 sequence suggests a 
definite preference for the G7 mono-adduct for SJG-136 in this sequence (Table 3.6, 
Figure 3.14B). During interaction with its favoured sequence Pu-GATC-Py, SJG-136 is 
thought to form van der Waals interactions between the methylene linker and A:T base-
pairs, while concurrently forming sequence-selective hydrogen bonds with bases 












Figure 3.14: Low energy snapshots: A, SJG-136 (green) covalently bound to G6 and G19 
(magenta) of the STAT3 sequence. The NH groups of each PBD form hydrogen bonds to cytosine 
residues (i.e., C17 illustrated in orange and C4 illustrated in yellow) and form covalent bonds 
with G6 and G19, spanning the sequence 5'-Py-CCGG-Pu-3'. B, SJG-136 (green) covalently 
bound to G7 (magenta) of the STAT3 sequence. The NH group of the PBD forms a stabilising H-
bond to C16 (yellow). 
 
In the case of the STAT3 sequence, every potential cross-linked adduct must form around 
the central 5'-CCGGG-3' tract. This would pose considerable steric difficulties due to the 
presence of C2-amino groups of guanines beneath the methylene linker in the case of 
every cross-linked adduct, thus preventing the interaction of SJG-136 with the minor 
groove floor. According to potential energy calculations, the G6-G19 adduct is the most 
favoured (potential energy of -3687.29 kcal/mol) of the cross-linked adducts as it would 
span across six base-pairs (i.e., Py-CCGG-Pu) forming hydrogen bonds in the process 
(Table 3.6, Figure 3.14A), followed by G6-G18 (Py-CGG-Pu), G5-G7 (Py-GGG-Pu), 
G7-G18 (Py-CGGG-Pu) and G7-G19 (Py-CCGGG-Pu). It is relevant to mention that the 
presence of a guanine triplet on the forward strand (5'-GGG-3') appears to interfere with 
the binding of SJG-136, possibly occurring due to steric hindrance between the guanine 
residues and methylene linker of SJG-136.   
 
The top three most favoured guanine residues and orientations are illustrated (Table 3.6) 
and it is evident that SJG-136 requires a considerable minor groove environment for 
interaction with DNA. For example, G7, G6 and G19 all feature in the top five most 
favoured drug/DNA adducts, and each of these bases is positioned at the centre of the 
DNA sequence, providing a large minor groove environment for ligand interaction and 
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thus maximising non-covalent interaction. G19, on the other hand, is located towards the 
3'-end of the DNA and produces poor potential energy results when facing away from the 
TTT-loop, and is therefore less favoured. 
 
Molecular dynamics results, overall, suggest that DNA cross-links are less favoured than 
mono-adducts in the case of the STAT3 consensus sequence, and it is likely that the three 
adducts produced in HPLC studies are mono-adducts. Furthermore, based on potential 
energy calculations, molecular modeling studies indicate that adducts should form in the 
priority: G7 (adduct facing away from loop) = G7 (loop-facing) > G19 (loop-facing) > 
G6 (loop-facing) = G6 (adduct facing away from loop), and, therefore, it is expected that 
adducts involving each of the three DNA bases G7, G19 and G6 are the most likely 
adducts formed. 
  
3.5.2 Summary of molecular modeling study 
 
Molecular dynamics simulations and potential energy calculations indicate that within 
the NF-κB-1 consensus sequence the most likely mono-adduct is formed at the guanine 
in position G3 (pointing towards the loop) as non-covalent interactions between the 
central methylene linker of the dimer and the A4:T20 base-pair assist the ligand to 
accommodate within the DNA-minor groove. The interstrand cross-link at G2-G19 is the 
most preferred cross-link adduct due to the formation of non-covalent interactions 
between the central methylene linker and A4:T20. Additionally, hydrogen bonds between 
N10-H of the PBDs and adjoining bases (i.e., G3 and T20) also assist in restraining the 
DNA in the minor groove.  
 
In the case of NF-κB-2 sequence, the molecular modeling study suggested that the most 
likely mono-alkylated adduct to occur is at the guanine in position G5 in forward 
orientation (i.e., pointing into the loop) due to stabilising van der Waals interactions 
between the methylene chain of SJG-136 with the T6:A18 base-pair of the DNA. Based 
on the potential energy calculations the most stable cross-link is the intrastrand cross-link 
at G1 and G3.  
 
For EGR-1 sequence, molecular dynamics simulations and potential energy calculations 
showed that the most likely mono-alkylated adduct is formed at G6 in reverse orientation 
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(i.e., pointing away from the loop) due to the maximum interaction of SJG-136 with the 
EGR-1 sequence though van der Waals interactions and hydrogen bond formation. 
According to the potential energy calculations the most likely cross-linked adduct is the 
interstrand cross-link at G5 and G14 due to the strong interaction of SJG-136 with 5'-
GGGC-3'.  
 
Molecular dynamics simulations and potential energy calculations conducted on AP-1 
sequence suggested that the most likely mono-alkylated adduct is formed at G7 in reverse 
orientation (i.e., away from the DNA loop) where the NH group of the PBD forms a 
hydrogen bond with an adjacent adenine base, A14. Based on the potential energy 
calculations the most likely cross-link adduct is the shorter interstrand cross-link at G1 
and G17 which suggests that A-ring 3'-orientation (as evident in 5'-GAC-3') is preferred 
to A-ring 5'-orientation (5'-CATTG-3').  
 
Finally, the molecular modelling study carried out on the STAT3 consensus sequence 
indicated that mono-alkylated adduct formation is preferred over cross-links. The most 
preferred mono-adduct may be formed at G7 orientated away from the loop (i.e., reverse). 
Based on the data, it is anticipated that the most favoured cross-linked adduct may be 




In conclusion, this is the first report of the PBD dimer SJG-136 binding to the consensus 
sequences of the oncogenic transcription factors NF-κB, EGR-1, AP-1 and STAT3. The 
HPLC/MS study has suggested that SJG-136 may be capable of binding to the cognate 
sequences of NF-κB, EGR-1, AP-1 and STAT3. Interestingly, the results revealed 
significant differences in the extent and rate of adduct formation between the individual 
sequences which may explain the previously observed differences in activity of SJG-136 
in various human tumours. For example, SJG-136 appeared to form rapidly adduct with 
NF-B-2 and AP-1 sequences while it reacted moderately with the EGR-1 sequence and 
slowly with NF-κB-1 and STAT3 sequences, despite their comparable GC-contents. 
Furthermore, significant variations in the rate of adduct formation were observed. As a 
dimer, SJG-136 can form intra-, inter-strand and mono-alkylated adducts within the DNA 
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minor groove96, 136. Even more important, on the basis of the HPLC/MS data, SJG-136 
formed three distinct adducts with the STAT3 sequence, two different adducts with the 
NF-κB-1 sequence, while only single adduct formation was observed in the case of NF-
B-2, EGR-1 and AP-1 sequences. These results indicate that SJG-136 favours one 
particular binding site within the NF-κB-2, EGR-1 and AP-1 sequences, as only one 
particular type of adduct had been formed. Moreover, the most remarkable observations 
have been made on the analysis of the AP-1 sequence. Based on the obtained data, the 
ligand has demonstrated a preference for this particular sequence as it reacted rapidly and 
to the full extent after 5 min with one main adduct formed. However, the limitations of 
the developed technique have been discussed previously. Therefore, the appeared high 
reactivity cannot be confirmed using this method and future studies have to be carried out 
in order to support this observation. The results were supported to some extent by FRET, 
CD and molecular modeling studies. Important to note are the different drug and DNA 
concentrations used for HPLC/MS (DNA 25 µM, SJG-136 100 µM), FRET (DNA 400 
nM, SJG-136 2 µM) and CD (DNA 5 µM, SJG-136 µM) studies. All these concentrations 
have been chosen according to previous studies carried out on PBD monomers and dimers 
with short oligonucleotides91, 96, 210. However, although different concentrations for the 
DNA and SJG-136 were used during this study, a 4:1 ratio (SJG-136/DNA) was kept for 
the HPLC, MALDI-TOF and CD study which was previously reported to ensure 
completion of adduct formation within a reasonable time frame210a. Due to the different 
concentrations used, the results may not be directly comparable. During the FRET study, 
the concentration of SJG-136 was gradually increased as no differences in ΔTm could be 
observed for most of the sequences (apart from AP-1).  
 
The data presented in this report suggests that SJG-136 may exert its pharmacological 
effect through interaction with cognate sequences of oncogenic transcription factors in 
addition to previously reported mechanisms including; strand breakage, inhibition of 
enzymes including endonucleases and RNA polymerases and arrest of the replication 
fork88a, 203. This wealth of new data considerably adds to the knowledge of the mechanism 
of action of SJG-136 and is of utmost importance for the correct interpretation of the 




To investigate whether a correlation exists between the biophysical results and the 
behaviour of SJG-136 in vitro, the ligand was evaluated in a biological study utilising 
two human tumour cell lines.  Based on the surprising results obtained for the AP-1 
sequence, the colon carcinoma cell line HT-29 has been selected for the experiments due 
to the reported involvement of AP-1 in the development and progression of colorectal 
tumorigenesis54, 211. Similarly, the STAT3-dependent breast cancer cell line MDA-MB-
231 was chosen for the biological evaluation of SJG-136 as the ligand has demonstrated 
a low preference for STAT3 during the HPLC/MS study. Elevated levels of STAT3 have 
been detected in breast cancer and are presumed to promote tumour growth and 
metastasis64, 212. Another reason for the selection of AP-1 and STAT3 was their 
intracellular localisation. STAT3 is present in a latent state in the cytosol and enters the 
nucleus after its activation through phosphorylation where it binds to promoter and 
enhancer regions on the DNA63a, whereas AP-1 is located within the nucleus where it can 
rapidly bind to its consensus sequences on the DNA53b. The results of the biological study 











Chapter 4: Mechanistic confirmation of transcription factor inhibition 




Proteins are the major components of cells in multicellular organisms. They perform 
almost all cellular functions in the human body. Enzymes, such as proteases, synthases 
and kinases catalyse and promote the chemical reactions in cells213. The transition of 
small molecules into the extracellular environment is carried out by proteins that are 
integrated into the membrane and form channels and pumps (i.e., Ca2+ pump in muscle 
cells)213.  Cell-to-cell messages and signals, as well as intracellular communication 
between the cytosol and the nucleus, are mediated by proteins213. Further examples of 
proteins are antibodies which bind with high specificity to specific proteins on the 
membrane of bacteria and viruses in order to label them for autologous destruction213.  
 
Many proteins are constantly required due to their indispensable tasks and functions in 
multicellular organisms (e.g., structural proteins of chromosomes)214. Those proteins are 
constitutively expressed in order to maintain their constant concentration in the organism. 
Other proteins are present only in specialised cells where they perform particular 
functions (i.e., haemoglobin in red blood cells) or are produced in response to external 
signals and changes in the environment of cells such as signalling or regulatory 
proteins214. The process from transcription to translation is exceedingly complex and 
involves various steps. It will be described only briefly in this chapter. 
 
Transcription factors (TFs) are sequence-specific DNA binding proteins. They contain 
DNA binding domains which enable them to bind to particular sequences of DNA called 
enhancer or promoter sequences. The DNA promoter sequence can be located near the 
transcription start site. TFs can also bind to regulatory sequences such as enhancer 
sequences located thousands of nucleotide pairs upstream or downstream away from the 
gene being transcribed. This step recruits RNA polymerase II to the promoter sequence 
(a short DNA sequence which indicates the transcription start-point for the enzyme) and 
where a transcription initiation complex is formed at the template strand consisting of 
transcription factors and RNA polymerase II. Following this, the RNA polymerase II 
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begins to translate the encoded DNA sequence and synthesise a complementary RNA 
single strand using the substrates ATP, CTP, UTP and GTP. When the RNA strand has 
been elongated for about 25 nucleotides the 5'-end of the emerging RNA is modified by 
the addition of a methyl cap. This modification signals the 5'-end of the precursor-mRNA 
and assists the cell to differentiate mRNAs from other existing types of RNAs in the cell. 
However, eukaryotic genes are not composed of continuously protein-coding DNA 
sequences (exons). Moreover, they are interspersed with longer non-coding regions, also 
referred to as introns. The process of intron removal and joining the exons to form one 
consistent protein-coding mRNA strand is termed RNA splicing. RNA splicing 
contributes to the genomic diversity and tissue specificity. This process allows the cell to 
rearrange exons, resulting in the production of a significant number of protein isoforms 
from a single gene215. Moreover, mutations can easily accumulate in the genome without 
causing problems due to the bigger fraction of non-coding sequences. Therefore, ligation 
of the exons decreases the likelihood of mutations to occur.   
 
Once transcription has been terminated, the 3'-end of the nascent mRNA molecule is 
modified by addition of about 200 adenine nucleotides (polyadenylation). Only when 
modifications, such as 5'-end capping, RNA splicing and 3' polyadenylation have all been 
completed, the mature mRNA is transported from the nucleus into the cytosol where the 
nucleotide sequence of a gene is translated into the amino acid sequence of a protein. This 
conversion from mRNA into a particular protein sequence is also known as translation. 
Translation is initiated by the binding of a small ribosomal subunit at AUG start codons 
which in turn is recognised by a special initiator tRNA molecule. Following this, a large 
ribosomal subunit assembles at the small subunit and forms the complete ribosome 
(located on the rough endoplasmic reticulum) in which protein synthesis takes place. 
Aminoacyl tRNAs that carry specific amino acids bind with their anticodon to the 
complementary codon on an mRNA molecule. Appropriate aminoacyl-tRNA synthetases 
recognise codons for their specific amino acid and connect them by forming a peptide 
bond between the carboxyl group at the end of a growing polypeptide chain and the free 
NH2 group of an incoming amino acid. Polypeptide chains are so produced stepwise from 
their N-terminus towards their C-terminus. Stop codons containing sequences UAA, 
UAG and UGA on mRNA mediate translation termination to the ribosomes. As a 
consequence, a water molecule is attached to the peptidyl-tRNA instead of an amino acid 
which locks the carboxyl group. The synthesised proteins then undergo various post-
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translational modifications such as quality control checking which all occurs in the Golgi 
network. Packed into vesicles, they are transported throughout the cell and distributed 
depending upon their localisation signals (if present) the synthesised protein is released 
into the cytosol. Lastly, the newly synthesised polypeptide chain is folded into its unique 
and correct three-dimensional structure with the assistance of chaperones. Misfolding of 
proteins will lead to their malfunction and cause damage to the cells. Therefore, they are 
destroyed by proteolytic degradation initiated by ubiquitin via the proteosome.  
 
It has become increasingly clear that each step between transcription initiation and 
translation has to be strictly regulated in order to avoid the synthesis of incorrect 
functioning proteins that will have crucial consequences for the organism they are 
expressed in. In the context of the aims of this project, only the post-transcriptional 
controls which take place following gene expression will be discussed. 
 
The earliest stage of post-transcriptional regulation is premature transcription attenuation. 
Anti-attenuators (special RNA binding proteins) assemble at nascent pre-mRNA and 
allow RNA polymerase II to transcribe a gene continuously without stopping216. Another 
post-transcriptional control mechanism is RNA editing. During this process, the 
nucleotide sequence of the mRNA transcript is altered by insertion or deletion of 
nucleotides or exchange of one base to another leading to various protein products217. 
Exosomes (large protein complexes with exonuclease activity) degrade any incompletely 
processed or damaged RNAs before they are exported to the cytosol214a. Additionally, 
translation initiation can be negatively regulated by translational repressors that bind to 
the 5'-end of the mRNA and prevent the small ribosomal subunit recognising the start 
codon AUG and thus preventing the initiation of translation214b. A further substantial 
control in protein synthesis is the phosphorylation of eIF2, a eukaryotic initiation factor, 
by kinases in response to stress situations, including deprivation of growth factors and 
nutrients or infection by viruses with the aim of decreasing cellular damage or inducing 
apoptosis218. This process inhibits the binding of methionyl initiator tRNA to the small 
ribosomal subunit. Alternatively, translation can be initiated at other specialised positions 
on the mRNA apart from the first start codon AUG at the 5'-end. Those internal 
recognition sites are called 'internal ribosome entry sites' (IRESs) and can be activated 
without the need of a 5'-cap structure219. The benefit of this regulation process for the cell 
is that translation of special mRNAs can take place even in the presence of a general 
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decrease in protein synthesis initiation. Many eukaryotic mRNAs are unstable, with half-
lives of 30 minutes or even less214a. Consequently, translation of those unstable mRNAs 
is regulated by changing their stability in the cytosol. Shortening of the poly-A tail by 
exonucleases or its cleavage at once by specific endonucleases leads to rapid mRNA 
degradation220. On the other hand, lengthening of the poly-A tail increases the stability of 
mRNAs. Having discussed the degradation of aberrant transcribed RNAs in the nucleus 
by exosomes an additional translation control mechanism occurs in the cytosol also 
referred to as 'nonsense-mediated mRNA decay'221. This process aims to degrade any 
aberrant mRNAs before efficient translation into proteins resulting in their malfunction. 
It has become increasingly clear that the exceedingly complex network of post-
transcriptional control plays a crucial and substantial role in the translation of mRNA into 
protein. But regardless of the versatility of all control processes, their fundamental role is 
to prevent translation of any incorrectly transcribed mRNAs into malfunctioning proteins 
which cause significant damage to cells. 
 
In context to the body of this work, interaction of the small-molecules with consensus 
sequences of TFs results in inhibition of transcription and all the following process as 
described in detail above. This may lead to inhibition of proteins that are known to play 
a major role in cancer development and progression. Therefore, targeting the consensus 
sequences of TFs is an option to treat malignancies, and is an interesting potential 
















Biophysical studies carried out on the cognate sequences of the oncogenic TFs NF-κB, 
EGR-1, AP-1 and STAT3 demonstrated that the PBD dimer SJG-136 may exert its 
pharmacological effect also through TF inhibition, in addition to previously reported 
mechanisms including strand breakage, inhibition of enzymes including endonucleases 
and RNA polymerases, and arrest of replication fork88a, 203 by binding to the consensus 
DNA target sequences (Chapter 3). During the HPLC/MALDI-TOF-MS study adduct 
formation between SJG-136 and NF-κB, EGR-1, AP-1 and STAT3 sequences was 
observed and identified, showing the ability of the ligand to interact with these particular 
TF binding sites. The HPLC/MS results were supported by FRET, CD, molecular 
dynamics simulations and free energy binding calculations where SJG-136 demonstrated 
the capability to interact with all studied target DNA sequences.  
 
As a consequence of the data obtained from the biophysical study we aimed to confirm 
the ability of SJG-136 to inhibit TF-mediated processes, such as gene and consequently 
protein expression in vitro by investigating the effect of SJG-136 on the human tumour 
breast cancer cell line MDA-MB-231 and the human colon carcinoma cell line HT-29. 
The hypothesis was that if the ligand is capable of binding to consensus sequences of the 
oncogenic transcription factors STAT3 and AP-1, the expression of genes that require 
STAT3 or AP-1 activation was assumed to decrease. As a consequence, subsequent 
protein synthesis of incorrectly regulated or functioning proteins involved in cancer 
development and progression was expected to be down-regulated. To address this issue, 
two most frequently used and established methods were applied in this study. Polymerase 
chain reaction was utilised to investigate changes in gene expression profiles and 










4.3 Selection of human tumour cell lines for biological study 
 
4.3.1 Human breast cancer cell line MDA-MB-231 
 
The MDA-MB-231 cell line (MDA-MB-231 ATCC® HTB-26™) is a triple negative 
metastatic human breast cancer cell line originally isolated in the early 1970s222. It is an 
immortal cell line due to the presence of an active telomerase, which prevents telomere 
shortening and allows the permanent division of cells223. Cells possess a spindle shaped 
morphology224 as illustrated in Figure 4.1A and B. General information about MDA-
MB-231 cell line obtained from ATCC® is shown in Table 4.1. Extensive research has 
been undertaken in order to identify mechanisms responsible for breast cancer cell 
migration, metastasis and its poor prognosis and STAT3 has been shown to promote 
tumour growth as well as tumour metastasis due to its elevated levels in breast cancer64, 
212, 225. This particular cell line has been selected for our biological experiments as SJG-
136 showed the lowest preference for the cognate sequence of the transcription factor 
STAT3 during the biophysical study. Very slow reaction was observed with the STAT3 
consensus sequence, with only ~14% adducts formed after 24 hours incubation of SJG-
136 with DNA. Furthermore, multiple adducts were formed. All these data suggest that 
SJG-136 is less selective for STAT3 with no preferred binding site. This cancer cell line 
did not act as a negative control as it was chosen to investigate whether the differences in 
activity observed for STAT3 and AP-1 during the biophysical study correlate with the in 




Figure 4.1: Microscope image of human breast cancer cell line MDA-MB-231 used in this study. 




Table 4.1: General information about MDA-MB-231 ATCC® HTB-26™. 
 
Organism   Homo sapiens 
Tissue  mammary gland/breast; derived from 
metastatic site: pleural effusion 
 
Cell Type/Morphology  epithelial 
 
Culture Properties   adherent 
Disease  adenocarcinoma 
 
Age  51 years adult 
 
Gender   Female 




4.3.2 Human colon carcinoma cell line HT-29 
 
The HT-29 cell line (HT-29 ATCC® HTB-38™) is a human colorectal adenocarcinoma 
cell line with epithelial morphology. This cell line was established in 1964. Under 
standard culture conditions, these cells grow as a nonpolarised, undifferentiated 
multilayer226 (Figure 4.2A and B). General information about the cell line HT-29 
obtained from ATCC® is shown in Table 4.2. Studies have been carried out to investigate 
the involvement of the TF AP-1 in human colorectal tumour promotion and progression54, 
227. The results have demonstrated over-expression of crucial AP-1 family members (i.e., 
Jun and Fos), thus contributing and promoting colorectal tumourigenesis. The cell line 
HT-2954, 211, 227 was chosen for our biological evaluation of SJG-136 on the basis of the 
surprising observations made on the AP-1 cognate sequence during the biophysical study. 
Remarkably rapid adduct formation was observed between SJG-136 and sequence AP-1 
with ~100% adduct formed after 5 min incubation. In addition, only one particular adduct 





Figure 4.2: Microscope image of human colon carcinoma cell line HT-29 used in this study. A: 
20 x magnification; B: 40 x magnification. Passage number: 16. 
 
 
Table 4.2: General information about HT-29. 
 
Organism   Homo sapiens 
Tissue  Colon 
 
Cell Type/Morphology  epithelial 
 
Culture Properties   Adherent 
Disease  colorectal adenocarcinoma 
 
Age  41 years adult 
 
Gender   Female 














Bcl-2, also known as B-cell like lymphoma 2, is a member of the Bcl-2 family of proteins 
that regulate all major types of cell death, including apoptosis, necrosis and autophagy228. 
The Bcl-2 protein has been shown to play a central role in cell death regulation229. Bcl-2 
was discovered in Non-Hodgkin’s lymphomas in 1985230. Elevated levels of Bcl-2 
expression have been documented in most chronic lymphocytic leukaemia due to 
mutations in encoding genes231. Aberrant Bcl-2 gene expression results in dysregulation 
of crucial cell-death mechanisms and contributes to the pathogenesis and progression of 
human cancers228. 
 
4.4.2 Cyclin D1 
 
The progression from one cell cycle stage to another is regulated by regulatory proteins, 
called cyclin-dependent-kinases (CDKs), which in turn are activated by other proteins, 
the cyclins232. Cyclin D1 binds to CDK4 and CDK6 in early G1 phase during which the 
cell is preparing for DNA synthesis232. The consequences of cyclin D1 overexpression 
are disruption and incorrect cell cycle regulation. Aberrant cyclin D1 expression is 
associated with the development and progression of several human cancers, such as 




Signal transducer and activator of transcription 3 (STAT3) belongs to the STAT family 
composed of seven proteins (STATs 1, 2, 3, 4, 5a, 5b, and 6) that transfer external signals 
to the nucleus in order to regulate gene transcription64. STAT3 regulates the expression 
of genes that are crucial for cell differentiation, proliferation, apoptosis, angiogenesis, 
metastasis, and immune responses65a. STAT3 is considered as an oncogene as in many 
human malignancies constitutive STAT3 activation and consequently elevated levels of 
STAT3-dependent genes has been associated with defects in apoptosis regulation, tumour 





In contrast to STAT3, STAT1 is a tumour suppressor235 as it negatively regulates tumour 
angiogenesis, growth and metastasis through expressions of anti-proliferative and pro-
apoptotic genes (e.g., Tgfbi, Gadd45g, Dab236). Furthermore, its activation inhibits the 




Fascin, an actin-bundling protein, is a member of the cytoskeletal protein family which 
is highly expressed in neurons and dendritic cells238. Its normal functions are the 
maintenance of cell adhesion, motility and invasion. Many malignant epithelial cells have 
been shown to express elevated levels of fascin including those of liver, ovary, lung, 
pancreas and breast cancer238-239 at levels which correlates with tumour invasiveness and 
metastasis240. Recent studies have demonstrated that STAT3 binds directly to fascin 




Nicotinamide N-methyltransferase (NNMT) is a cytoplasmic enzyme that is thought to 
play a crucial role in the biotransformation of many drugs and xenobiotic compounds241. 
Recent studies have demonstrated aberrant expression of NNMT in several malignant 
tumours including thyroid cancer242, glioblastoma243, gastric cancer244, renal 
carcinoma245, lung cancer246, pancreatic cancer247, colorectal cancer248 and ovarian 
carcinoma249. NNMT overexpression has been shown to correlate with cancer cell 
migration and tumour stage250, and has been linked to cancer cell differentiation and poor 
prognosis251. An increasing body of evidence suggests that NNMT contributes to tumour 
development and progression through the induction of Complex I activity and ATP 
production, thereby supplying the tumour cells with energy252. Furthermore, studies have 
shown that NNMT promotes the activation of matrix metallopeptidase-2 via the 
PI3K/Akt signaling pathway, hence initiating tumour cell invasion and metastasis in renal 






VEGF is an essential vascular endothelial growth factor that stimulates vasculogenesis 
and angiogenesis in endothelial cells254. Besides its indispensability for vascular 
endothelial cells, VEGF is also important in bone formation255, haematopoiesis256 and 
wound healing257. Enhanced VEGF gene expression is induced by EGF (epithelial growth 
factor), TNF (tumour necrosis factor), IL-1 (interleukin-1) or hypoxia258. VEGF has been 
identified as a promoter of tumourigenesis and cancer progression in various human 
cancers259. The growth factor exerts this effect by stimulating tumour blood vessels 




Cyclic adenosine monophosphate response element binding protein (CREB) is a proto-
oncogenic TF260 that plays a crucial role in cell survival261. Following external stimulation 
by hormones, growth factors and neuronal activity262 CREB is phosphorylated by 
kinases, such as mitogen-activated protein kinase (MAPK) or protein kinase A (PKA)262a, 
263 resulting in activation of CREB dependent gene transcription. Several reports have 
demonstrated its overexpression and involvement in malignant diseases, including 




Elk-1 belongs to the Ets (E twenty six) family of oncogenic TFs with critical roles in 
biological processes such as cell growth, differentiation and survival, haematopoiesis, 
angiogenesis, wound healing, cancer and inflammation270. It regulates transcription rather 
indirectly by interaction with co-regulatory proteins resulting in the combinatorial control 
of gene expression and enhanced specificity instead of directly binding to its DNA target 
sequences271. Elk-1 regulates AP-1 activation up-stream as it encodes genes for c-Fos, a 








The AP-1 (activating protein-1) dimeric TFs are composed of the subfamilies Jun, Fos, 
ATF, and MAF273. They execute and promote important biological functions including 
cell proliferation, migration, survival and apoptosis in specific cell types59b. AP-1 has 
been linked to cancer development and progression. Several reports have demonstrated 
aberrant activation of AP-1 in various malignant diseases such as melanoma274, 
nasopharyngeal carcinoma275, glioblastoma276, liver cancer277, breast cancer278, 




P53, the most important tumour suppressor protein, is often referred to as 'guardian of the 
genome' due to its fundamental roles in maintaining genetic stability and prevention of 
tumour formation281. It executes defensive functions such as such as cell-cycle arrest, 
DNA synthesis and repair, apoptosis and energy metabolism282 after DNA damage, 
nutrient starvation, heat shock, virus infection, hypoxia and oncogene activation283. 
Following its activation, p53 promotes induction of p21 which in turn forms a complex 
with Cdk2 leading to cell cycle arrest in phase G1 in addition to the activation of GADD45 
which stops cell division in G2
284
. Disruptions in p53 expression have significant 
consequences to cells. On the one hand, overproduction of p53 is toxic to normal cells 















4.5 Evaluation of SJG-136 in the breast cancer cell line MDA-MB-231 
 
4.5.1 Results  
 
4.5.1.1 SJG-136 down-regulated Bcl-2, cyclin D1, STAT1, STAT3, fascin and NNMT 
mRNA expression in PCR experiments 
 
Polymerase Chain Reaction (PCR) analysis was used to evaluate changes in expression 
of Bcl-2, cyclin D1, STAT3, STAT1, fascin and NNMT in the breast cancer cell line MDA-
MB-231. Gene expression profiles were compared before and after treatment with SJG-
136 in the presence of bacterial lipopolysaccharide (LPS).  
 
Initially, a general model was established in order to mimic the malignant disease. MDA-
MB-231 cells were stimulated with 500 µg/mL LPS for 24 hours at 37 °C. LPS is the 
major component of the outer surface membrane of gram-negative bacteria which 
functions as an extremely effective stimulator of innate and natural immunity in 
eukaryotic cells285. LPS stimulates an extraordinary range of host responses (i.e., shock, 
fever) by releasing cytokines including TNF and IL-1. Pre-treatment of MDA-MB-231 
with LPS aimed to activate the transcription factor STAT3 resulting in elevation of 
STAT3-dependent gene expression. Following this, SJG-136 was added at 1 µM to the 
cells and incubated for another 24 hours at 37 °C. Finally, PCR was used to determine 
changes in gene expression profiles between stimulated-untreated and stimulated-treated 
cells.  
 
PCR results are depicted in Figure 4.3. Activation of STAT3 and consequently, 
enhancement in STAT3-dependent gene expression, was successful using our established 
method. Bcl-2, cyclin D1, STAT1, STAT3, fascin and NNMT mRNAs were detected as 
single PCR products in MDA-MB-231 cells. For all analysed genes of interest an increase 
in band intensity was observed compared to the untreated cells (Figure 4.3, lane 1 versus 
lane 2) confirming STAT3 activation and STAT3-dependent gene over-expression. This 
result was surprising as it was expected to detect slightly elevated gene expression levels 
in the non-stimulated untreated cells (Figure 4.3, lane 1) as genes such as Bcl-2 are 
known to be present at higher levels in human cancers229a. Following treatment of MDA-
MB-231 with 1 µM SJG-136 for 24 hours at 37 °C decreased levels of mRNA expression 
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for all genes were detected (Figure 4.3, lane 2 versus lane 3) demonstrating down-
regulation of STAT3 and STAT3-induced mRNA expression. The down-regulation was 
markedly pronounced for Bcl-2, fascin and NNMT. The consistent bands of the GAPDH 
control show equal loading of mRNA onto the agarose gel. These results suggest that 
SJG-136 may bind to consensus DNA sequences of the transcription factor STAT3 and, 
therefore, inhibit the expression of the STAT3-dependent genes Bcl-2, cyclin D1, STAT3, 
fascin and NNMT. Furthermore, the gel shown in Figure 4.3 also demonstrates down-





Figure 4.3: PCR detection of Bcl-2, cyclin D1, STAT1, STAT3, fascin, NNMT and control 
GAPDH expression in MDA-MB-231. Lane 1: untreated cells; lane 2: cells stimulated with 500 
µg/mL LPS for 24 hours; lane 3: cells stimulated with 500 µg/mL LPS for 24 hours followed by 






4.5.1.2 SJG-136 showed concentration dependent effects on Bcl-2, cyclin D1, STAT1, 
STAT3, fascin, and NNMT mRNA down-regulation 
 
To investigate the concentration-dependent activity of SJG-136 on the expression of 
STAT3-dependent genes and STAT1 in MDA-MB-231 cells, the ligand was tested at 
various concentrations (0.001 - 1 µM) following the protocol described in Section 4.5.1.1. 
The results shown in Figure 4.4 demonstrate down-regulation of Bcl-2, STAT1, STAT3 
and NNMT at 1 µM and 0.1 µM but no visible down-regulation at concentrations of 0.01 
µM and 0.001 µM. Cyclin D1 and fascin were slightly down-regulated at 1 µM but no 
detectable down-regulation was achieved at 0.1 µM, 0.01 µM and 0.001 µM SJG-136. 
From these data we can propose that the effect of SJG-136 on STAT3 consensus 




Figure 4.4: PCR detection of Bcl-2, cyclin D1, STAT1, STAT3, fascin, NNMT and control 
GAPDH expression in MDA-MB-231. Lane 1: untreated cells; lane 2: cells stimulated with 500 
µg/mL LPS for 24 hours; lane 3: cells stimulated with 500 µg/mL LPS for 24 hours followed by 
1 µM SJG-136 for 24 hours; lane 4: cells stimulated with 500 µg/mL LPS for 24 hours followed 
by 0.1 µM SJG-136 for 24 hours; lane 5: cells stimulated with 500 µg/mL LPS for 24 hours 
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followed by 0.01 µM SJG-136 for 24 hours; lane 6: cells stimulated with 500 µg/mL LPS for 24 
hours followed by 0.001 µM SJG-136 for 24 hours. 
 
4.5.1.3 SJG-136 significantly down-regulated Bcl-2, VEGF, p53, STAT3, CREB5, and 
Elk-1 mRNA expression in qPCR study 
 
Quantitative PCR (qPCR) was used to verify the observed changes in our PCR study in 
gene expression profiles after the cells were stimulated with LPS and treated with SJG-
136. Nine genes, cyclin D1, VEGF, AP-1, Bcl-2, p53, CREB5, STAT3, survivin and Elk-
1 were chosen for evaluation by qPCR and normalised against the reference gene β-actin. 
Statistical analysis was performed using 1-way ANOVA followed by Turkey’s Multiple 
Comparison post-test. P-values < 0.05 were considered as significant. qPCR results are 
shown in Figure 4.5. The qPCR data showed that a total of six genes (VEGF, Bcl-2, p53, 
CREB5, STAT3 and Elk-1) were significantly down-regulated with fold changes ranging 
from 2.3- to 2.0-fold after the cells were stimulated with LPS and treated with SJG-136 
(Figure 4.5, blue column) compared to the LPS-stimulated and non-treated cells (Figure 











































Figure 4.5: The effect of SJG-136 on the expression of cyclin D1, VEGF, AP-1, Bcl-2, p53, 
CREB5, STAT3, survivin and Elk-1 mRNA in MDA-MB-231. All data are mean ± SD. * = p < 
0.05, ** = p < 0.01, *** = p < 0.001, NS = not significant. Statistical analysis was performed 
using a 1-way ANOVA followed by a Turkey’s Multiple Comparison post-test, n = 3. An increase 
in ΔCt equates to a decrease in gene expression.  
 
Analysis of variance with a p-value of 0.15 for AP-1 and a p-value of 0.11 for survivin 
were found not to be significant (Figure 4.5). Surprisingly, the most striking change in 





regulator of the cell cycle (Figure 4.5). A possible explanation for this surprising 
observation shall be discussed in detail in Section 4.7. 
 
4.5.1.4 No significant over-expression of STAT3-dependent genes was achieved after 
stimulation with LPS 
 
No significant up-regulation of STAT3-dependent gene expression was achieved after 
stimulation of MDA-MB-231 with LPS (red versus green column, Figure 4.5). This was 
not consistent with the results obtained from the PCR study, in which for each case, over-
expression of STAT3 was observed (lane 1 versus lane 2, Figure 4.3). Possible reasons 
for this observation will be discussed in Section 4.7 in detail. 
 
4.5.1.5 SJG-136 inhibited cyclin D1 protein expression and up-regulated 
phosphorylated STAT1 protein expression  
 
To further validate the PCR findings, Western blotting was performed to correlate 
changes in gene and protein expression levels in LPS-stimulated non-treated and LPS-
stimulated SJG-136-treated MDA-MB-231 cells. Cyclin D1 and Bcl-2 were chosen for 
the Western blotting study due to their crucial involvement in tumour development and 
progression228, 233a. STAT1 was selected for the study because of its tumour suppressive 
features and to investigate the selectivity of SJG-136 toward STAT3. Statistical analysis 
was performed using 1-way ANOVA followed by Turkey’s Multiple Comparison post-
test. P-values < 0.05 were considered as significant. Western blot results are shown in 
Figure 4.6, 4.7 and 4.8. All proteins were detected as single bands of the following sizes: 
cyclin D1 ~36 kDa286, Bcl-2 ~28 kDa287, phosphorylated STAT1 (pSTAT1) ~87 kDa236b, 
total STAT1 (tSTAT1) ~87 kDa288, phosphorylated STAT3 (pSTAT3) ~88 kDa236b, total 
STAT3 (tSTAT3) ~88 kDa288 and α-tubulin ~50 kDa289. In all experiments, no non-
specific binding of the antibodies (appearance of multiple bands of different sizes) was 
detected on the membranes, confirming specific binding of the primary antibodies to the 
proteins of interest. Figure 4.6 shows visible down-regulation of cyclin D1 and up-
regulation of pSTAT1 protein expression after the cells were stimulated with LPS and 
treated with SJG-136 (lane 2 versus lane 3). The subsequent statistical analysis confirmed 
significant down-regulation in cyclin D1 protein expression in LPS-stimulated and SJG-
136-treated cells (Figure 4.7, green versus blue column). Accordingly, the 
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pSTA1:tSTAT1 ratio significantly increased after the cells were stimulated with LPS and 





















Figure 4.6: Western blots of MDA-MB-231 for cyclin D1, Bcl-2, pSTAT1, tSTAT1, pSTAT3, 
tSTAT3 and α-tubulin expression. Molecular weights: cyclin D1 ~36 kDa, Bcl-2 ~28 kDa, 
pSTAT1 ~87 kDa, tSTAT1 ~87 kDa, pSTAT3 ~88 kDa, tSTAT3 ~88 kDa, α-tubulin ~50 kDa. 
Lane 1: untreated cells; lane 2: 500 µg/mL LPS for 24 hours; lane 3: 500 µg/mL LPS for 24 hours 








cyclin D1 36 kDa 
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Figure 4.7: The effect of SJG-136 on the protein expression of cyclin D1, Bcl-2, pSTAT1, 
tSTAT1, pSTAT3 and tSTAT3 in MDA-MB-231. All data are mean ± SD. * = p < 0.05, ** = p 
< 0.01, *** = p < 0.001, NS = not significant. Statistical analysis was performed using a 1-way 



















Figure 4.8: The effect of SJG-136 on the protein expression of pSTAT1, tSTAT1, pSTAT3 and 
tSTAT3 in MDA-MB-231. All data are mean ± SD. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, 
NS = not significant. Statistical analysis was performed using a 1-way ANOVA followed by a 
Turkey’s Multiple Comparison post-test, n = 3. STAT1 phosphorylation was calculated by 
dividing the pSTAT1 intensity by the tSTAT1 intensity to produce the pSTAT1:tSTAT1 ratio. 




















4.5.1.6 SJG-136 did not change levels of Bcl-2, phosphorylated STAT3 and total 
STAT1 and STAT3 proteins 
 
No visible down- or up-regulation was detected for Bcl-2, tSTAT1, pSTAT3 and tSTAT3 
(Figure 4.6) using the LPS model. Additionally, statistical analysis confirmed no 
significant changes in Bcl-2 and tSTAT1 protein expression (Figure 4.7, green versus 
blue column). The pSTAT3:tSTAT3 ratio did not increase after the cells were stimulated 
with LPS and treated with SJG-136 confirming no significant changes in phosphorylated 
STAT3 protein expression (Figure 4.8, green versus blue column). In agreement with the 
qPCR results, no over-expression of any protein investigated was achieved after 
stimulation with LPS, suggesting no increased expression of STAT3-dependent genes 




























4.6.1.1 SJG-136 down-regulated VEGF, cyclin D1, CREB5, AP-1 and p53 mRNA 
expression in PCR experiments 
 
PCR analysis was undertaken to investigate differences in expression of AP-1 down-
stream target genes VEGF, cyclin D1, CREB5, Elk-1, AP-1 and p53 in the colon 
carcinoma cell line HT-29 before and after incubation with SJG-136 to correlate the 
observations made during the biophysical analysis of SJG-136. Using the developed 
model, 30 ng/mL tumour necrosis factor α (TNF-α) was added to HT-29 cells and 
incubated for 24 hours at 37 °C with the aim to increase the expression of  AP-1. TNF-α 
is a proinflammatory cytokine with a variety of biological functions including cell 
proliferation, differentiation, apoptosis, lipid metabolism, and coagulation290. TNF-α has 
been demonstrated to induce the AP-1 signalling pathway by activation of specific 
kinases required for phosphorylation c-Jun and ATF2 which are part of AP-1291. 
Following this, cells were treated with 1 µM SJG-136 for another 24 hours at 37 °C in 
the presence of TNF-α and gene expression profiles were compared using PCR analysis. 
The obtained results are shown in Figure 4.9. Over-expression of AP-1 and consequently 
over-expression of AP-1-dependent genes, was successful after the cells were stimulated 
with TNF-α (Figure 4.9, lane 1 versus lane 2). VEGF, cyclin D1, CREB5, Elk-1, AP-1 
and p53 mRNAs were detected as single PCR products in HT-29 cells. Figure 4.9 shows 
an increase in band intensity compared to untreated cells for all analysed genes (lane 1 
versus lane 2) confirming activation of AP-1 and over-expression AP-1-dependent genes. 
After treatment of HT-29 with TNF-α and 1 µM SJG-136 for 24 hours at 37 °C the mRNA 
expression levels decreased for all genes as visible on the decrease of band intensities 
(Figure 4.9, lane 2 versus lane 3). This result demonstrates down-regulation of AP-1 and 
AP-1-depentent gene expression. The consistent bands of the control GAPDH confirm 
equal loading of mRNA onto the agarose gel. Interestingly, no visible down-regulation 
was observed for Elk-1 as shown in Figure 4.9, lanes 2 & 3. The band intensities of the 
cells treated with only TNF-α and the cells treated with TNF-α and SJG-136 are similar. 
A possible explanation for this observation will be discussed later. These PCR results 
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indicate that SJG-136 may be able to bind to the DNA consensus sequences of AP-1, 
thereby inhibiting the expression of AP-1-dependent genes such as VEGF, cyclin D1, 




Figure 4.9: PCR detection of VEGF, cyclin D1, CREB5, Elk-1, AP-1, p53 and control GAPDH 
expression in HT-29. Lane 1: untreated cells; lane 2: cells stimulated with 30 ng/mL TNF-α for 
24 hours; lane 3: cells stimulated with 30 ng/mL TNF-α for 24 hours followed by 1 µM SJG-136 
for 24 hours. 
 
4.6.1.2 SJG-136 significantly down-regulated Bcl-2, p53, CREB5 and survivin mRNA 
expression in qPCR study 
 
Validation of the HT-29 PCR results was carried out using qPCR. Differences in mRNA 
expression levels of cyclin D1, VEGF, AP-1, Bcl-2, p53, CREB5, STAT3, survivin and 
Elk-1 were quantified in TNF-α-stimulated non-treated cells and TNF-α-stimulated and 
SJG-136-treated cells. Results were normalised against the reference gene β-actin. 
Statistics was conducted using 1-way ANOVA followed by Turkey’s Multiple 
174 
 
Comparison post-test. P-values < 0.05 were considered as being significant. Obtained 
qPCR results are shown in Figure 4.10. Statistical analysis showed that the expression of 
Bcl-2, p53, CREB5 and survivin were significantly down-regulated after TNF-α-
stimulated cells were treated with SJG-136 (Figure 4.10, green versus blue column). The 
fold changes in mRNA expression levels decreased from 3.7- to 2.9 (TNF-α-stimulated 
non-treated cells) to 2.6- to 2.0-fold (TNF-α-stimulated and SJG-136-treated cells) 






















Figure 4.10: The effect of SJG-136 on the expression of cyclin D1, VEGF, AP-1, Bcl-2, p53, 
CREB5, STAT3, survivin and Elk-1 mRNA in HT-29. All data are mean ± SD. * = p < 0.05, ** = 
p < 0.01, *** = p < 0.001, NS = not significant. Statistical analysis was performed using a 1-way 
ANOVA followed by a Turkey’s Multiple Comparison post-test, n = 3. An increase in ΔCt 




Statistical analysis using 1-way ANOVA showed no significant differences in gene 
expression for VEGF, AP-1 and STAT3 (Figure 4.10, green versus blue column).  
 
Cyclin D1 produced a similar change in expression in HT-29 cells as that observed in 
MDA-MB-231 with an increased expression after stimulation with TNF-α and treatment 
SJG-136 (Figure 4.10, green versus blue column). Furthermore, Elk-1 was also found to 
be significantly up-regulated after treatment with SJG-136 with an increase in expression 
from 3.4- to 4.4-fold (Figure 4.10, green versus blue column).  
 
4.6.1.3 No significant over-expression of AP-1-dependent genes was achieved after 
stimulation with TNF-α 
 
Lastly, no significant over-expression of AP-1-dependent genes was achieved after 
stimulation with TNF-α (Figure 4.10, red versus green column). However, cyclin D1 
showed significant up-regulation in its expression after stimulation of HT-29 with TNF-
α. This will be discussed in Section 4.7 in detail. 
 
4.6.1.4 SJG-136 significantly inhibited cyclin D1 protein synthesis in Western blot 
experiments 
 
Protein expression levels of cyclin D1, p53 and VEGF in HT-29 were determined using 
Western blotting to investigate whether any correlation is present between the gene 
expression and protein expression levels after treatment with SJG-136. HT-29 cells were 
stimulated with TNF-α for 24 hours and treated for another 24 hours with SJG-136 in the 
presence of TNF-α. Analysis of variance was carried out using 1-way ANOVA followed 
by Turkey’s Multiple Comparison post-test. P-values < 0.05 were taken as being 
significant. Western blot results are depicted in Figure 4.11 and Figure 4.12). Analysed 
proteins were detected as single bands with the following sizes: cyclin D1 ~36 kDa286, 
p53 ~53 kDa292, VEGF ~43 kDa293 and α-tubulin (loading control) ~50 kDa289. No 
additional protein bands were present on the membranes, thus demonstrating a specific 
interaction of the primary antibodies with the investigated proteins. As visible in Figure 
4.11, only cyclin D1 was significantly down-regulated in its expression after the cells 















Figure 4.11: Western blot analysis of cyclin D1, p53 and VEGF protein expression in HT-29, 
using α-tubulin as a loading control (n = 3). Detected kDa: cyclin D1 ~36 kDa, p53 ~53 kDa, 
VEGF ~43 kDa, and control α-tubulin ~50 kDa. Lane 1: untreated cells; lane 2: 30 ng/mL TNF-














Figure 4.12: The effect of SJG-136 on the protein expression of cyclin D1, p53 and VEGF in 
HT-29. All data are mean ± SD. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, NS = not significant. 
Statistical analysis was performed using a 1-way ANOVA followed by a Turkey’s Multiple 
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4.6.1.5 SJG-136 had no effect on VEGF and p53 protein expression 
 
No significant down-regulation was observed in p53 and VEGF protein expression after 
stimulating of HT-29 cells with TNF-α followed by treatment with SJG-136 (Figure 4.12, 
green versus blue column). These results were confirmed by subsequent statistical 
analysis using 1-way ANOVA followed by Turkey’s Multiple Comparison post-test 
which demonstrated a significant decrease in cyclin D1 protein expression (p = 0.0185) 
and no significant changes in p53 (p = 0.0726) and VEGF (p = 0.1688) protein expression 
(Figure 4.12). In agreement with the qPCR data, no protein over-expression was 
observed for p53 and VEGF after the cells were treated with TNF-α. This result suggests 
that the activity of AP-1 may have been induced but that the consequences upon p53 and 
VEGF protein expression have not occurred after 24 hours (Figure 4.12, red versus green 
column). Time-course experiments could help to see any effect on protein expression 
after treatment with SJG-136 which is not apparent at the single time-point of 24 hours 




















The biological evaluation of SJG-136 on AP-1- and STAT3-dependent gene expression 
on the human colon carcinoma cell line HT-29 and the breast cancer cell line MDA-MB-
231 have shown that SJG-136 may bind to the response elements on DNA of AP-1 and 
STAT3, thereby inhibiting AP-1- and STAT3 dependent gene expression. The PCR study 
demonstrated down-regulation of cyclin D1, VEGF, CREB5, p53 and AP-1 mRNA 
expression levels after HT-29 cells were stimulated with TNF-α and treated with SJG-
136. Similarly, Bcl-2, cyclin D1, STAT3, fascin and NNMT were found to be down-
regulated in their expression after the MDA-MB-231 cells were stimulated with LPS and 
treated with SJG-136 during the same PCR experiment. The qPCR study showed 
significant down-regulation of Bcl-2, p53, CREB5 and survivin mRNA expression after 
stimulation of HT-29 with TNF-α and treatment with SJG-136 and a significant decrease 
mRNA expression of VEGF, Bcl-2, p53, CREB5, STAT3 and Elk-1 in LPS-stimulated 
and SJG-136-treated MDA-MB-231. Finally, Western blotting results demonstrated a 
significant decrease in cyclin D1 protein expression in both, TNF-α-stimulated and SJG-
136-treated HT-29 and LPS-stimulated and SJG-136-treated MDA-MB-231 cells. 
 
It is clear however, that the PCR results where SJG-136 appeared to down-regulate the 
majority of the analysed genes are not fully consistent with Western blot data, where only 
down-regulation of cyclin D1 protein expression was observed in both the HT-29 and 
MDA-MB-231 cells. A possible explanation for this inconsistency may be the fact that 
changes in mRNA expression do not always correlate with changes in protein expression. 
The process of mRNA expression is very rapid and transient. mRNA turnover happens 
within minutes and does not last for longer than a few hours214a. In contrast, the process 
of protein expression is very slow. Some proteins have half-lives of ~16 hours such as 
Bcl-2 (t1/2 ~22 hours
294) and STAT1 (t1/2 ~18 hours
295), whereas the average is 4 – 8 hours. 
This means that a number of half-lives are required in order to observe a reduction in 
protein expression. Moreover, a down-regulation in mRNA expression should lead to a 
decrease in protein expression. However, this process can take a while. As such, any 
changes in mRNA expression may not translate to changes in protein expression over the 
course of the experiment. Therefore, the single time-point of 24 hours used in the LPS 
model may not be long enough to detect any correlation between the mRNA and protein 
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expression levels. Western blot time-course studies adjusted to the half-lives of the 
proteins of interest, may help to observe any effect on protein expression after treatment 
of the cells with SJG-136 
 
Furthermore, post-translational regulation mechanisms may contribute to the observed 
differences in mRNA and protein expression levels during the study. Additional 
modifications made on the proteins can be phosphorylation, acetylation, ubiquination, 
methylation, glycosylation, and nitrosylation which all at the end determine whether or 
not the protein will be active214b. 
 
In addition, the PCR and qPCR data did not correlate after the cells were stimulated with 
TNF-α (HT-29) and LPS (MDA-MB-231). This step aimed to induce an increased 
expression of AP-1- and STAT3-dependent genes. However, during the PCR study over-
expression was achieved for all studied genes in both HT-29 and MDA-MB-231, visible 
on the increased band intensity, whereas the qPCR study demonstrated significant over-
expression only of cyclin D1 in HT-29 after the cells were treated with TNF-α. Moreover, 
the PCR results showed a visible down-regulation of cyclin D1 after treatment with SJG-
136 in both cell lines whereas the qPCR data demonstrated significant over-expression of 
cyclin D1 after the cell were incubated with the ligand.  
 
This discrepancy is likely due to some major limitations of the PCR. PCR is semi-
quantitative, as the used DNA intercalators such as ethidium bromide lack specificity. 
They bind to any double-stranded DNA which may result in misleading results. 
Furthermore, the staining with intercalators can prevent further amplification, thereby 
complicating quantification of the genes of interest. Moreover, PCR is non-linear and 
may not be exponential for the first several cycles, and the reaction will plateau at a 
certain point because essential reagents such as dNTP, enzyme and primers get depleted. 
This results in saturation of the UV or colourimetric signal which will not increase in 
intensity when the reaction proceeds further. This all affects subsequent quantitative 
analysis. Therefore, end-point PCR is not a very useful tool to accurately determine 
whether a particular gene is expressed or not in a given sample. In order to precisely 
quantify any changes in gene expression, the amount of product formed needs to be 




The observations made for phosphorylated STAT1 during Western blot analysis are 
interesting. The results showed a significant over-expression of phosphorylated STAT1 
protein after the MDA-MB-231 cells were treated with LPS and SJG-136 suggesting its 
increased expression in tumour cells. This enhanced expression of the active form of 




In conclusion, the biological evaluation of the effect of SJG-136 on AP-1- and STAT3-
dependent gene expression has demonstrated that the ligand may be able to interact with 
the AP-1 and STAT3 cognate sequences and thereby inhibit the expression of AP-1- and 
STAT3-dependent genes involved in tumourigenesis and progression, such as Bcl-2, 
fascin, NNMT, VEGF, CREB5 and p53. This observed down-regulation may be due to 
interaction with the consensus sequences of the transcription factors AP-1 and STAT3 
which was observed during the biophysical study.  
 
The Western blot data have not clearly confirmed the ability of SJG-136 to down-regulate 
AP-1- and STAT3-dependent protein expression as, from the panel of investigated 
proteins, only cyclin D1 was found to be significantly down-regulated by SJG-136. 
Possible reasons for the observed discrepancies between the PCR and Western blot data 
are discussed in Section 4.7 in detail. This will be investigated in future studies in detail 



















During a study of the interaction of SJG-136 (2, Figure 5.1) with various DNA 
transcription factor recognition sequences191b (see also Chapter 3), it was observed that 
SJG-136 (2) rapidly formed an adduct with the AP-1 hairpin DNA sequence (Figure 5.2), 
with a major new peak appearing in the chromatogram at retention time (RT) 7.53 min 
after 24 hours of incubation, and with reaction complete by 24 hours (Figure 3.5A and 
3.5B, see also Section 3.2.1). The stoichiometry of the adduct was confirmed as 1:1 SJG-
136/AP-1 by MALDI-TOF-MS with an observed mass of 6351.2 m/z (theoretical mass: 
6350.41 m/z) (Figure 3.5C, Section 3.2.1). Given that it has previously been shown96 
that 2 can form mono-adducts and intra- and interstrand cross-links of different lengths 
according to the following rank order of preference: Pu-GAATG-Py > Pu-GATC-Py >> 
Pu- GATG-Py and Pu-GAATC-Py205, it was initially assumed that the adduct formed was 
most likely to be either the extended G7-G17 3'-GTAAC-5' interstrand cross-link, a G7 




Figure 5.1: Structures of the naturally occurring PBD anthramycin (1), the synthetic PBD Dimer 







Figure 5.2: Schematic diagram of the possible interstrand (red) and mono-alkylated (blue) 




The objective of this study was to investigate what particular type of adduct SJG-136 had 
formed during the HPLC study with the AP-1 sequence using the RP-HPLC/MALDI-
TOF method developed in Chapter 2. In order to examine this, a range of inosine modified 
DNA hairpins und duplexes were designed (shown in the individual sections) which are 
based on the same AP-1 sequence but allow SJG-136 to form mono-alkylated and cross-
linked adducts with the AP-1 sequence. The guanines were consecutively replaced with 
inosine bases to remove the nucleophilic C2-NH2 functionalities and prevent covalent 
interaction of SJG-136.    
 
5.3 Interaction of SJG-136 with inosine modified AP-1 hairpin sequences to 
study cross-link formation 
 
The substitution patterns of the hairpins AP-1 1, 17I, AP-1 7, 17I, AP-1 7, 12I and AP-1 
1, 12I (Figure 5.3) allowed the possibility of cross-linking at G7 and G12, G1 and G12, 
G1 and G17, and G7 and G17 due to the replacement of two out of the four guanines with 
non-nucleophilic inosines, thereby allowing the possibility of interstrand cross-link 








Figure 5.3: Structures of inosine modified AP-1 hairpins used to study cross-link formation of 
SJG-136 which are based on the same AP-1 sequence but with two of the four guanines replaced 
with inosines in each case to study cross-linking. 
 
5.3.1 Results and discussion 
 
Working solutions of inosine modified hairpins were prepared according to the protocol 
described in Section 7.2.1.4. SJG-136 working solutions were prepared as described in 
Section 7.2.1.9. SJG-136/DNA complexes were prepared according to the protocol 
described in Section 7.2.1.10. Briefly, a SJG-136 working solution of 100 µM was added 
to a DNA working solution of 25 µM in a 4:1 ratio (SJG-136/DNA). The mixture was 
agitated and incubated for 24 hours at 25 °C. Following the incubation, the samples were 
subjected to ion pair RP-HPLC/MALDI-TOF-MS analysis as described in Sections 7.2.2 
and 7.2.4 in detail.  
 
HPLC analysis of annealed AP-1 1, 17I (Figure 5.3), with guanines G7 and G12 available 
showed a single peak at retention time (RT) 6.50 min (Figure 5.4A) which provided the 
correct m/z (5764.8) for this oligonucleotide by MALDI-TOF-MS. After incubation with 
2 at 25 °C for 24 hours in a 4:1 ratio (2/DNA), two new minor peaks emerged at RT 12.50 
min and RT 14.38 min with the parent AP-1 1, 17I DNA peak still present at RT 6.48 min 
by 24 hours (Figure 5B). The adduct stoichiometry was confirmed by MALDI-TOF-MS 
as 1:1 2/AP-1 1, 17I on the basis of an observed mass of 6320.6 m/z (theoretical mass: 
6320.4 m/z) (Figure 5C). This result suggested that 2 may form two mono-alkylated 
adducts at G7 and G12 as an interstrand cross-link between G7 and G12 would be too 








Figure 5.4: A, HPLC chromatogram showing the annealed AP-1 1, 17I (Figure 5.3) alone at RT 
6.50 min; B, HPLC chromatogram after incubation of annealed AP-1 1, 17I with 2 for 24 hours, 
showing approximately 20% conversion to the adduct peaks at RT 12.50 min and RT 14.38 min; 
C, MALDI-TOF spectrum of the adducts at RT 12.50 min and RT 14.38 min from Chromatogram 
B above. Observed mass of 1:1 2/AP-1 1, 17I: 6320.6 m/z (theoretical mass: 6320.4 m/z), 
observed mass AP-1 1, 17I alone from Chromatogram A: 5764.8 m/z (theoretical mass: 5763.8 
m/z). 
 
Next, the interaction of 2 with the AP-1 7, 17I (Figure 5.3), with guanines G1 and G12 
available for covalent attachment of 2 was studied. Annealed AP-1 7, 17I alone gave a 
single peak at RT 7.43 min (Figure 5.5A) and a m/z of 5764.2 m/z (theoretical mass: 
5763.8 m/z). After 24 hours incubation with 2 at 25 °C in a 4:1 ratio (2/DNA), a new 
major peak appeared in the HPLC chromatogram at RT 8.08 min, with ~87% adduct 
formed (Figure 5.5B). The 1:1 stoichiometry of the new peak was confirmed by MALDI-
TOF-MS (observed mass: 6321.0 m/z; theoretical mass: 6320.4 m/z) as the 2/ AP-1 7, 
17I adduct (Figure 5.5C). This was a surprising result as a PBD had not previously been 
observed to bond to a terminal guanine (i.e., G1), and G12 was considered to be too close 
to the TTT-loop to covalently bond to a PBD (Figure 5.3). Furthermore, an interstrand 
cross-link between G1 and G12 would be too long to form. Therefore, our conclusion 
was that, for AP-1 7, 17I, 2 was bonding to the terminal G1, pointing in the A-ring-3' (i.e., 






Figure 5.5: A, HPLC chromatogram showing the annealed AP-1 7, 17I (Figure 5.3) alone at RT 
7.43 min; B, HPLC chromatogram after incubation of annealed AP-1 7, 17I with 2 for 24 hours, 
showing approximately 87% conversion to the adduct peak at RT 8.08 min; C, MALDI-TOF 
spectrum of the adduct at RT 8.08 min from Chromatogram B above. Observed mass of 1:1 2/AP-
1 7, 17I: 6321.0 m/z (theoretical mass: 6320.4 m/z), observed mass AP-1 7, 17I alone from 
Chromatogram A: 5764.2 m/z (theoretical mass: 5763.8 m/z). 
 
In a similar experiment AP-1 7, 12I (Figure 5.3), with guanines G1 and G17 available, 
was incubated with 2 for 24 hours at 25 °C in a 4:1 ratio (2/DNA). Initially, AP-1 7, 12I 
alone gave a single peak at RT 7.44min (Figure 5.6A) with an observed mass of m/z 
5764.0 (theoretical mass: m/z 5763.8) (Figure 5.6C). After 24 hours incubation, a new 
major peak at RT 8.08 min was observed (Figure 5.6B) with ~89% adduct formation. 
The stoichiometry of the adduct formed was found to be 1:1 2/AP-1 7, 12I by MALDI-
TOF-MS analysis (observed mass: 6321.1 m/z, theoretical mass, 6320.4 m/z) (Figure 
5.6C). In this case, the inosine substitution pattern could have allowed mono-adducts to 








Figure 5.6: A, HPLC chromatogram showing the annealed AP-1 7, 12I (Figure 5.3) alone at RT 
7.44 min; B, HPLC chromatogram after incubation of annealed AP-1 7, 12I with 2 for 24 hours, 
showing approximately 89% conversion to the adduct peak at RT 8.08 min; C, MALDI-TOF 
spectrum of the adduct at RT 8.08 min from Chromatogram B above. Observed mass of 1:1 2/AP-
1 7, 12I: 6321.4 m/z (theoretical mass: 6320.4 m/z), observed mass AP-1 7, 12I alone from 
Chromatogram A: 5764.0 m/z (theoretical mass: 5763.8 m/z). 
 
HPLC analysis of annealed AP-1 1, 12I (Figure 5.3), with guanines G7 and G17 available 
showed a single peak at RT 6.88 min (Figure 5.7A) which provided the correct m/z 
(5764.5) for this oligonucleotide by MALDI-TOF-MS. After incubation with 2 at 25 °C 
for 24 hours in a 4:1 ratio (2/DNA), a new major peak emerged at RT 8.41 min with a 
complete disappearance of the parent AP-1 1, 12I peak by 24 hours (Figure 5.7B). The 
adduct stoichiometry was confirmed by MALDI-TOF-MS as 1:1 2/AP-1 1, 12I on the 
basis of an observed mass of 6321.7 m/z (theoretical mass: 6320.4 m/z) (Figure 5.7C). 
This result suggested that 2 may form a single interstrand cross-link across the G7 and 
G17 guanines.  Furthermore, the extent of reaction after 24 hours was similar to that for 






Figure 5.7: A, HPLC chromatogram showing the annealed AP-1 1, 12I sequence alone at RT 
6.88 min; B, HPLC chromatogram after incubation of annealed AP-1 1, 12I with 2 for 24 hours, 
showing 100% conversion to an adduct at RT 8.41 min with complete loss of the original hairpin 
peak at RT 6.88 min; C, MALDI-TOF spectrum of the adduct (from peak at RT 8.41 min in 
Chromatogram B above). Observed mass of 1:1 2/AP-1 1, 12I adduct: 6321.7 m/z (theoretical 
mass: 6320.4 m/z), observed mass of AP-1 1, 12I alone from Chromatogram A: 5764.5 m/z 
(theoretical mass: 5763.8 m/z). 
 
5.3.2 Summary of cross-link formation study of SJG-136 
 
Based on the results obtained from the study on the hairpins shown in Figure 5.3, 
considering that only the extent of reaction of 2 with hairpin AP-1 1, 12I matched its 
extent of reaction with the parent AP-1 sequence (i.e., 100% adduct formed in 24 hours), 







5.4 Interaction of SJG-136 with inosine modified AP-1 hairpin sequences to 
study mono-alkylation 
 
Based on the observations made for the AP-1 7, 17I sequence (see also Section 5.3.1), 
the study was continued to investigate the mono-alkylation pattern within the AP-1 
sequence by SJG-136. To study the mono-adduct distribution using the developed 
HPLC/MS methodology, a further four AP-1 hairpins (Hairpin 1-4, Figure 5.8) were 
designed, based on the same AP-1 sequence but which have three of their four guanines 
replaced with inosines, thus leaving only one reactive guanine (i.e., G1, G7, G12 or G17) 





Figure 5.8: Structures of the AP-1 Hairpins 1-4 which are based on the same AP-1 sequence but 
with three of the four guanines replaced with inosines in each case to study mono-alkylation. 
 
5.4.1 Results and discussion 
 
Working solutions of inosine modified hairpins were prepared according to the procedure 
described in Section 7.2.1.4. SJG-136 working solutions were prepared as described in 
Section 7.2.1.9. SJG-136/DNA complexes were prepared according to the protocol 
described in Section 7.2.1.10. In brief, a SJG-136 working solution of 100 µM was added 
to a DNA working solution of 25 µM in a 4:1 ratio (SJG-136/DNA). The mixture was 
mixed and incubated for 24 hours at 25 °C. Following the incubation, the samples were 
subjected to ion pair RP-HPLC/MALDI-TOF-MS analysis as described in Sections 7.2.2 
and 7.2.4 in detail.  
 
HPLC analysis of annealed AP-1 Hairpin-1 (Figure 5.8), with only the terminal guanine 
available gave a single peak at RT 7.64 min (Figure 5.9A) which provided the correct 
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m/z (5748.3) for this oligonucleotide by MALDI-TOF-MS. Following a 24 hour 
incubation with 2 at 25 °C in a 4:1 molar ratio (2/DNA), a new peak appeared in the 
HPLC chromatogram at RT 14.03 min (Figure 5.9B). The adduct stoichiometry was 
confirmed by MALDI-TOF-MS as 1:1 2/AP-1 Hairpin-1 based on an observed mass of 
6305.1 m/z (theoretical mass: 6305.41 m/z) (Figure 5.9C). Although the reaction had not 
gone to completion by 24 hours (approximately 50%), this result confirmed that a PBD 
unit could bond to a terminal G1 base, with the body of the PBD spanning two rather than 
three base pairs. The most likely explanation for this is that one PBD unit of 2 bonds to 
the terminal 5'-guanine with its C-ring protruding just outside of the minor groove, and 
with the second PBD unit laying in the minor groove (pointing toward the loop) and 
making non-covalent interactions without forming a second cross-linking covalent bond. 
This structure was supported by a molecular dynamics simulation (see also Section 5.9) 
which suggested that a stable adduct should form with 2 arranged in this way. The fact 
that adduct formation did not go to completion after 24 hours is also consistent with a 
mono-alkylation event in which the covalently bonded PBD is interacting with two rather 













Figure 5.9: A, HPLC chromatogram showing the annealed AP-1 Hairpin-1 (Figure 5.8) alone at 
RT 7.64 min; B, HPLC chromatogram after incubation of annealed AP-1 Hairpin-1 with 2 for 24 
hours, showing approximately 50% conversion to the adduct peak at RT 14.03 min; C, MALDI-
TOF spectrum of the adduct at RT 14.03 min from Chromatogram B above. Observed mass of 
1:1 2/AP-1 Haipin-1 adduct: 6305.1 m/z (theoretical mass: 6305.41 m/z), observed mass of AP-
1 Hairpin-1 alone from Chromatogram A: 5748.3 m/z (theoretical mass: 5748.8 m/z). 
 
Next, the interaction of 2 with the AP-1 Hairpin-2 (Figure 5.8) was studied. Annealed 
AP-1 Hairpin-2 alone resulted in the appearance of a single peak at RT 8.01 min (Figure 
5.10A), which was identified by MALDI-TOF-MS (m/z 5749.2). After 24 hours 
incubation with 2 at 25 °C in a 4:1 molar ratio (2/DNA), a new peak emerged in the HPLC 
chromatogram at RT 9.24 min, although reaction had not gone to completion (Figure 
5.10B). The 1:1 stoichiometry of the adduct (2/DNA) was confirmed by MALDI-TOF-
MS (observed mass: 6306.1 m/z, theoretical mass: 6305.41 m/z) (Figure 5.10C), and the 
structure was concluded to be the mono-alkylated adduct with 2 bonded to G7 and with 
the bulk of the PBD Dimer lying in the minor groove pointing away from the loop. The 
conversion within 24 hours (approximately 50%) was assumed to reflect the lower 






Figure 5.10: HPLC chromatograms: A, Annealed AP-1 Hairpin-2 at RT 8.01 min; B, Annealed 
AP-1 Hairpin-2 after incubating with 2 for 24 hours, showing one new major adduct peak at RT 
9.24 min with reaction not complete after 24 hours; C, MALDI-TOF spectrum of the adduct (from 
peak at RT 9.24 min in Chromatogram B above). Observed mass of AP-1 Hairpin-2: 5749.2 m/z 
(theoretical mass: 5748.8 m/z); Observed mass of 2/AP-1 Hairpin-2 adduct: 6306.1 m/z 
(theoretical mass: 6305.41 m/z). 
 
Similar results were obtained for AP-1 Hairpin-3 (Figure 5.8), with only G12 available 
for covalent interaction with 2. HPLC analysis of annealed AP-1 Hairpin-3 alone 
provided a single peak at RT 8.14 min (Figure 5.11A) identified by MALDI-TOF-MS 
(m/z 5748.60).  After incubation with 2 for 24 hours at 25 °C in a 4:1 molar ratio (2/DNA), 
a new peak was observed at RT 9.07 min (Figure 5.11B), identified as the 1:1 2/AP-1 
Hairpin-3 adduct by MALDI-TOF-MS (observed mass: 6305.0 m/z, theoretical mass: 
6305.41 m/z) (Figure 5.11C). Again, the reaction was approximately 80% complete, 
consistent with mono-adduct formation. This result was also surprising due to the 
proximity of G12 to the loop structure. Molecular Dynamics Simulations (see also 
Section 5.9) suggested that, although located close to the TTT-loop, a 2:G12 mono-
alkylated adduct may be feasible, with the second PBD of the dimer orientated away from 






Figure 5.11: HPLC chromatograms: A, Annealed AP-1 Hairpin-3 at RT 8.14 min; B, Annealed 
AP-1 Hairpin-3 after incubating with 2 for 24 hours, showing one new major adduct peak at RT 
9.07 min with reaction not complete after 24 hours; C, MALDI-TOF spectrum of the adduct (from 
peak at RT 9.07 min in Chromatogram B above). Observed mass of AP-1 Hairpin-3: 5748.6 m/z 
(theoretical mass: 5748.8 m/z); Observed mass of 2/AP-1 Hairpin-3 adduct: 6305.0 m/z 
(theoretical mass: 6305.41 m/z). 
 
Lastly, 2 was incubated with the AP-1 Hairpin-4 (Figure 5.8) for 24 hours at 25 °C in a 
4:1 molar ratio (2/DNA). The HPLC chromatogram of annealed AP-1 Hairpin-4 alone 
provided a distinct peak at RT 8.03 min (Figure 5.12A) identified by MALDI-TOF-MS. 
After 24 hours incubation with 2, a new peak was observed at 8.86 min (Figure 5.12B) 
with reaction proceeding to approximately 70% completion. MALDI-TOF-MS analysis 
confirmed the new peak at RT 8.86 min to be the 1:1 2/AP-1 Hairpin-4 adduct, with an 
observed mass of 6305.6 m/z (theoretical mass: 6305.41 m/z) (Figure 5.12C). For this 
adduct there should be no steric issues, with one of the PBD units bonding to G17 and 






Figure 5.12: HPLC chromatograms: A, Annealed AP-1 Hairpin-4 at RT 8.03 min; B, Annealed 
AP-1 Hairpin-4 after incubating with 2 for 24 hours, showing one new major adduct peak at RT 
8.86 min with reaction not complete after 24 hours; C, MALDI-TOF spectrum of the adduct (from 
peak at RT 8.86 min in Chromatogram B above). Observed mass of AP-1 Hairpin-4: 5748.9 m/z 
(theoretical mass: 5748.8 m/z); Observed mass of 2/AP-1 Hairpin-4 adduct: 6305.6 m/z 
(theoretical mass: 6305.41 m/z). 
 
5.4.2 Summary of mono-alkylation study of SJG-136 
 
In summary, the results from the experiments with the AP-1 Hairpins 1-4 demonstrated 
that all four guanines (i.e., G1, G7, G12 or G17) are reactive toward 2, and are capable 
of forming mono-alkylated adducts. The reactivity of G1 was particularly surprising, as 
it means that the covalently bonded PBD must span only two base pairs, a phenomenon 
not previously observed and not previously thought to be possible. Previous studies on 
the DNA binding characteristics of PBDs have suggested that a minimum of three 









5.5 Interaction of anthramycin (1) and GWL-78 (3) with the inosine-modified 
AP-1 Hairpin-1 sequence 
 
To determine whether the size of the PBD molecule might affect the mode of binding to 
the AP-1 hairpins, similar experiments were carried out with the PBD monomers 
anthramycin (1) and the PBD C8-conjugate GWL-78 (3) (Figure 5.1).  
 
5.5.1 Results and discussion 
 
Working solutions of inosine modified AP-1 Hairpin-1 sequence were prepared 
according to the protocol described in Section 7.2.1.4. Anthramycin and GWL-78 
working solutions were prepared as described in Sections 7.2.1.6 and 7.2.1.7. PBD/DNA 
complexes were prepared according to the procedure described in Section 7.2.1.10. In 
brief, a PBD working solution of 100 µM was added to a DNA working solution of 25 
µM in a 4:1 ratio (PBD/DNA). The mixture was agitated and incubated for 24 hours at 
25 °C. Following the incubation, the samples were subjected to ion pair RP-
HPLC/MALDI-TOF-MS analysis as described in Sections 7.2.2 and 7.2.4 in detail.  
 
First, 1 was incubated with the AP-1 Hairpin-1 (with only the 5'-terminal guanine 
available for covalent binding) (Figure 5.8) in a 4:1 ratio (1/DNA) for 24 hours at 25 °C. 
However, no changes were observed in the HPLC chromatogram, with the unreacted AP-
1 Hairpin-1 peak at RT 7.90 min remaining the major peak (Figures 5.13A and 5.13B) 
as confirmed by MALDI-TOF-MS (observed mass: 5748.0 m/z, theoretical mass: 5748.8 
m/z) (Figure 5.13C). This suggested that substitution at the C8-position, as in SJG-136 
(2) may have a significant influence on the binding properties of a PBD, enhancing 
interaction of the molecule in the DNA minor groove through non-covalent interactions 
(e.g., van der Waals, hydrogen bonds and/or electrostatic interactions). The next step was 
to study GWL-78 (3), a synthetic PBD monomeric conjugate substituted at the C8 
position with a bis-pyrrole side-chain that allows the molecule to span a total of five to 
six DNA base pairs. It was anticipated that this molecule may behave more like SJG-136 
(2) than anthramycin (1) due to the large non-covalent DNA-binding moiety at the C8-
position. As predicted, when 3 was incubated with the AP-1 Hairpin-1 (RT 8.69 min, 
Figure 5.13D) in a 4:1 ratio (3/DNA) for 24 hours at 25 °C, a new peak was observed at 
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11.13 min (Figure 5.13E), although the extent of reaction was much lower compared to 
2. The new peak was identified as the 1:1 3/AP-1 Hairpin-1 adduct by MALDI-TOF-MS 




Figure 5.13: A, HPLC chromatogram showing annealed AP-1 Hairpin-1 at RT 7.90 min; B, 
Annealed AP-1 Hairpin-1 after incubating with 1 for 24 hours showing no adduct formation after 
24 hours; C, MALDI-TOF spectrum of 1 with the AP-1 Hairpin-1 confirming that no adduct had 
formed (AP-1 Hairpin-1 observed mass: 5748.0 m/z, theoretical mass: 5748.8 m/z); D, Annealed 
AP-1 Hairpin-1 at RT 8.69 min; E, Annealed AP-1 Hairpin-1 after incubating with 3 for 24 hours 
showing the appearance of an adduct peak at RT 11.13 min with approximately 23% complete 
reaction after 24 hours; F, MALDI-TOF spectrum of 3/AP-1 Hairpin-1 confirming the identity of 
adduct formation (AP-1 Hairpin-1 observed mass: 5749.5 m/z, theoretical mass: 5748.8 m/z, AP-
1 Hairpin-1 adduct observed mass: 6338.6 m/z, theoretical mass: 6339.4 m/z). The observed 
differences in the RT of AP-1 Hairpin-1 alone (i.e., Figure 5.13A and Figure 5.13D) occurred 




5.5.2 Summary of the interaction of anthramycin and GWL-78 with the AP-1 
Hairpin-1 sequence 
 
From these results it was concluded that covalent bonding of a PBD to a terminal guanine 
may only occur when there is sufficient molecular bulk at the C8-position (e.g., another 
PBD unit in the case of SJG-136, or a bis-pyrrole unit in the case of GWL-78) to provide 
stabilisation to the adduct by interacting non-covalently in the adjacent minor groove. 
 
5.6 Interaction of anthramycin (1), SJG-136 (2) and GWL-78 (3) with the AP-
1 1 Guanine sequence 
 
In order to rule out whether these new observations of a PBD monomer (3) and dimer (2) 
bonding to a terminal guanine might be due to a change in DNA conformation caused by 
the insertion of inosine bases, the interaction of 1, 2, and 3 with AP-1 1 Guanine (1G) 
(Figure 5.14) was studied. This hairpin contains a 5'-terminal guanine without any 
inosine modifications. Instead, G7, G12 and G17 were replaced with adenine bases, and 








Figure 5.14: AP-1 1 Guanine hairpin sequence which is based on the same AP-1 sequence but 
with three of the four guanine bases (except the 5'-terminal-guanine) mutated to an A. 
 
5.6.1 Results and discussion 
 
Working solutions of inosine modified AP-1 1G 1 sequence were prepared according to 
the protocol described in Section 7.2.1.4. Anthramycin, GWL-78 and SJG-136 working 
solutions were prepared as described in Sections 7.2.1.6, 7.2.1.7 and 7.2.1.9. PBD/DNA 
complexes were prepared according to the procedure described in Section 7.2.1.10. 
Briefly, a PBD working solution of 100 µM was added to a DNA working solution of 25 
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µM in a 4:1 ratio (PBD/DNA). The mixture was agitated and incubated for 24 hours at 
25 °C. Following the incubation, the samples were subjected to ion pair RP-
HPLC/MALDI-TOF-MS analysis as described in Sections 7.2.2 and 7.2.4 in detail.  
 
The AP-1 1G hairpin sequence (Figure 5.14) was incubated with 1, 2, and 3 in a 4:1 ratio 
(PBD/DNA) for 24 hours at 25 °C, and immediately subjected to HPLC and MALDI-
TOF-MS analysis. AP-1 1G hairpin alone gave a single peak at RT 9.56 min (Figure 
5.15A) identified by MALDI-TOF-MS. After reaction with 2, one new major peak at RT 
14.19 min appeared along with a minor peak at RT 18.40 min (Figure 5.15B). The 
stoichiometry of the main new peak as the 1:1 2/AP-1 1G hairpin was confirmed by 
MALDI-TOF-MS analysis with an observed mass of 6347.9 m/z (theoretical mass: 
6347.5 m/z) (Figure 5.15E). Incubation of 3 with the AP-1 1G hairpin gave one new 
major peak at RT 12.07 min and a minor peak at RT 18.81 min (Figure 5.15C). Reaction 
was not complete after 24 hours with some AP-1 1G hairpin remaining (Figure 5.15C). 
The stoichiometry of the main adduct formed was confirmed by MALDI-TOF-MS 
analysis as the 1:1 3/AP-1 1G hairpin with a mass of 6381.2 m/z (theoretical mass: 6381.5 
m/z) (Figure 5.15F). The identity of the minor peaks at RT 18.40 min (for 2) and RT 
18.81 min (for 3) could not be confirmed. Lastly, HPLC analysis of the interaction of 1 
with the AP-1 1G hairpin provided no changes in the chromatogram (Figure 8D), with 







Figure 5.15: HPLC chromatograms: A, Annealed AP-1 1G hairpin at RT 9.56 min; B, Annealed 
AP-1 1G hairpin after incubating with 2 for 24 hours with the appearance of one new major adduct 
peak at RT 14.19 and a minor peak at RT 18.40 min; C, Annealed AP-1 1G hairpin after incubating 
with 3 for 24 hours with the appearance of one new major adduct peak at RT 12.07 and a minor 
peak at RT 18.81 min; D, Annealed AP-1 1G hairpin after incubating with 1 for 24 hours showing 
no adduct formation after 24 hours; E, MALDI-TOF spectrum of 2 with the AP-1 1G hairpin 
confirming the identity of adduct formation, AP-1 1G hairpin observed mass: 5790.5 m/z 
(theoretical mass: 5790.9 m/z), 2/ AP-1 1G hairpin adduct observed mass: 6347.9 m/z (theoretical 
mass: 6347.5 m/z); F, 3 with the AP-1 1G hairpin confirming the stoichiometry of adduct 
formation, AP-1 1G hairpin observed mass: 5790.1 m/z (theoretical mass: 5790.9 m/z), 3/AP-1 
1G hairpin adduct observed mass: 6381.2 m/z (theoretical mass: 6381.5 m/z); G, 1 with the AP-
1 1G hairpin confirming no adduct formation, AP-1 1G hairpin observed mass: 5791.5 m/z 






5.6.2 Summary of the interaction of anthramycin, GWL-78 and SJG-136 with AP-1 
1G hairpin sequence  
 
In summary, these results supported the observations made with the AP-1 Hairpin-1, and 
confirmed that the inosine mutations had not altered the reactivity of the DNA toward the 
PBDs in any way. 
 
5.7 Interaction of SJG-136 (2) with double-stranded inosine-modified AP-1 
sequences 
 
In order to explore whether the observations made within the inosine-modified AP-1 
hairpins were a consequence of their hairpin structure, a similar series of experiments was 
carried out on the sequence-related DNA duplexes shown in Figure 5.16. As with the AP-
1 hairpin oligonucleotides 1-4 (Figure 5.8), three of the four guanines available for 
covalent attachment of a PBD were replaced with non-nucleophilic inosines resulting in 
only one guanine available for covalent bonding in each case. Each duplex 
oligonucleotide had a length of 8 base pairs, as it has been previously demonstrated by 
this laboratory (unpublished data) that a minimum of 7 base pairs is required to ensure a 




Figure 5.16: Structures of the inosine-modified DNA duplexes used in the study. Duplexes 1-4 
are analogous to AP-1 Hairpins 1-4 (Figure 5.8) in that three of the four guanines have been 





5.7.1 Results and discussion 
 
Working solutions of inosine modified duplex oligonucleotides were prepared according 
to the procedure described in Section 7.2.1.5. SJG-136 working solutions were prepared 
as described in Section 7.2.1.9. SJG-136/DNA complexes were prepared according to the 
procedure described in Section 9.2.1.10. Briefly, a SJG-136 working solution of 100 µM 
was added to a DNA working solution of 25 µM in a 4:1 ratio (PBD/DNA). The mixture 
was mixed and incubated for 24 hours at 25 °C. Following the incubation, the samples 
were subjected to ion pair RP-HPLC/MALDI-TOF-MS analysis as described in Sections 
7.2.2 and 7.2.4 in detail.  
 
Annealed Duplex-1 (Figure 5.16) gave two peaks in the HPLC chromatogram at RT 7.16 
min (Seq-2) and RT 7.46 min (Seq-1) (Figure 5.17A) identified as the single strands of 
Duplex-1 by MALDI-TOF-MS with detected masses: Seq-2, 2378.8 m/z and Seq-1, 
2395.2 m/z (theoretical masses: Seq-2, 2379.6 m/z and Seq-1, 2394.6 m/z) (Figure 
5.17C). This result was in accord with previous reports that double-stranded 
oligonucleotides of this length denature under these HPLC conditions157. Duplex-1 was 
then incubated with 2 in a 4:1 ratio (2/DNA) for 24 hours at 25 °C, and subjected to HPLC 
analysis. A new minor peak appeared at RT 19.30 min (Figure 5.17B) suggesting that an 
adduct had formed. Reaction was incomplete after 24 hours, with peaks corresponding to 
Seq-2 (RT 7.20 min) and Seq-1 (RT 7.52 min) remaining (Figure 5.17B). Subsequent 
MALDI-TOF-MS analysis confirmed the presence of a 1:1 2/Seq-1 adduct with an 
observed mass of 2951.8 m/z (theoretical mass: 2951.21 m/z) (Figure 5.17C). It is 
noteworthy that in a similar manner to the denaturation that occurs during the HPLC 
process, under MALDI-TOF-MS conditions the duplex denatures into single strands with 
the PBD still attached to the guanine-containing strand. This observation was consistent 
with the data obtained for AP-1 Hairpin-1, as Duplex-1 contains only one available 








Figure 5.17: HPLC chromatograms; A, Annealed Duplex-1 at RT 7.16 min (Seq-2) and RT 7.46 
min (Seq-1), showing that the duplex had denatured under the HPLC conditions. B, Annealed 
Duplex-1 after incubating with 2 for 24 hours showing the appearance of one new adduct peak at 
RT 19.30 min (2/Seq-1), with the reaction not complete after 24 hours (~13% adduct conversion); 
C, MALDI-TOF spectrum of 2 with Duplex-1, confirming the stoichiometry of the adduct 
formed; single strands of Duplex-1, observed masses: Seq-2, 2378.8 m/z and Seq-1, 2395.2 m/z 
(theoretical mass: Seq-2 2379.6 m/z and Seq-1 2394.6 m/z), and Duplex-1 observed mass: 4774.9 
m/z (theoretical mass: 4774.2 m/z), 2/Seq-1 adduct observed mass: 2951.8 m/z (theoretical mass: 
2951.21 m/z). The insignificant differences in the RT for the single-stranded oligonucleotides in 
chromatograms A and B are due to HPLC run-time variations. 
 
Next, Duplex-2 (Figure 5.16) was studied. The resulting chromatogram provided two 
peaks at RT 7.13 min and RT 7.27 min corresponding to Seq-4 and Seq-3, respectively 
(Figure 5.18A). Their stoichiometry was confirmed by MALDI-TOF-MS with detected 
masses of m/z 2378.9 and 2394.5 (theoretical masses: Seq-4, 2379.6 m/z and Seq-3, 
2394.6 m/z) (Figure 5.18C). After 24 hours incubation with 2 at 25 °C in a 4:1 molar 
ratio (2/DNA), a new minor peak appeared at RT 19.30 min (Figure 5.18B). Reaction 
was incomplete after 24 hours (~14% adduct formation) with the two major peaks at RT 
7.16 min (Seq-4) and RT 7.32 min (Seq-3) remaining (Figure 5.18B). The stoichiometry 
of the adduct formed was confirmed by MALDI-TOF-MS analysis as the 1:1 2/Seq-3 
adduct with a detected mass of 2952.0 m/z (theoretical mass: 2951.21 m/z) (Figure 
5.18C). This result was similar to that obtained for AP-1 Hairpin-2, and the slow extent 
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of reaction may be explained by the least preferred A-ring-5' oriented adduct that must 




Figure 5.18: HPLC chromatograms; A, Annealed Duplex-2 at RT 7.13 min (Seq-4) and RT 7.27 
min (Seq-3); B, Annealed Duplex-2 after incubating with 2 for 24 hours showing a new adduct 
peak at RT 19.30 min (2/Seq-3), with the reaction not complete after 24 hours; C, MALDI-TOF 
spectrum of 2 with Duplex-2, confirming the stoichiometry of the adduct formed; single strands 
of Duplex-2, observed masses: Seq-4, 2378.9 m/z and Seq-3, 2394.5 m/z (theoretical mass: Seq-
4 2379.6 m/z and Seq-3 2394.6 m/z), and Duplex-2 observed mass: 4773.9 m/z (theoretical mass: 
4774.2 m/z), 2/Seq-3 adduct observed mass: 2952.0 m/z (theoretical mass: 2951.21 m/z). 
 
HPLC analysis of Duplex-3 (Figure 5.16) provided two peaks at RT 6.86 min (Seq-6) 
and RT 7.40 min (Seq-5) (Figure 5.19A) identified by MALDI-TOF-MS as the 
component strands with observed masses of 2378.9 m/z (Seq-5) and 2394.2 m/z (Seq-6) 
(theoretical masses: Seq-5, 2379.6 m/z and Seq-6, 2394.6 m/z) (Figure 5.19C). 
Incubation for 24 hours at 25 °C with 2 in a 4:1 ratio (2/DNA) provided a major new peak 
at RT 18.30 min, the stoichiometry of which was confirmed by MALDI-TOF-MS as the 
1:1 2/Seq-6 adduct with an observed mass of 2951.5 m/z (theoretical mass: 2951.21 m/z) 
(Figure 5.19C). However, the reaction was incomplete after 24 hours with ~43% adduct 
formation (Figure 5.19B). Interestingly, the extent of reaction of 2 with Duplex-3 was 
greater than that for Duplex-1 or Duplex-2, providing further evidence that a PBD can 







Figure 5.19: HPLC chromatograms; A, Annealed Duplex-3 at RT 6.86 min (Seq-6) and RT 7.40 
min (Seq-5); B, Annealed Duplex-3 after incubating with 2 for 24 hours showing a new adduct 
peak at RT 18.30 min (2/Seq-6), with the reaction not complete after 24 hours; C, MALDI-TOF 
spectrum of 2 with Duplex-3, confirming the stoichiometry of the adduct formed; single strands 
of Duplex-3, observed masses: Seq-5, 2378.9 m/z and Seq-6, 2394.2 m/z (theoretical mass: Seq-
5 2379.6 m/z and Seq-6 2394.6 m/z), and Duplex-3 observed mass: 4774.6 m/z (theoretical mass: 
4774.2 m/z), 2/Seq-6 adduct observed mass: 2951.5 m/z (theoretical mass: 2951.21 m/z). 
 
Lastly, HPLC analysis of Duplex-4 (Figure 5.16) gave two peaks at RT 7.07 min (Seq-
8) and RT 7.41 min (Seq-7) (Figure 5.20A) confirmed by MALDI-TOF-MS as Seq-7 
with an observed mass of 2378.7 m/z (theoretical mass: 2379.6 m/z) and Seq-8, 2394.9 
m/z (theoretical mass: 2394.6 m/z) (Figure 5.20C). After incubation with 2 at 25 °C in a 
4:1 molar ratio (2/DNA), a new minor peak at RT 18.30 min was observed although 
reaction did not go to completion with ~7% adduct formation (Figure 5.20B). The 
stoichiometry of the peak at RT 18.30 min was confirmed by MALDI-TOF-MS analysis 
as the 1:1 2/Seq-8 adduct with a detected mass of 2951.7 m/z (theoretical mass: 2951.21 






Figure 5.20: HPLC chromatograms; A, Annealed Duplex-4 at RT 7.07 min (Seq-8) and RT 7.4 
min (Seq-7); B, Annealed Duplex-4 after incubating with 2 for 24 hours showing a new adduct 
peak at RT 18.30 min (2/Seq-8), with the reaction not complete after 24 hours; C, MALDI-TOF 
spectrum of 2 with Duplex-4, confirming the stoichiometry of the adduct formed; single strands 
of Duplex-4, observed masses: Seq-7, 2378.7 m/z and Seq-8, 2394.9 m/z (theoretical mass: Seq-
7 2379.6 m/z and Seq-8 2394.6 m/z), and Duplex-4 observed mass: 4774.8 m/z (theoretical mass: 
4774.2 m/z), 2/Seq-8 adduct observed mass: 2951.7 m/z (theoretical mass: 2951.21 m/z). 
 
5.7.2 Summary of the interaction of SJG-136 (2) with double-stranded inosine-
modified AP-1 sequences 
 
In summary, the results obtained from the interaction of 2 with Duplexes 1-4 (Figure 
5.16) were consistent with those obtained for AP-1 Hairpins 1-4 (Figure 5.8). Duplex-1 
and Duplex-3 both contain a guanine at the 5'-terminus and 2 was able to react with both. 
 
5.8 Interaction of anthramycin (1) and GWL-78 (3) with double-stranded 
inosine modified Duplex-1 sequence 
 
Based on the data obtained for AP-1 Hairpin-1, anthramycin (1) was not expected to react 
with Duplex-1 as it lacks a substituent at the C8-position that would help stabilise its 
accommodation in the DNA minor groove. In contrast, 3 was expected to react due to its 




5.8.1 Results and discussion 
 
The working solution of inosine modified Duplex-1 was prepared according to the 
procedure described in Section 7.2.1.5. Anthramycin and GWL-78 working solutions 
were prepared as described in Sections 7.2.1.6 and 7.2.1.7. PBD/DNA complexes were 
prepared according to the protocol described in Section 7.2.1.10. Briefly, a PBD working 
solution of 100 µM was added to a DNA working solution of 25 µM in a 4:1 ratio 
(PBD/DNA). The mixture was mixed and incubated for 24 hours at 25 °C. Following the 
incubation, the samples were subjected to ion pair RP-HPLC/MALDI-TOF-MS analysis 
as described in Sections 7.2.2 and 7.2.4 in detail.  
 
The results shown in Figure 5.21A-C confirm that there is no reaction of 1 with Duplex-
1 after 24 hours incubation. However, Figures 5.21D-F show that incubation of 3 with 
Duplex-1 for 24 hours provides an additional peak in the chromatogram at RT 14.27 min 
(Figure 5.21E), although the reaction was incomplete with ~8% adduct formation.  The 
stoichiometry of the adduct formed was confirmed to be the 1:1 3/Seq-1 adduct by 
MALDI-TOF-MS analysis with a detected mass of 2985.7 m/z (theoretical mass 2985.2 






Figure 5.21: HPLC chromatograms: A, Annealed Duplex-1 at RT 6.39 min (Seq-2) and RT 6.76 
min (Seq-1); B, After incubation with 1 for 24 hours showing no reaction; C, MALDI-TOF 
spectrum of 1 with Duplex-1 confirming no reaction; Single strands of Duplex-1 observed 
masses: Seq-2, 2378.9 m/z and Seq-1, 2394.8 m/z (theoretical masses: Seq-2, 2379.6 m/z and 
Seq-1, 2394.6 m/z);  D, Annealed Duplex-1 at RT 6.39 min (Seq-2) and 6.76 min (Seq-1); E, 
Annealed Duplex-1 after incubating with 3 for 24 hours showing a new peak at RT 14.27 min, 
although reaction was incomplete (~8% adduct formed); F, MALDI-TOF spectrum of 3 with 
Duplex-1 confirming the stoichiometry as the 1:1 3/Seq-1 adduct; Single strands of Duplex-1 
observed masses: Seq-2, 2378.7 m/z and Seq-1, 2394.0 m/z (theoretical masses: Seq-2, 2379.6 
m/z and Seq-1, 2394.6 m/z) and double-stranded Duplex-1 observed mass of 4774.3 m/z 
(theoretical mass: 4774.2 m/z), 3/Seq-1 adduct observed mass of 2985.7 m/z (theoretical mass: 
2985.2 m/z). 
 
5.8.2 Summary of the interaction of anthramycin and GWL-78 with double-
stranded inosine modified Duplex-1 sequence 
 
Taken together, these results suggest that the C8-substitution status of a PBD molecule 
can have a significant effect on its binding behaviour to a target DNA sequence. For 
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example, 1 lacks a C8-substituent and is unable to interact with the guanine located at the 
5'-terminus of AP-1 Hairpin-2 and Duplex-1, whereas 3 can bond to both sequences due 
to its C8-bis-pyrrole substituent. For similar reasons, SJG-136 (2) can also bond to the 5'-
terminal guanine of AP-1 Hairpin-2 and Duplex-1 because the second PBD unit joined 
through the C8-O-(CH2)3-O-C8' linker can also provide stabilisation by interacting in the 
minor groove, even if there is no suitable guanine available for alkylation by the second 
PBD unit. 
 
5.9 Molecular dynamics simulations* 
 
Molecular dynamics simulations were carried out to attempt to predict the most preferred 
reacting guanine(s) in the AP-1 hairpin sequence and correlate with biophysical results. 
In these simulations, 2 was covalently bound to every potentially reacting guanine base 
(i.e., G1, G7, G12 and G17) in an effort to rationalise the structures of the adducts formed 
in the HPLC studies. As 2 is known to form mono-adducts and inter- and intrastrand 
cross-links191b, 205, all of these adduct types were investigated and, in the case of mono-
adducts, both loop-facing (i.e., forward) and non-loop-facing (i.e., reverse) orientations 
were considered. The study design also considered potential reaction sites based on the 
span of the molecule. For example, in the case of G7 and G12, mono-adducts with the 
bulk of the molecule pointing toward the loop were not analysed due to potential steric 
hindrance with the TTT-loop. However, adducts at G17 in both orientations were 
investigated despite the fact that the significant bulk of a 3'-oriented adduct would be 
positioned outside of the minor groove environment. 
 
Potential energy calculations (kcal/mol) on each adduct were undertaken to establish the 
most preferred reacting guanines for either mono-adduct or cross-link formation. 
Although 2 is known to prefer to form cross-linked adducts over a six or seven base-pair 
sequence (i.e., Pu-GATC-Py, Pu-GATG-Py, Pu-GAATG-Py or Pu-GAATC-Py205), initial 
potential energy calculations suggested that the shorter interstrand cross-linked adduct 
spanning 5'-GAC-3' (i.e., G1-G17) is preferred by 12.41 kcal/mol compared to  
 





the extended G7-G17 interstrand cross-linked adduct (i.e., 5'-CATTG-3') (Figure 5.2),  
despite the G1-bonded PBD unit interacting with two rather than the usual three base 
pairs at the terminal 5'-guanine.  Although this result was surprising, especially as the 
extended 5'-ATT-3' bases in the centre of the hairpin should form van der Waals 
interactions with the C8/C8'-linker of 2, it is possible that DNA breathing and base-pair 
separation affects the ability of 2 to stretch across the extended 5'-CATTG-3' sequence 
which may have a detrimental effect on potential energy values. Furthermore, previous 
studies have suggested that the A-ring-3' orientation for a PBD (i.e., 5'-GAC-3') is 
preferred to A-ring-5' (i.e., 5'-CATTG-3'), and although less favourable than Pu-GATC-
Py, a 5'-GAC-3' adduct of 2 has been previously reported205. For possible mono-adducts, 
the potential energy calculations suggested that G7 is the preferred reacting guanine 
(Figure 5.22). During simulations of this adduct, a stabilising hydrogen bond was 
observed to form between the N10-H of the PBD and the N3 of A14. Furthermore, the 
second PBD unit of the dimer formed favourable non-covalent interactions with the 
central AT-tract of the sequence (i.e., 5'-ATT-3'), with both interactions likely to contribute 
to enhanced stability within the minor groove environment. The potential energy 
calculations suggested a hierarchy of mono-adduct formation of G7 > G17 (in the forward 
orientation) > G1 > G12 > G17 (in the reverse orientation). This ranking was broadly 
consistent with the observations from the inosine replacement experiments which 
suggested that G7 and G17 are favoured for nucleophilic attack based on the faster 
reaction rates of the parent AP-1 sequence, AP-1 1, 12I and AP-1 7, 12I, AP-1 Hairpins 2 
and 4, and Duplexes 2 and 4. Conversely, potential energy calculations predicted that less 
favourable binding sites would include G12 where the TTT-loop is likely to inhibit 
interaction of 2, or G17 (in the reverse orientation) where the second PBD unit of the 
dimer would be positioned outside of the groove where it would not be able to form non-













Figure 5.22: Low energy snapshot of a molecular dynamics simulation showing the 
accommodation of 2 (green sticks) in the minor groove while covalently bonded to G7 of the 
parent AP-1 sequence (Figure 5.2). The NH group of the PBD formed a hydrogen bond with the 
adjacent A14 adenine base (yellow), and the molecule maintained good isohelicity with the minor 
groove for the duration of the simulation (10 ns). 
 
It is noteworthy that potential energy calculations for the bonding of a PBD molecule to 
G1, both in mono-adduct and cross-linking modes, suggest that it is viable as a reacting 
guanine. G1 adducts were observed by HPLC for the reaction of both 2 (Figure 5.23) and 
3 (Figure 5.24C and D) with 5'-GACATTIC-TTT-IAATITC-3' (AP-1 Hairpin-1) where 
G1 is the only available guanine for reaction, and also in the sequence 5'-GATATTAT-
TTT-ATAATATC-3' (AP-1 1G hairpin) which is also devoid of other reactive guanines. 
However, when anthramycin (1) was reacted with the same sequences (Figure 5.24A and 
B), no adducts were formed. Although molecular dynamics simulations of 1 covalently 
bound to G1 suggested that an adduct in the C11-S configuration is theoretically possible, 
it is likely that the lack of non-covalent interactions from a C8-substituent, as available 
in case of 2 and 3, leads to low overall stabilisation of the adduct. Further evidence for 
this hypothesis was obtained through molecular dynamics simulations of 2 and 3 bound 
non-covalently to AP-1 Hairpin-1, where non-covalent interactions from the C8-pyrrole 
chain (in the case of 3) and the non-alkylating PBD unit (in the case of 2), oriented the 
alkylating PBD component over G1 for a covalent attack. However, in the case of 1 which 
does not have a C8-side chain, it moved up and down the minor groove during the 







Figure 5.23: A, Schematic model of 2 bound covalently to G1 of AP-1 Hairpin-1 with the bulk 
of the molecule positioned within the minor groove and pointing towards the TTT-loop (i.e., the 
forward direction); B, Low energy snapshot of a molecular dynamics simulation (10 ns) of the 
adduct shown in Panel A, illustrating the good accommodation of 2 (green sticks) in the minor 
groove and forming non-covalent interactions between the central methylene linker of the ligand 
and the A2:T18 and C3:I17 base-pairs. 2 is covalently bound to the 5'-terminal G1 of AP-1 








Figure 5.24: A, Schematic model of 1 (green) covalently bound to G1 (magenta) of AP-1 Hairpin-
1 (Figure 5.8) with the A-ring pointing towards the TTT-loop (A-ring-3' orientation); B, Low 
energy snapshot of 10 ns molecular dynamics simulation illustrating the C2-tail of 1 orienting 
outside of the DNA, suggesting a DNA triplet is necessary for accommodation of the molecule; 
C, Schematic model of 3 covalently bound to G1 of AP-1 Hairpin-1 with the A-ring pointing 
towards the TTT-loop; D, Low energy snapshot of 10 ns molecular dynamics simulation of 3 
(blue) covalently bound to G1 (magenta) of AP-1 Hairpin-1, illustrating the comfortable 
accommodation of the poly-pyrrole tail of 3 in the minor groove. It is likely that the poly-pyrrole 
tail forms non-covalent interactions with 5'-ACAT-3' (yellow), guiding the PBD core to G1.         
 
Simulations of 1, 2 and 3 covalently bound to G1 of AP-1 Hairpin-1 were also undertaken 
with the ligands pointing away from the loop (Figures 5.25, 5.26 and 5.27) to investigate 
the orientation of the G1 adduct. Potential energy calculations of 2 and 3 in both 
orientations suggest a potential energy difference of between 40 kcal/mol and 43 
kcal/mol, respectively, in favour of the loop-facing orientation. This most likely reflects 
the unfavourable energetics when the bulk of the molecule is pointing out of the DNA 
helix into a water environment rather than laying in the minor groove where it can provide 
adduct stabilisation through non-bonding interactions. As anticipated, the energy 
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difference between the two possible orientations of 1 covalently bonded to G1 was less 
(i.e., -2736.10 kcal/mol versus -2733.60 kcal/mol) due to the lack of a C8-substituent that 






Figure 5.25: A, Schematic model of 2 (green) covalently bound to G1 (magenta) of AP-1 Hairpin-
1 with the A-ring pointing away from the TTT-loop (A-ring-3' orientation) and the second PBD 
of the dimer orienting outside of the minor groove; B, Low energy snapshot of 10 ns molecular 














Figure 5.26: A, Schematic model of 3 (blue) covalently bound to G1 (magenta) of AP-1 Hairpin-
1 with the A-ring pointing away from the TTT-loop (A-ring-3' orientation) and poly-pyrrole chain 
orienting outside of the minor groove; B, Low energy snapshot of 10 ns molecular dynamics 
simulation illustrating the poly-pyrrole chain of 3 orienting outside of the DNA minor groove and 
















Figure 5.27: A, Schematic model of 1 (light green) covalently bound to G1 (magenta) of AP-1 
Hairpin-1 with the A-ring pointing away from the TTT-loop (A-ring-3' orientation) B, Low 
energy snapshot of 10 ns molecular dynamics simulation illustrating the PBD (1) bound to the 













In summary, the data obtained from the study on the hairpins outlined in Figure 5.3, 
suggest that the G7-G17 interstrand cross-link may be the preferred formed adduct 
between SJG-136 and the parent AP-1 hairpin sequence as only for the AP-1 1, 12I 
sequence the same extent of reaction was observed as for the parent AP-1 sequence during 
the HPLC/MS study. 
 
Moreover, this is the first report of PBD molecules covalently binding to a guanine base 
located at the end of a DNA hairpin or duplex sequence. To date, PBDs have been 
reported to span three DNA base pairs with a preference for the 5'-Pu-G-Pu-3' motif, and 
were not thought to be able to bond to a reactive guanine at a 3'- or 5'-terminus. The 
results presented in this study clearly demonstrate the ability of the C8-conjugated PBD 
GWL-78 (3) and the PBD dimer SJG-136 (2) to covalently interact with a terminal 
guanine, whereas the monomeric anthramycin (1) does not react. This is most likely due 
to the C8-substituent of 3, or one of the C8-linked PBD units of 2, interacting in the minor 
groove to provide stability for the adduct. This has possible implications for the 
mechanism of the cellular cytotoxicity and in vivo anti-tumour activity of C8-substituted 
PBD monomers and C8-linked PBD dimers, as they may be able to covalently interact 
















Chapter 6: Overall conclusion and future work 
 
An ion pair reversed phase HPLC and MALDI-TOF-MS assay has been developed to 
study the interaction of the pyrrolobenzodiazepine (PBD) dimer SJG-136 with the 
cognate target DNA sequences of the oncogenic transcription factors NF-B, EGR-1, AP-
1 and STAT3. Initially, the assay was validated by using it to investigate the interaction 
of the PBD monomers GWL-78 and KMR-28-39 with the target sequences. These 
molecules had already been reported to interact with the consensus sequences of the 
transcription factors NF-Y and NF-B90, 102, respectively. The data obtained (see Chapter 
2) indicated that the analytical method developed may be capable of identifying and 
quantitating the rate and extent of reaction of these PBD monomers with NF-B, EGR-
1, AP-1 and STAT3 cognate sequences. After validating the HPLC/MS assay, it was then 
used to evaluate the ability of SJG-136 to bind to these transcription factor sequences 
with a view to using the information obtained to help interpret the activity of SJG-136 in 
various tumour cell lines. For example, SJG-136 is particularly potent in NF-κB-
dependent (e.g., leukaemia and lung cancer) and AP-1-dependent cell lines (e.g., colon 
carcinoma) according to NCI 60 cell line screen data158, while the STAT3-dependent 
breast cancer cell line MDA-MB-435 appeared to be one of the least sensitive cell lines 
toward SJG-136. 
  
The data presented in Chapter 3 represent the first report in which SJG-136 appears to 
bind to the consensus sequences of NF-κB (two possible consensus sequences were 
studied), EGR-1, AP-1 and STAT3 based on the HPLC/MS methodology developed. 
Significant differences in the extent and rate of reaction with these individual sequences 
were observed. For example, SJG-136 reacted rapidly with the NF-B-2 and AP-1 
sequences, but more slowly with the EGR-1 sequence. This observation however may be 
due to the insufficient peak resolution of the applied method. Future studies will include 
improvement of the HPLC method in order to address this issue. The reaction rate was 
slowest with the NF-κB-1 and STAT3 sequences.  In accord with previous reports that 
SJG-136 can form intra- and interstrand cross-links and mono-alkylated adducts within 
the DNA minor groove96, 136, multiple adducts were observed for the reaction of SJG-136 
with some of the transcription factor sequences due to their structures which contain 
multiple GC base pairs. For example, SJG-136 formed three distinct adducts with the 
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STAT3 consensus sequence and two with the NF-κB-1 sequence, while only a single 
adduct was observed to form with the NF-B-2, EGR-1 and AP-1 sequences. These 
results may be useful in future studies to further understanding of the mechanism of action 
of SJG-136, and to help correctly interpret the results of biochemical and pharmacological 
assays. 
 
SJG-136 was also evaluated for its ability to affect protein expression in the human colon 
carcinoma cell line HT-29 (AP-1 dependent) and the human breast cancer cell line MDA-
MB-231 (STAT3 dependent) using the polymerase chain reaction (PCR) and Western 
blotting methodologies, and the results are presented in Chapter 4. Although SJG-136 
was observed to significantly down-regulate AP-1- and STAT3-dependent protein 
expression (e.g., Bcl-2, fascin, NNMT, VEGF, CREB5 and p53) in the PCR study, 
equivalent down-regulation was not observed by Western blotting, and only cyclin D1 
protein expression levels were significantly reduced. This discrepancy was surprising, 
and future studies could include time-course studies using a wide range of inducer agents 
applied to the cells for different time intervals as well as at different concentrations. 
Furthermore, time-course experiments, and especially longer incubation times adjusted 
to the half-lives of the proteins of interest, could be carried out to provide further 
information. Also, a broader range of proteins implicated in tumour development and 
progression could be investigated. 
 
The surprising observations made with the AP-1 cognate sequence (i.e., fastest reaction 
with SJG-136 with 100% adduct formation in the HPLC/MS study) led to a DNA binding 
site analysis on this particular sequence in order to identify the reactive guanines 
responsible for the observed rate and extent of reaction. For this reason, the study further 
included inosine replacement experiments as a strategy for trying to elucidate the type of 
adducts formed within the AP-1 sequence. The guanines were consecutively replaced 
with inosine bases which lack the nucleophilic C2-NH2 functionalities and prevent 
covalent interaction of SJG-136. The results presented in Chapter 5 suggest that the 
interstrand cross-link at G7-G17 may be the preferred formed adduct between SJG-136 
and the parent AP-1 hairpin sequence. Moreover, the results presented in Chapter 5 
demonstrate for the first time, that PBD monomers and dimers can covalently bond to a 
guanine base located at the end of DNA hairpin or duplex fragments.  Before these results 
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were obtained, PBDs were thought to require three DNA bases (with a preference for a 
5'-Pu-G-Pu-3' motif) for covalent attachment within the DNA minor groove298. 
Furthermore, for C8/C8'-linked dimers such as SJG-136 and DSB-120, 6 or 7 base pairs 
were reported to be essential for covalent binding to DNA97. However, the discovery that 
PBD monomers and dimers can covalently bond to terminal guanine residues highlights 
the importance of the C8-substituent in dictating the formation of particular types of 
adduct.  The biological relevance of these findings may have implications for the 
mechanism of the cellular cytotoxicity and in vivo anti-tumour activity of C8-substituted 
PBD monomers and C8-linked PBD dimers. To date, PBDs have been reported to exert 
their anti-tumour activity through the formation of mono-alkylated or intra- or interstrand 
cross-linked adducts within stretches of DNA, thus inhibiting crucial processes including 
transcription factor binding, enzyme processing, transcription, or arrest of the replication 
fork. However, the data presented in Chapter 5 suggest that a mechanism involving 
binding of C8-substituted PBDs to the ends of DNA double-strand breaks in cells could 
also occur. This finding may have significance for the PBD-based Antibody-Drug 
Conjugates (ADCs) currently in clinical evaluation, and numerous others at the pre-
clinical stage. 
 
Other future studies could include evaluation of SJG-136 in NF-κB and EGR-1 over-
expressing cell lines such as leukaemia and ovarian tumour cells in order to correlate 
protein expression with the observations made during the HPLC/MS studies. 
Furthermore, the HPLC/MS assay developed during this project could be applied to novel 
PBD monomers and dimers produced in the future to investigate their ability to inhibit 













Chapter 7: Experimental (biophysical and biological evaluation) 
 
7.1 Consumables and reagents used for biophysical and biological 
experiments 
 
Consumables and reagents including their manufacturer used for biophysical and 
biological experiments are listed in Table 7.1. 
 




Sigma-Aldrich, Dorset, UK Tris-HCl, ethylenediamine-tetraacetic 
acid (EDTA), ammonium acetate, 
dimethylsulfoxide (DMSO), 1 M 
triethylammonium bicarbonate (TEAB) 
buffer, 3-hydroxypicolinic acid (HPA), 1 
M triethylammonium acetate buffer 
(TEAA), ammonium citrate dibasic 
(DAC), potassium hydroxide (KOH), 
cacodylic acid, trypan blue solution, 
agarose, trizima HCl, Laemmli sample 
buffer, goat-anti-rabbit IgG secondary 
antibody, Carestream Kodak 
autoradiobiography GBX 
developer/replenisher, Carestream Kodak 
autoradiobiography GBX fixer  
Fisher Scientific, Loughborough, UK Sodium chloride (NaCl), biology grade 
nuclease-free water, acetonitrile, water 
HPLC grade, potassium chloride (KCl), 
tris-base, methanol, sodium 
dodecylsulfate (SDS), glycerine, bovine 
serum albumin (BSA) 
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Millipore, Millipore Corporation, 
Billerica, MA, USA 
C18 ZipTips™ 
Invitrogen, Paisley, UK Ambion DEPC (diethylpolycarbonate) -
treated water, DMEM Glutamax medium 
(Dulbecco’s Modified Eagle Medium 
containing 4.5 g/L D-Glucose and 110.0 
mg/L Sodium Pyruvate), fetal bovine 
serum (FBS), minimum essential medium 
non-essential amino acids (MEM NEAA 
100 X), Penstrep (10,000 Units/mL 
Penicillin, 10,000 µg/mL streptomycin, 
Dulbecco’s Phosphate Buffered Saline 
(PBS [-] CaCl₂, [-] MgCl₂),  0.25% 
trypsin-EDTA, 10 X PCR reaction buffer, 
10 mM dNTP mix, 50 mM MgCl₂, 
Platinum Taq polymerase, 10 X Tris-
acetate-EDTA (TAE) buffer, 100 bp 
ladder, 4-12% NuPage Novex Bis-Tris 
SDS-PAGE gel, NuPage MOPS SDS 
running buffer 20 X, Novex Sharp Pre-
stained protein standard 
American Type Culture Collection 
(ATCC), Manassas, VA, USA 
MDA-MB-231, HT-29, Mc Coy’s 5A 
medium 
Quiagen, Hilden, Germany RNeasy® Plus Mini kit 
Applied Biosystems, California, USA High Capacity RNA-to-cDNA kit 
Alpha Laboratories, Eastleigh, UK 0.2 mL thin-walled, dome-capped 
polymerase chain reaction (PCR) tubes 
Roche Diagnostics, Mannheim, Germany PCR grade water, Fast Start Universal 
Probe Master Mix 
New England Biolabs, Ipswich, USA 6 X blue gel loading buffer 
Biotinum, California, USA GelRed 
VWR, Leicestershire, UK Triton X-100 
Bio-Rad, Hemel Hempstead, UK Bio-Rad DC Protein assay reagent, Quick 
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Draw Filter  (QDF) paper, StrepTactin-
HRP conjugate 
Thermo Scientific, Loughborough, UK Restore Western blot stripping buffer 
GE Healthcare Life Sciences, 
Buckinghamshire, UK 
Hybond-ECL nitrocellulose membrane, 
ECL detection kit, Amersham Hyperfilm 
ECL 
Cell Signalling Technology, Cambridge, 
UK 
Rabbit monoclonal anti-cyclin D1,-Bcl-2 





7.2 Experimental (biophysical evaluation of SJG-136) 
 
7.2.1 Sample preparation for HPLC analysis 
 
7.2.1.1 General  
 
The single-stranded oligonucleotides were purchased from Eurogentec, Southampton, 
UK in lyophilised forms and prepared for experiments as described in Sections 7.2.1.2 – 
7.2.1.5. Anthramycin and SJG-136 were supplied by Spirogen Ltd. and prepared as 
described in Sections 7.2.1.6 and 7.2.1.9. Identity and purity was confirmed by LC-MS 
analysis prior to further processing. The PBD monomers GWL-78 and KMR-28-39 were 
synthesised by the Thurston and Rahman group and prepared as described in Sections 
7.2.1.5 and 7.2.1.6. Consumables and reagents including their manufacturer used for 
HPLC experiments are listed in Table 7.1. Preparations of solutions required for HPLC 









Table 7.2: Composition and preparation of solutions required for HPLC analysis. 
 
Solution Composition 
Annealing buffer 60.57 mg Tris-HCl (121.14 g/mol) (10 
mM), 146.1 mg NaCl (58.44 g/mol) (50 
mM), and 14.612 mg EDTA (292.24 
g/mol) (1 mM) were weight out, mixed 
and dissolved in 20 mL of deionised 
water. The volume was made up to 50 mL 
with deionised water. pH was adjusted to 
8.5. 
100 mM ammonium acetate buffer 385.4 mg ammonium acetate (77.08 
g/mol) was dissolved in 20 mL deionised 
water. The volume was made up to 50 mL 
with deionised water. 
20 mM ammonium acetate buffer 77.08 mg ammonium acetate (77.08 
g/mol) was dissolved in 20 mL deionised 
water. The volume was made up to 50 mL 
with deionised water. 
100 mM TEAB buffer 100 mL 1 M TEAB buffer were mixed 
with 900 mL HPLC grade water. 
40% acetonitrile in water 400 mL of 100% acetonitrile were mixed 
with 600 mL HPLC grade water. 
 
 
7.2.1.2 Preparation of working solutions of hairpin oligonucleotides 
 
Each single-stranded oligonucleotide was dissolved in annealing buffer and 100 mM 
ammonium acetate in a 1:1 ratio to form stock solutions of 1 mM. To ensure hairpin 
formation, the solutions were heated to 85 °C for 10 min in a heating/cooling block (Grant 
Bio, UK). The solutions were allowed to cool slowly down to room temperature followed 
by storage at -20 °C overnight to ensure completion of the annealing process. Working 
solutions of hairpin oligonucleotides of 25 µM were prepared by diluting the stored stock 
solutions with 100 mM ammonium acetate and storage at -20 °C.  
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7.2.1.3 Preparation of working solutions of duplex oligonucleotides 
 
The single-stranded oligonucleotides were dissolved in annealing buffer and 100 mM 
ammonium acetate in a 1:1 ratio to form stock solutions of 1 mM. Double-stranded 
oligonucleotides were prepared by heating the single-stranded DNA sequences to 85 °C 
for 10 min in a heating/cooling block (Grant Bio, UK). The solutions were allowed to 
cool slowly down to room temperature followed by storage at -20 °C overnight to ensure 
completion of the annealing process. Working solutions of duplex oligonucleotides of 25 
µM were prepared by diluting the stored stock solutions with 20 mM ammonium acetate 
and storage at -20 °C.  
 
7.2.1.4 Preparation of working solutions of inosine modified hairpin oligonucleotides 
 
Inosine modified oligonucleotides have been used for binding site analysis of SJG-136 
within the AP-1 consensus sequence. Inosine modified sequences were purchased from 
Eurogentec, Southampton, UK in lyophilised forms. Preparation of working solutions of 
inosine modified hairpin oligonucleotides is described in Section 7.2.1.2 in detail. 
 
7.2.1.5 Preparation of working solutions of inosine modified duplex oligonucleotides 
 
Single-stranded inosine modified sequences were purchased from Eurogentec, 
Southampton, UK in lyophilised forms. Preparation of working solutions of inosine 
modified duplex oligonucleotides is described in Section 7.2.1.3 in detail. 
 
7.2.1.6 Preparation of working solution for PBD monomer anthramycin 
 
Anthramycin was dissolved in DMSO to form stock solution of 10 mM which was stored 
at -20 °C. Ligand working solution of 100 µM was prepared by diluting the stock solution 
with nuclease-free water. The final working solution was stored at -20 °C and thawed to 





7.2.1.7 Preparation of working solution for PBD monomer GWL-78 
 
GWL-78 was dissolved in DMSO to form stock solution of 10 mM which was stored at 
-20 °C. Ligand working solution of 100 µM was prepared by diluting the stock solution 
with nuclease-free water. The final working solution was stored at -20 °C and thawed to 
room temperature when required. 
 
7.2.1.8 Preparation of working solution for PBD monomer KMR-28-39  
 
The PBD monomer KMR-28-39 was dissolved in DMSO to form the stock solution of 
10 mM which was stored at -20 °C. Ligand working solution of 100 µM was prepared by 
diluting the stock solution with nuclease-free water. The final working solution was 
stored at -20 °C and thawed to room temperature when required. 
 
7.2.1.9 Preparation of working solution for PBD dimer SJG-136  
 
The PBD dimer SJG-136 was dissolved in DMSO to form stock solution of 10 mM which 
was stored at -20 °C. Ligand working solution of 100 µM was prepared by diluting the 
stock solution with nuclease-free water. The final working solution was stored at -20 °C 
and thawed to room temperature when required. 
 
7.2.1.10 Preparation of ligand/DNA complexes 
 
Ligand/DNA complexes were prepared in Eppendorf tubes by adding a PBD working 
solution of 100 µM to a hairpin or duplex oligonucleotide working solution of 25 µM in 
a 4:1 (PBD/DNA) ratio. The mixture was agitated for 5-10 s using a vortex mixer and 
incubated in a heating/cooling block for various time intervals at 25 °C and subjected to 
ion pair reversed-phase HPLC and mass spectrometry analysis as described below. 
 
7.2.2 Ion pair reversed-phase HPLC 
 
Liquid chromatography was performed on a Dionex UltiMate 3000 system (Thermo 
Scientific, Loughborough, UK) equipped with a 2.1 x 50 mm XBridge™ OST C18 column 
packed with 2.5 µm particles (Waters Ltd., UK). The gradient system used for LC 
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analysis consisted of 100 mM TEAB as buffer A and 40% acetonitrile in water as buffer 
B. Flow gradients used for HPLC analysis are described in the individual chapters in 
detail. Sampler temperature was held at 15 °C and the column temperature at 20 °C. 
Samples were injected using a full loop injection of 50 µL. UV absorbance was monitored 
at 254 nm. Sample peaks were integrated and results expressed as “Area Under the 
Curve” (AUC) using a Chromeleon 7 software Version 7.1.1.1127 (Thermo Scientific, 
Loughborough, UK). 
  
7.2.3 Sample preparation for mass spectrometry (MALDI-TOF-MS) analysis 
 
7.2.3.1 General  
 
Consumables and reagents including their manufacturers used for mass spectrometry 
experiments are listed in Table 7.1. Preparation of solutions required for mass 
spectrometry analysis is described in Table 7.3 in detail. All prepared solutions were 
stored at room temperature. 
 
Table 7.3: Composition and preparation of solutions required for mass spectrometry analysis. 
 
Solution Composition 
0.1 M TEAA buffer 10 mL 1 M TEAA was mixed with 90 mL 
HPLC grade water. 
50% acetonitrile in water 50 mL 100% acetonitrile was mixed with 
50 mL HPLC grade water. 
50% acetonitrile 0.1M TEAA buffer in 
a 1:1 ratio 
0.1 M TEAA and 50% acetonitrile were 
mixed in a 1:1 ratio. 
MALDI matrix 9 parts 50 mg/mL HPA in 50% 
acetonitrile in water was mixed with 1 part 
50 mg/mL DAC in HPLC grade water. 0.1 
part formic acid was added to the solution. 





7.2.3.2 Sample preparation for MALDI-TOF analysis 
 
Anthramycin, GWL-78, KMR-28-39, and SJG-136 were prepared and incubated with 
hairpin or duplex oligonucleotides as described in Section 7.2.1. Incubation was carried 
out for 24 hours to ensure maximum drug/DNA interaction. The covalently bound 
drug/DNA adducts samples for MALDI-TOF-MS were diluted with 0.1 M TEAA in 1:1, 
1:4, and 1:10 ratios. A ZipTipC18™ reversed phase sample preparation methodology was 
used in order to desalt and concentrate the oligonucleotide samples prior to MALDI-TOF 
analysis as this procedure provides better data quality (Figure 7.1). 
 
Initially, the ZipTipC18™ was equilibrated for sample binding by aspirating and 
dispensing the equilibration solution (which was composed of 50% acetonitrile and 0.1 
M TEAA in a 1:1 ratio) followed by washing with wash solution of 0.1 M TEAA. 
Equilibration and wash steps were repeated 3-4 times. Binding and washing of 
oligonucleotides was carried out by aspirating the same ZipTipC18™ into the sample 
solution. For maximum sample binding this step was repeated 10 times. Afterwards, the 
ZipTipC18™ was washed for 3 cycles by aspirating and dispensing the wash solution (0.1 
M TEAA) followed by a wash with HPLC grade water for 3 cycles. Drug/DNA samples 
were eluted from the ZipTipC18™ and mixed with 0.5 µL matrix. 0.2 µL of sample/matrix 
mix were spotted onto the MALDI-TOF target plate (MTP AnchorChip 384TF, Bruker 
Daltonik, Bremen, Germany) and allowed to air-dry prior to MALDI-TOF-MS analysis.  
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7.2.3.3 MALDI-TOF sample preparation flowchart using ZipTipC18™ methodology 
 




Oligonucleotides binding and washing 
 
 
Figure 7.1: Flow chart of sample preparation of oligonucleotides prior to MALDI-TOF-MS 
analysis using ZipTipC18™ methodology. 
 
 
aspirate and dispense wash solution
3-4 cycles
aspirate and dispense equilibration solution
3-4 cycles
wash ZipTip with water
3 cycles 
wash ZipTipC18™ with  100 % 0.1 M TEAA
3 cycles 
aspirate sample into ZipTipC18™
10 cycles
dissolve oligonucleotide in 100 % 0.1 M TEAA
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7.2.4 MALDI-TOF-MS analysis 
 
MALDI-TOF analysis was carried out on a Bruker Daltonics Autoflex™ (Bruker 
Daltonik, Bremen, Germany) automated high-throughput Matrix-Assisted Laser 
Desorption/Ionisation Time of Flight (MALDI-TOF) system with a nitrogen laser in 
positive linear mode using delayed extraction of 500 ns and an accelerating voltage of 
25000 V. Acquisition was between 1000-10000 Dalton with 100 shots per spectrum. The 
instrument was calibrated prior to sample analysis using insulin as the standard. 1 µL 
insulin was spotted onto the MALDI-TOF target plated and dried naturally followed by 
addition of 1 µL α-Cyano-4-hydroxycinnamic acid (CHCA) matrix. Data were processed 
using AutoFlex software (Bruker Daltonik, Bremen, Germany). 
 
7.2.5 Sample preparation for Circular Dichroism (CD) study 
 
7.2.5.1 General  
 
Consumables and reagents and preparation of solutions required for CD analysis are listed 
in Table 7.1. 
 
7.2.5.2 Preparation of working solutions of hairpin oligonucleotides 
 
5 µL of hairpin forming oligonucleotide was annealed in Eppendorf tubes as described in 
Section 7.2.1.2 in detail. To obtain DNA working solutions of 5 µM in a final volume of 
1000 µL 995 µL of 100 mM ammonium acetate were added and the resulting solution 
homogenised for 5 s using a vortex mixer. 
 
7.2.5.3 Preparation of ligand/DNA complexes 
 
2 µL of 10 mM SJG-136 stock solution was added to 1000 µL 5 µM oligonucleotide 
solution resulting in a 4:1 (drug/DNA) ratio and incubated for 24 hours at 25 °C in a 
heating/cooling block. For t = 0 h experiments 2 µL of 10 mM SJG-136 stock solution 
was added to 1000 µL of 5 µM DNA working solution and subjected immediately to CD 




7.2.6 CD analysis 
 
The CD spectra of the hairpin forming oligonucleotides and oligonucleotides/ligand 
complexes were acquired on a Chirascan plus spectrometer (Applied Photophysics 
Limited, Leatherhead, UK). The instrument was flushed continuously with pure 
evaporated nitrogen throughout the experiment. The CD spectra were measured between 
200-400 nm in a strain-free rectangular 10 mm cell. Spectra were recorded using a 1 nm 
step size, a 1 s time-per-point and a spectral bandwidth of 1 nm. All spectra were recorded 
at 23 °C and the baseline was buffer (100 mM/20 mM ammonium acetate) corrected. 
Oligonucleotides were initially measured alone at a final concentration of 5 µM in an 
appropriate buffer. SJG-136 was added from a 10 mM stock solution in DMSO for a final 
concentration of 20 µM for a t = 0 experiment and CD spectra were recorded immediately 
followed by analysis of 24 hours incubation samples. Measurement was carried out while 
maintaining a constant concentration of oligonucleotides. Data were processed using 
OriginPro software (version 7.0). Differences in CD signals were plotted against the 
wavelength. 
 
7.2.7 Sample preparation for Fluorescence Resonance Energy Transfer (FRET) 
DNA Melting assay 
 
7.2.7.1 General  
 
Hairpin forming oligonucleotides (Figure 3.8, Chapter 3) were fluorescence tagged with 
FAM (6-carboxyfluorescein) on 5'-end and TAMRA (6-carboxytetramethylrhodamine) 
on 3'- end. The sequences were purchased in lyophilised form from Eurogentec, 
Southampton, UK. Consumables and reagents including their manufacturer used for 
FRET experiments are listed in Table 7.1. Preparations of solutions required for FRET 
analysis are described in Table 7.4 in detail. All prepared solutions were stored at room 








Table 7.4: Composition and preparation of solutions required for FRET analysis. 
 
Solution Composition 
50 mM cacodylic acid 0.345 g cacodylic acid (137.99 g/mol) was 
dissolved in 20 mL distilled water. The 
volume was made up to 50 mL with 
distilled water. 
FRET buffer 0.28 g KOH (56.11 g/mol) (100 mM) and 
0.37 g KCl (74.55 g/mol) (100 mM) were 
dissolved in 20 mL distilled water. The 
volume was made up to 50 mL. pH was 




7.2.7.2 Preparation of working solutions of hairpin oligonucleotides 
 
Lyophilised hairpin forming oligonucleotides were dissolved in DEPC 
(diethylpolycarbonate)-treated water to form a stock solution of 100 µM. 20 µL of DNA 
stock solution was mixed with 80 µL FRET buffer to obtain a DNA solution of 20 µM. 
20 µL of 20 µM DNA solution was mixed with 980 µL FRET buffer to form a working 
solution of 400 nM of each hairpin forming oligonucleotide. Fresh prepared working 
solutions were annealed by heating to 85 °C for 5 min in Eppendorf tubes in a  
heating/cooling block before cooling down to room temperature over 5 hours. All DNA 
solutions were stored at -20 °C and thawed to room temperature when required. 
 
7.2.7.3 Preparation of working solutions of the PBD dimer SJG-136 
 
Ligand working solutions were prepared by diluting a 10 mM SJG-136 DMSO stock 
solution in FRET buffer to double the required final concentration of 100 µM, 50 µM, 10 
µM, 1 µM, 0.1 µM, and 0.01 µM to a final volume of 500 µL. Working solutions of SJG-




7.2.7.4 Preparation of ligand/DNA complexes  
 
25 µl of each annealed DNA working solution of 400 nM was pipetted in triplicates into 
a 96-well PCR multi plate (Bio-Rad, Hemel Hempstead, UK) followed by addition of 
25µl of SJG-136 working solution in the desired concentration. This resulted in DNA 
final concentration of 200 nM. PCR plates were covered with Optical Flat 8-cap strips 
(Bio-Rad, Hemel Hempstead, UK) and incubated directly in the 96-well plate for 24 hours 
in the dark. Prior to FRET experiments 25 µL of each DNA working solutions of 400 nM 
was mixed with 25 µL FRET buffer and added in triplicates into the 96-well plate for 
background measurement. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A a a a a a a a a a    
B b b b b b b b b b    
C c c c c c c c c c    
D d d d d d d d d d    
E a a a a a a       
F b b b b b b       
G c c c c c c       
H d d d d d d       
 
Figure 7.2: An example of a typical plate layout used for FRET analysis. a = representing 
annealed DNA mixed with FRET buffer for background measurement. b – d representing 
different concentrations of SJG-136 tested in the FRET assay. 
 
 
7.2.8 FRET assay 
 
FRET analysis was performed on a DNA Engine Opticon2 (Bio-Rad, Hemel Hempstead, 
UK) using the following cycling conditions: incubation at 30 °C for 5 s, fluorescence 
measurement every 0.5 °C for 30 s while heating from 30-100 °C, and finally incubation 
at 100 °C for 2 min. Fluorescence was captured at 515-545 nm. Obtained data were 
processed using OriginPro software (version 7.0, Origin Lab Corp.). The differences in 
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the melting temperature (ΔTm) between adduct solution and blank (DNA sequences 
alone) were plotted against SJG-136 concentration using GraphPad Prism software 
Version 5.0 (GraphPad, California, USA). 
 
7.2.9 Molecular modeling methodology 
 
Molecular dynamics simulations were undertaken on SJG-136 non-covalently and 
covalently bound to the transcription factor consensus sequences used in the study. The 
DNA sequence in every case (including the TTT-loop) was constructed using the 
AMBER299 module nab. The TTT-loop was then covalently linked to the backbone of 
DNA using parameters derived in-house. SJG-136 was docked in the minor groove using 
AMBER xleap, parm99SB and modified parmbsc0300 and Gaff AMBER force field 
parameters. Antechamber was used to construct .mol2 files through the addition of 
Gasteiger charges and missing parameters were generated using parmchk. A covalent 
bond was generated between exocyclic amine groups of selected guanines (guided by 
molecular mechanics calculations301), forming either mono-adducts or inter/intra-strand 
cross-links. Energy minimisation was then undertaken in a gradient manner by initially 
placing the DNA under a high force constraint (i.e. 500 kcal mol-1 Å-2), and this was then 
reduced in stages to zero to enable the ligand to find its local energy minimum, followed 
by reduction in force in a periodic manner with a relaxation of restraints. Production 
simulations in an implicit solvent (GBSA) were run for a period of 10 ns, and atomic 
coordinates were saved at 1ps intervals. Analysis of molecular dynamics simulations was 













7.3 Experimental (biological evaluation of SJG-136) 
 
7.3.1 Cell culture 
 
7.3.1.1 General  
 
The human breast cancer cell line MDA-MB-231 and the human colon cancer cell line 
HT-29 were maintained as described in Section 7.3.1.2. Consumables and reagents used 
during cell culture are listed in Table 7.1. All solutions were prepared in a class II 
microbiological safety cabinet (MSC). Commonly used solutions during cell culture are 
outlined in Table 7.5. 
 
Table 7.5: Media preparation used during cell culture MDA-MB-231 and HT-29 human tumour 
cell lines. 
 
Name  Ingredients 
10% FBS media for MDA-MB-231 
 
DMEM-Glautamax media was 
supplemented with 10% FBS, 1% MEM 
NEAA and 1% Penstrep solution. The 
media was mixed and stored at 2-8 °C. 
10% FBS media for HT-29 Mc Coy’s 5A media was supplemented 
with 10% FBS, 1% MEM NEAA and 1% 
Penstrep solution. The media was mixed 
and stored at 2-8 °C. 
 
 
7.3.1.2 Maintenance and culture of cell lines 
 
Unless otherwise stated, cells were maintained in 15 mL cell-line appropriate media 
containing 10% FBS in T75 flasks (75 cm2) at 37 °C and 5% CO2 in a Sanyo CO₂ 
incubator. Cell passaging was carried out within a Class II MSC. All solutions were pre-
warmed to 37 °C in a water bath prior to use. Media was replaced every second day by 
aspiration, followed by addition of 15 mL fresh media. 
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7.3.1.3 Cell trypsinisation, centrifugation and counting 
 
When cells reached approximately 70% confluence, media was aspirated and cells were 
washed by addition of 4 mL PBS. The PBS was aspirated and 2 mL of 0.25% trypsin-
EDTA was added into the flask followed by incubation at 37 °C for 2 min. Cells were 
removed from the growing surface by tapping the flask on each side with hands. Trypsin-
EDTA was inactivated and neutralised using 8 mL of appropriate growth media and 
pipetting up and down several times over the flask bottom to detach remaining adherent 
cells. The resulting suspension was transferred into a 20 mL universal falcon and 
centrifuged for 5 minutes at 21 °C and 1,500 rpm (Allegra™ X-22R centrifuge, Beckman 
Coulter, California, USA). The supernatant was aspirated, discarded and the resulting cell 
pellet re-suspended by addition of 10 mL appropriate media straight into the falcon 
followed by pipetting up and down to ensure re-suspension of the cell pellet. Viable cell 
number was counted using trypan blue exclusion method. A 1:1 trypan blue: cell 
suspension solution was prepared by mixing 100 µL of the cell suspension with 100 µL 
trypan blue, mixed and pipetted onto a haemocytometer. Due to the damaged cell 
membrane in non-viable cells, they are not able to remove the dye via exocytose and are 
therefore stained blue. Viable cells however, can exclude the trypan blue because of their 
intact cell membrane and are consequently not stained. The number of cells per mL of 
solution was calculated by counting all viable cells within 8 randomly selected grids of 
the haemocytometer under a microscope at 10 x magnification. The number of viable 
cells per ml was calculated using the following equation: 
 
Cells/mL = (total cells counted/8) x 20,000 
 
The cell suspension was diluted to the desired cell densities with appropriate media 
(stated in the individual assay descriptions) and plated in 6-well plates for polymerase 
chain reaction or T75 flasks western blot analysis. 
 
7.3.1.4 Sample preparation for polymerase chain reaction (PCR) and Western blotting 
 
Prior to RNA or protein extraction, cells were trypsinised and centrifuged as described in 
Section 7.3.1.3. The supernatant was aspirated, discarded and the resulting cell pellet was 
re-suspended in 10 mL of PBS followed by centrifugation for 5 min at 21 °C and 1,500 
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rpm in order to remove remaining media. The supernatant was aspirated, discarded and 
the cell pellets snap-frozen in liquid nitrogen. Frozen pellets were stored at -80 °C until 
PCR or Western blot analysis.  
 
7.3.2 Reverse Transcription (RT-PCR) 
 
7.3.2.1 General  
 
All isolation, RT-PCR and PCR sample preparation steps were performed in a PCR hood 
(SLEE, Mainz, Germany). Consumables and reagents used during RT-PCR are listed in 
Table 7.1. 
 
7.3.2.2 RNA isolation from frozen cell pellets 
 
Total RNA was extracted from snap-frozen cell pellets using the RNeasy® Plus Mini Kit 
according to the manufacturer’s instructions. Briefly, the frozen cell pellet was re-
suspended in 350 µL RLT Plus lysis buffer, pipetted up and down multiple times and 
homogenised for 30 s using a vortex mixer. The lysate was transferred into a gDNA 
Eliminator spin column placed in 2 mL collection tube and centrifuged for 30 s at 8,000 
g in a Sigma 1-14 Microcentrifuge (Appleton Woods, Birmingham, UK) in order to 
remove remaining genomic DNA. The gDNA eliminator spin column was discarded, the 
flow-through mixed with 350 µL 70% ethanol, and mixed by pipetting up and down 10 
times. The entire volume of 700 µL was transferred into RNeasy spin column placed in a 
2 mL collection tube and spun for 15 s at 8,000 g in order to bind the RNA to the silica 
membrane. The flow-through was discarded and 700 µL of buffer RW1 were added to 
the RNeasy spin column placed in a new 2 mL collection tube followed by centrifugation 
at 8,000 g for 15 s. Next, the flow-through was again discarded and 500 µL of buffer RPE 
were added into the RNeasy spin column. After centrifugation at 8,000 g for 15 s, the 
flow-through was removed and the wash step with 500 µL buffer RPE repeated with 
centrifugation at 8,000 g for 2 min. Finally, the RNeasy spin column was placed in a new 
1.5 mL collection tube and 50 µL of RNase-free water was added directly to the spin 
column membrane, followed by centrifugation at 8,000 g for 1 min. The isolated RNA 




7.3.2.3 RT of mRNA 
 
Isolated mRNA was reverse-transcribed into cDNA using the High Capacity RNA-to-
cDNA as per manufacturer’s instructions. Briefly, a mixture was prepared consisting of 
10 µL 2 X RT buffer containing dNTPs, random octamers, oligodT-16, 1 µL 20 X enzyme 
mix containing MuLV (Murine Leukaemia Virus) reverse transcriptase and RNase 
inhibitor protein and 9 µL extracted RNA. A negative RT control was prepared following 
the same procedure. 1 µL 20 X enzyme mix was replaced with 1 µL nuclease-free water 
to ensure samples do not contain remaining genomic DNA. Each sample tube was 
homogenised for 5 s and spun briefly prior to transfer into a PCR Sprint thermal cycler 
(Thermo Scientific, Loughborough, UK). Incubation was carried out at 37 °C for 1 hour 
followed by 5 min at 94 °C in order to terminate the reaction. Complementary DNA 




7.3.3.1 General  
 
Primers used for PCR experiments were purchased in lyophilised form from Integrated 
DNA Technologies, Coralville, USA. Primer preparation for PCR is described below 
(Section 7.3.3.2) in detail. All PCR primer and sample preparation steps were performed 
in a PCR hood (SLEE, Mainz, Germany). Consumables and reagents used during PCR 
analysis including their manufacturer are listed in Table 7.1. 
 
7.3.3.2 Primers preparation for PCR experiments 
 
Specific primers used for genes of interest are listed in Table 7.6 and 7.7. Prior to use, 
lyophilised primers were centrifuged for 5 s and diluted with PCR grade water to form 
stock solutions of 100 µM. For PCR experiments appropriate primer pairs were further 
diluted 1:10 with PCR grade water to form working solutions of 10 µM. Stock and 











Bcl-2 F: 5'-CAT CTT CTC CTC CCA GCC C-3' 
R: 5'-CCG AAC TCA AAG AAG GCC AC-3' 
Cyclin D1 F: 5'-ACA GAT CAT CCG CAA ACA CG-3' 
R: 5'-CTC CTC CTC TTC CTC CTC CT-3' 
NNMT F: 5'-TGGCCCCACTATCTATCAGC-3' 
R: 5'-CCTCTTTCACAGCAGCCTCT-3' 
STAT3 F: 5'-CTT TGA GAC CGA GGT GTA TCA CC-
3' 
R: 5'-GGT CAG CAT GTT GTA CCA CAG G-
3' 
STAT1 F: 5'-CTA GTG GAG TGG AAG CGG AG-3' 
R: 5'-CAC CAC AAA CGA GCT CTG AA-3' 
Fascin F: 5'-ACT GGC TAC ACG CTG GAG TT-3' 
R: 5'-GGA AGG CAC ACT TTT TGG TG-3' 
GAPDH F: 5'-AGC CAC ATC GCT CAG ACA C-3'  

















Table 7.7: Primers used during RT-PCR for expression of AP-1 dependent genes. F = Forward; 




VEGF F: 5'-CTA CCT CCA CCA TGC CAA GT-3' 
R: 5'-GGT GCT CCA GAA GTG AAT GC-3' 
Cyclin D1 F: 5'-CCC TCG GTG TCC TAC TTC AA-3' 
R: 5'-GGC GGA TTG GAA ATG AAC T-3' 
CREB5 F: 5'-ATT CCC ACC TTC ATG CAC A-3' 
R: 5'-TTG TGT TGC TGG TGA AAC CT-3' 
Elk-1 F: 5'-GCT TCC TAC GCA TAC ATT GAC C -3' 
R: 5'-GGT GCT CCA GAA GTG AAT GC-3' 
AP-1 F: 5'-CCA AAG GAT AGT GCG ATG TTT-3' 
R: 5'-CTG TCC CTC TCC ACT GCA AC-3' 
p53 F: 5'-AGG CCT TGG AAC TCA AGG AT-3' 
R: 5'-CCC TTT TTG GAC TTC AGG TG-3' 
GAPDH F: 5'-AGC CAC ATC GCT CAG ACA C-3' 
R: 5'-GCC CAA TAC GAC CAA ATC C-3' 
 
 
7.3.3.3 PCR amplification of cDNA 
 
Obtained cDNA samples from RT-PCR reaction were prepared as followed: 24 µL of a 
master mixture consisting of 2.5 µL 10 X PCR reaction buffer, 0.5 µL 10 mM 
deoxyribonucleotide triphosphate bases (dNTP mix, 0.2 mM final concentration), 0.75 
µL 50 mM MgCl₂ (1.5 mM final concentration), 0.625 µL of 10 µM forward primer (250 
nM final concentration), 0.625 µL of 10 µM reverse primer (250 nM final concentration), 
0.1 µL of 5 U/µL platinum Taq polymerase (0.02 U/µL final concentration), and 18.9 µL 
water PCR grade. 24 µL of the master mix was added to 1 µL cDNA sample and mixed 
up and down several times. PCR was performed in a PCR Sprint thermal cycler (Thermo 
Scientific, Loughborough, UK) using the following cycle conditions: 94 °C for 5 min, 30 
cycles of 94 °C for 30 s, 55 °C for 30 s, and finally 72 °C for 1 min, with a final extension 
at 72 °C for 5 min. For each gene a GAPDH control was prepared and run under the same 
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conditions. Once the reaction was complete, the samples were held at 4 °C.  
 
7.3.4 Agarose gel electrophoresis  
 
7.3.4.1 General  
 
Consumables and reagents used during agarose gel electrophoresis including their 
manufacturer are listed in Table 7.1.  
 
7.3.4.2 Agarose gel electrophoresis of amplified DNA 
 
Confirmation of target gene amplification was carried out using agarose gel 
electrophoresis. 0.75 g agarose was dissolved in 50 mL 1 X TAE buffer (prepared by 
mixing 30 mL of 10 X TAE stock solution with 270 mL deionised water) in a conical 
flask and heated in a microwave for 1 min and 10 s. The heating process was interrupted 
every 20 s and the flask mixed gently to ensure homogenisation of the agarose in the 
buffer. While agarose solution cooled down, a 12-well gel comb was placed into the gel 
tray. 2.5 µL of 10,000 x GelRed were added into the agarose solution and mixed before 
poured into the tray and left to set for approximately 30-40 min. 5 µL of each PCR sample 
were mixed with 1 µL 6 X blue gel loading buffer and loaded into a well of the agarose 
gel submerged in TAE buffer. 1 µL of 100 bp ladder were mixed with 1 µL loading buffer 
and 4 µL deionised water before 2 µL were loaded to the leftmost well of the gel. 
Electrophoresis was performed at 50 V for 40 min and visualised at 300 nm using UV 
transillumination (U:GENIUS, Syngene, Cambridge, UK) and then digitally scanned. 
Band size was determined by comparison with a 100 bp ladder. Amplified PCR samples 
were stored at -20 °C. 
 
7.3.5 Quantitative PCR (qPCR) 
 
7.3.5.1 General  
 
Primers used for qPCR were purchased in lyophilised form from Integrated DNA 
Technologies, Coralville, USA. UPL probes were supplied by the Genomic Centre, 
Waterloo Campus, King’s College London.  
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7.3.5.2 Primers preparation for qPCR experiments 
 
Preparation of primer pairs specific genes of interest for qPCR analysis is described in 
Section 7.3.3.2 in detail. Primers used in the qPCR study are listed in Table 7.8. 
 
Table 7.8: Primers used during qPCR for expression of STAT3 and AP-1 dependent genes. F = 
















F: 5'-AGT ACC TGA ACC GGC ACC T-3' 
R: 5'-GCC GTA CAG TTC CAC AAA GG-3' 
1998– 2016 
2052 - 2071 
74 75 
Cyclin D1 ENSG 
000001100
92 
F: 5'-CCC TCG GTG TCC TAC TTC AA-3' 
R: 5'-GGC GGA TTG GAA ATG AAC T-3' 
226 – 245 




F: 5'-TCT GCT TCA AGG AGC TGG A-3' 
R: 5'-AAA GTG CTG GTA TTA CAG GCG TA-
3' 
202 – 220 





F: 5'-GAG CAG AGA TGT GGG AAT GG-3' 
R: 5'-CGG TCT CAA AGG TGA TCA GG-3' 
1375– 1394 





F: 5'-CTA CCT CCA CCA TGC CAA GT-3' 
R: 5'-GGT GCT CCA GAA GTG AAT GC-3' 
1111– 1130 





F: 5'-ATT CCC ACC TTC ATG CAC A-3' 
R: 5'-TTG TGT TGC TGG TGA AAC CT-3' 
996 – 1014 





F: 5'-GCT TCC TAC GCA TAC ATT GAC C-3' 
R: 5'-GGT GCT CCA GAA GTG AAT GC-3' 
1168– 1189 





F: 5'-CCA AAG GAT AGT GCG ATG TTT-3' 
R: 5'-CTG TCC CTC TCC ACT GCA AC-3' 
3012– 3032 





F: 5'-AGG CCT TGG AAC TCA AGG AT-3' 
R: 5'-CCC TTT TTG GAC TTC AGG TG-3' 
979 – 998 




F: 5'-CCA ACC GCG AGA AGA TGA-3' 
R: 5'-CCA GAG GCG TAC AGG GAT AG-3'  
425 - 442 







7.3.5.3 qPCR of cDNA 
 
qPCR was used to quantify changes in gene expression in the human cancer cell lines 
MDA-MB-231 and HT-29. Data for qPCR analysis were collected from three 
independently performed assay rounds for each cell line. Primers were tested with non-
quantitative PCR to optimise reaction conditions to generate a single PCR product, as 
confirmed by gel electrophoresis.  
 
Briefly, 18 µL of each resulting cDNA sample including no RT control were pipetted 
onto a well of a 96-well PCR plate and diluted to 200 µL by the addition of 182 µL DEPC 
water. A pooled reference control DNA was used as a quality control for plate – to – plate 
variation. The pool was created by mixing 2 µL of each cDNA sample and dilution to 
200 µL with DEPC (diethylpolycarbonate)-treated water. From this pool three different 
dilutions 1:10, 1:100, and 1:1000 were prepared to create a dilution series that covered 
the entire range of concentration measured in the assay. 1:10 dilution was prepared by 
removing 20 µL of pool solution and pipetting into a new well followed by addition of 
180 µL of DEPC water. 1:100 dilution was created by removing 20 µL of 1:10 dilution 
and pipetting into a new well followed by addition of 180 µL of DEPC water. 1:1,000 
dilution was prepared by removing 20 µL of 1:100 dilution and pipetting into a new well 
followed by addition of 180 µL of DEPC water. The last well of the dilution series 
contained 200 µL DEPC water for background measurement. The assay mix was 
prepared in Eppendorf tubes for each gene separately by mixing  953.01 µL of fast start 
universal probe master mix, 76.245 µL of 10 µM forward primer, 76.245 µL of 10 µM 
reverse primer, and 19.06 µL appropriate UPL probe. Primers and UPL probes used for 
qPCR experiments are listed in Table 7.8. The master mix was homogenised by pipetting 
up and down multiple times. 179 µL of appropriate master mix were pipetted into a deep 
well block according to sample number. 4 µL of diluted cDNA were combined with 6 µL 
of the assay mix in a 384-well plate on a Biomek FX liquid handling robot (Beckman 
Coulter, UK). Once the mixing process was finished, the plate was removed from the 
robot, sealed with a plastic lid and spun for 10 s to collect the liquid at the bottom of the 
384-well plate. qPCR was performed on an ABI Prism 7000 thermal cycler (Applied 
Biosystems) using the following cycling conditions: 95 °C for 10 min, followed by 40 
cycles at 95 °C for 15 s and 60 °C for 1 min. All samples were run in triplicate together 
with their corresponding negative control. Negative template controls and the pooled 
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reference control DNA were run on every 384-well plate. ß-actin was utilised as a 
reference gene to normalise mRNA expression. Results were analysed using the Data 
Assist Software Version 3.0 (Applied Biosystems) and gene expression levels were 
quantified using the comparative ΔΔCt method(6). Results were expressed as ΔCt (Ct 
sample – Ct ß–actin) and the fold change in gene expression compared to the untreated 
sample. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1 1 1 1 1 1 Pool      
B 1a 1a 1a 1a 1a 1a 1:10      
C 2 2 2 2 2 2 1:100      
D 2a 2a 2a 2a 2a 2a 1:1,000      
E 3 3 3 3 3 3 water      
F 3a 3a 3a 3a 3a 3a       
G             
H             
 
Figure 7.3: A typical plate layout used for qPCR. 1 = untreated cells, 1a = no RT control of 1; 2 
= stimulated cells, 2a = no RT control of 2; 3 = stimulated cells followed by drug treatment, 3a = 
no RT control of 3.  
    
 
7.3.6 Western Blotting 
 
7.3.6.1 General  
 
Consumables and reagents including their manufacturer required for Western blotting are 
listed in Table 7.1. Preparation of solutions used for Western blotting is described in 








Table 7.9: Buffer solutions and preparation used during Western blotting. 
 
Name  Ingredients 
RIPA buffer (Radioimmunioprecipitation 
buffer) 
5 mL of 1 M (157.6 g/L in water) Trizima 
HCl (50 mM, pH 7.4), 1 mL of 1% (v/v) 
Nonidet P40 (0.1%), 0.5 g 0.5% sodium 
deoxycholate (0.0025%), 15 mL of 1 M 
(58.4 g/L in water) NaCl (150 mM), 0.15 
g EDTA (5 mM), 0.1 g 0.1% (w/v) SDS 
(0.0001%) were mixed and made up to 
100 mL deionised water. The buffer was 
aliquoted followed by addition of 
complete Protease Inhibitor Cocktail and 
PhosSTOP tablet to each aliquot. RIPA 
buffer was stored at -20 °C and thawed 
prior to use. 
TBS (Tris Buffered Saline) 6 g Trizima HCl (50 mM Tris) and 12 g 
NaCl (200 mM) were dissolved in 500 
mL deionised water, adjusted to pH 7.4 
and made up to 1 L with deionised water. 
TBS buffer was stored at room 
temperature. 
TBST (Tris Buffered Saline – Triton X – 
100) 
500 µL of Triton X-100 was added to 1 
L TBS for a final concentration of 
0.05%. TBST buffer was stored at room 
temperature. 
MTBST (Milk - Tris Buffered Saline – 
Triton X – 100) 
50 g of skimmed milk powder was 
dissolved in 1 L TBST for a final 
concentration of 5%. MTBST solution 
was prepared fresh when required. 
AB I (Anode buffer I) 18.15 g Tris base (0.3 M) was dissolved 
in 50 mL methanol before 400 mL of 
deionised water were added. pH was 
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adjusted to 10.4 and solution was made 
up to 500 mL using deionised water. AB 
I was stored at room temperature. 
AB II (Anode buffer II) 1.51 g Tris base (25 mM) was dissolved 
in 50 mL methanol before 400 mL of 
deionised water were added. pH was 
adjusted to 10.4 and solution was made 
up to 500 mL using deionised water. AB 
II was stored at room temperature. 
CB (Cathode buffer) 1.51 g Tris base (25 mM) and 1.5 g 
glycine (40 mM) were dissolved in 50 
mL methanol followed by addition of 
400 mL of deionised water. pH was 
adjusted to 9.4 and solution was made up 
to 500 mL using deionised water. CB 
was stored at room temperature. 
 
 
7.3.6.2 Sample preparation for protein assay 
 
Snap-frozen cell pellets were lysed directly in 20 mL universal tubes using 100 µL RIPA 
buffer and vortexed for 30 s to improve lysis. The lysates were transferred into new 
Eppendorf tubes and centrifuged at 13,000 rpm for 10 min in a Sigma 1-14 
Microcentrifuge in order to precipitate the cells. Supernatants were transferred into new 
Eppendorf tubes and two different dilutions (1:5 and 1:10) were prepared using RIPA 
buffer as described in Section 7.3.6.4 in detail. Samples not used for protein assay were 
kept on ice until further processing. 
 
7.3.6.3 Protein assay  
 
A protein assay was carried out prior to SDS PAGE in order to determine the total protein 
concentration in each sample to ensure that approximately same amount of total protein 
is loaded onto the gel. Briefly, lysed samples were prepared in labelled Eppendorf  in a 
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1:5 dilution by mixing 6 µL original sample with 24 µL RIPA buffer resulting in a total 
volume of 30 µL. From this 1:5 dilution 10 µL were removed and mixed with 10 µL 
RIPA buffer in a new labelled Eppendorf tube to a final volume of 20 µL. Protein 
standards of 1.0 mg/mL, 0.8 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 0.2 mg/mL, and 0.0 mg/mL 
were made from a 10 mg/mL stock solution of BSA prepared in RIPA buffer. Volumes 
of RIPA buffer and BSA stock solution required for the dilution series are described in 
Table 7.10 in detail. The protein assay, based on the methodology of Lowry et al. 1951 
was performed using Bio-Rad DC Protein Assay as per manufacturer’s instructions. For 
one 96-well plate (Thermo Scientific, Loughborough, UK) 2 mL of Bio-Rad DC Protein 
Reagent A were mixed with 40 µL of Solution S resulting in Solution A. 5 µL of each 
BSA standard concentration and 5 µL of each sample dilution were pipetted in triplicates 
into a 96-well plate as outlined in Figure 7.4. 25 µL of Solution A were added with a 
multichannel pipette to each well and the plate was carefully vortexed covered with its 
lid. 200 µL of Bio-Rad Reagent B were added to each well using a multichannel pipette 
followed by homogenisation using the vortex mixer. The plate was incubated at room 
temperature in the dark for 15 min and existing bubbles were removed with a needle 
before the absorbance was read at 750 nm using a spectrophotometer (Wallac Victor 2, 
1420 Multilabel Counter, PerkinElmer, Hopkinton, USA). The total protein concentration 
in each sample was determined based on the albumin calibration curve and represent in 
µg/µL.  
 





BSA stock solution 
(µL) 
RIPA lysis buffer 
(µL) 
1.0 10 90 
0.8 8 92 
0.6 6 94 
0.4 4 96 
0.2 2 98 






 1 2 3 4 5 6 7 8 9 10 11 12 
A 1.0 1.0 1.0 1:5 1:5 1:5 1:10 1:10 1:10 Sample 1 
B 0.8 0.8 0.8 1:5 1:5 1:5 1:10 1:10 1:10 Sample 2 
C 0.6 0.6 0.6 1:5 1:5 1:5 1:10 1:10 1:10 Sample 3 
D 0.4 0.4 0.4          
E 0.2 0.2 0.2          
F 0.0 0.0 0.0          
G             
H             
 
Figure 7.4: A typical 96-well plate layout used for protein assays. Numbers 1.0 – 0.0 represent 
BSA standard concentrations in mg/ mL in RIPA buffer. Sample 1 = untreated cells (MDA-MB-
231/HT-29); sample 2 = stimulated cells (MDA-MB-231/HT-29); sample 3 = stimulated cells 
followed by drug treatment (MDA-MB-231/HT-29). 1:5 and 1:10 represent the dilution factor of 




















7.3.6.4 Sample preparation for Western blotting 
 
Once the protein concentration was calculated a dilution using RIPA buffer was prepared 
to give a protein concentration of 3 µg/µL in each sample. Laemmli sample buffer was 
mixed with each sample in a 1:1 ratio for a final protein concentration of 1.5 µg/µL and 
heated for 5 min to 100 °C in an Eppendorf heater (Grant Instruments, Shepreth, UK). 
This boiling step aims to reduce disulfide linkages initiated by the reducing agent 2-
mercaptoethanol contained in the Laemmli buffer. This results in breaking up the 
quaternary protein structure, and protein separation during gel electrophoresis occurs due 
to protein size.  
 
7.3.6.5 SDS – polyacrylamide gel electrophoresis (PAGE) 
 
SDS–PAGE was carried out using pre-cast 4–12% NuPage Bis–Tris SDS–PAGE gel 
submerged in 1 L 1 X MOPS (3-(N-morpholino)propanesulfonic acid) running buffer 
(prepared by mixing 50 mL 20 X MOPS running buffer with 950 mL deionised water). 
60 µL of each sample (equivalent to 30 µg total protein) were loaded into the wells of the 
gel. For protein size comparison 5 µL of Novex Sharp Pre-stained Protein Standard were 
loaded to the leftmost well of the gel. Protein separation was performed at 200 V for 50 
min. 
 
7.3.6.6 Semi – dry transfer of proteins to nitrocellulose membrane 
 
The semi-dry transfer onto a Hybond-ECL nitrocellulose membrane was carried out 
according to the semi-dry transfer protocol reported in Martin et al. 2013. Briefly, AB I, 
AB II and CB were poured into separate trays. Once SDS-PAGE was finished, the gel 
was carefully removed from the electrophoresis assembly followed by the opening of the 
gel plates. Wells and the left top corner were cut off in order to determine the gel 
orientation. Gel was soaked in CB and placed on a rocking platform (Labnet International, 
New Jersey, USA) for minimum 10 min to equilibrate the gel with the buffer. Hybond-
ECL nitrocellulose membrane was cut to the size of the Quick Draw Filter (QDF) paper 
and soaked for 2 min in deionised water before being transferred into AB II and placed 
on the rocking platform for 5 min. Quick Draw Filter paper was soaked in appropriate 
buffer and a gel/membrane “sandwich” was built as shown in Figure 7.6 starting from 
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the bottom of the Trans-Blot® SD Semi-Dry Transfer Cell tank (Bio-Rad, Hemel 
Hertfordshire, UK). Once all the layers have been set up, transfer was performed at 19 V 
for 36 min if only one gel and for 42 min if two gels were being transferred.  
 
 
Figure 7.6: Gel/membrane “sandwich” composition used during the semi-dry transfer of proteins 





Once the transfer was finished, the gel/membrane sandwich was disassembled and the 
nitrocellulose membrane was quickly cut to the size of the gel. The membrane was 
transferred into a tray containing MTBST and blocked for at least 1 hour on a rocking 
platform at room temperature. This blocking step aims to circumvent non-specific 
binding which might occur due to interactions between the membrane and the antibody 
applied to detect the target protein resulting in “noise” and false positive results. The 
proteins contained in the blocking solution will bind to the membrane in all places where 
the proteins of interest have not attached. Consequently, the primary antibody will bind 
only to its target protein. Antibodies against the target proteins are listed in Table 7.1 in 
Section 7.1. They were prepared in 50 mL falcon tubes by mixing with MTBST in 1:250 
dilution and stored at -20 °C and thawed on ice prior to use. The membrane was 
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transferred straight into the falcon tube and incubated with primary antibodies overnight 
at 4 °C on a tube roller (Spiramix, Thermo Scientific, Loughborough, UK). On the next 
day, the blot was rinsed with MTBST at room temperature before being incubated for 2 
hours in MTBST at room temperature on a rocking platform. The secondary antibody 
conjugated to horseradish peroxidase (HRP) was prepared in 20 mL universal tube by 
mixing with MTBS in a 1:1,000 dilution and addition of StrepTactin-HRP conjugate in a 
1:4,000 ratio. The membrane was incubated with the secondary antibody mixture for 1 
hour under the same conditions. The StrepTactin-HRP conjugate was added to the 
secondary antibody mix to enhance the signal of the Strep-tagged protein markers. The 
secondary antibody was discarded and the membrane was rinsed and washed with 
MTBST at room temperature on a rocking platform for 5 min. MTBST was removed and 
the blot washed twice in TBST for 5 min using the same conditions. Lastly, TBST was 
discarded and the membrane was submerged in TBS prior to detection. The ECL 
detection mixture was prepared by mixing equal volumes of solution A and B contained 
in the ECL detection kit as per manufacturer’s instructions. The membrane was removed 
from TBS and slightly tapped with its corner on tissue paper in order to remove remaining 
TBS. ECL reagent was applied onto the membrane and incubated for 5 min at room 
temperature and dried as described above. Membranes were visualised using a ChemiDoc 
MP transilluminator (Bio-Rad, Hemel Hempstead, UK). To re-probe α-tubulin as loading 
control the blots were stripped with Restore™ western blot stripping buffer for 1 hour at 
room temperature on a rocking platform followed by rinsing and re-blocking for another 
hour. The immunoblotting process was repeated using α-tubulin as described above. 
Images were digitally captured and band intensities were quantified by densitometry 
utilising the ImageLab software (Version 4.1, Bio-Rad, Hertfordshire, UK) and 
normalised for α-tubulin. Protein quantification was carried out by dividing the integrated 
peak area of the protein of interest by the integrated peak area of the reference gene α-
tubulin.  Alternatively, blots were captured using the traditional X-ray film development. 
This developing procedure was carried out in a dark room. ECL detection kit was 
prepared and applied onto the nitrocellulose membrane as described above. The blot was 
placed in a developing cassette and closed with a thin film covered by an X-ray film. The 
cassette was closed for approximately 1 min in order to press the membrane onto the film. 
The cassette was opened carefully, the film directly placed into the film developer 
solution and developed until protein bands appeared. Once bands were visible, the film 
was transferred into the fixation solution for approximately 5 min and finally placed in 
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water for wash. The developed films were air-dried overnight and scanned before 
quantified by densitometry using ImageJ software (version 1.49, National Institutes of 
Health, USA) and normalised for α-tubulin expression. Quantification of band intensity 
was performed as described above.  
 
7.3.7 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism software (GraphPad, 

























































Figure A2.1A: HPLC chromatograms and the corresponding RTs for the sequence NF-κB-1 





Figure A2.1B: HPLC chromatograms and the corresponding RTs for the sequence NF-κB-2 







Figure A2.1C: HPLC chromatograms and the corresponding RTs for the sequence EGR-1 after 






Figure A2.1D: HPLC chromatograms and the corresponding RTs for the sequence AP-1 after 






Figure A2.1E: HPLC chromatograms and the corresponding RTs for the sequence STAT3 after 






Figure A2.2: Time-course HPLC chromatograms: (A) Annealed NF-κB-1 sequence; (B) 
Annealed NF-κB-1 sequence after incubating with GWL-78 for 5 min showing the appearance of 
two new peaks at RT 7.229 min (adduct 1) and RT 7.719 min (adduct 2); (C) after 3 hours 
incubation; (D) after 24 hours incubation showing increase of adduct 2 formation with reaction 









Figure A2.3: MALDI-TOF spectra of GWL-78 with sequence NF-κB-1 confirming the identity 
of adduct formation relating to the chromatographic peaks shown in Figure (NF-κB-1 observed 
mass: 7033.2 m/z, theoretical mass: 7032.6 m/z, GWL-78/NF-κB-1 adduct observed mass: 7624 
m/z, theoretical mass: 7623.2 m/z). (A) NF-κB-1 alone; (B) after 5 min; (C) 3 hours; (D) 24 hours 















Figure A2.4: Time-course HPLC chromatograms: (A) Annealed NF-κB-2 sequence; (B) 
Annealed NF-κB-2 sequence after incubating with GWL-78 for 5 min showing the appearance of 
one new peak at RT 7.183 min (adduct); (C) 3 hours incubation; (D) after 24 hours incubation 
showing increase in adduct formation at RT 7.265 min and complete disappearance of the NF-
κB-2 sequence peak at RT 7.097 min with reaction complete after 24 hours. Refers to Chapter 2, 










Figure A2.5: MALDI-TOF spectra of GWL-78 with sequence NF-κB-2 confirming the identity 
of adduct formation relating to the chromatographic peaks shown in Figure (NF-κB-2 observed 
mass: 7034.3 m/z, theoretical mass: 7032.6 m/z, GWL-78/NF-κB-2 adduct observed mass: 
7625.1 m/z, theoretical mass: 7623.2 m/z). (A) NF-κB-2 alone; (B) after 5 min; (C) 3 hours; (D) 


















Figure A2.6: Time-course HPLC chromatograms: (A) Annealed EGR-1 sequence; (B) Annealed 
EGR-1 sequence after incubating with GWL-78 for 5 min showing no changes in the 
chromatogram; (C) after 3 hours; (D) after 24 hours incubation showing the appearance of three 
different adducts at RT 8.536 min (adduct 1), 9.258 min (adduct 2), and 11.399 min (adduct 3) 










Figure A2.7: MALDI-TOF spectra of GWL-78 with sequence EGR-1 confirming the identity of 
adduct formation relating to the chromatographic peaks shown in Figure (EGR-1 observed mass: 
6417.3 m/z, theoretical mass: 6416.2 m/z, GWL-78/EGR-1 adduct observed mass: 7007.4 m/z, 
theoretical mass: 7006.8 m/z). (A) EGR-1 alone; (B) after 5 min; (C) 3 hours; (D) 24 hours 


















Figure A2.8: Time-course HPLC chromatograms: (A) Annealed AP-1 sequence; (B) Annealed 
AP-1 sequence after incubating with GWL-78 for 5 min showing the appearance of a new major 
peak at RT 7.494 (adduct) min with disappearance of the DNA peak indicating reaction is 
complete; (C) after 3 hours; (D) after 24 hours incubation showing no further changes in the 












Figure A2.9: MALDI-TOF spectra of GWL-78 with sequence AP-1 confirming the identity of 
adduct formation relating to the chromatographic peaks shown in Figure (AP-1 observed mass: 
5792.5 m/z, theoretical mass: 5793.8 m/z, GWL-78/AP-1 adduct observed mass: 6383.9 m/z, 
theoretical mass 6384.4 m/z). (A) AP-1 alone; (B) after 5 min; (C) 3 hours; (D) 24 hours 

















Figure A2.10: Time-course HPLC chromatograms: (A) Annealed STAT3 sequence; (B) 
Annealed STAT3 sequence after incubating with GWL-78 for 5 min showing the appearance of 
three new minor peaks at RT 8.658 min (adduct 1), RT 9.487 min (adduct 2) and 14.484 min 
(adduct 3); (C) after 3 hours; (D) after 24 hours incubation showing no further changes in the 
chromatograms with the adduct peaks at RT 8.595 min, RT 9.244 min and RT 14.400 min still 










Figure A2.11: MALDI-TOF spectra of GWL-78 with sequence STAT3 confirming the identity 
of adduct formation relating to the chromatographic peaks shown in Figure (STAT3 observed 
mass: 6411.7 m/z, theoretical mass: 6412.2 m/z, GWL-78/STAT3 adduct observed mass: 7001.9 
m/z, theoretical mass 7002.8 m/z). (A) STAT3 alone; (B) after 5 min; (C) 3 hours; (D) 24 hours 




















Figure A2.12: Time-course HPLC chromatograms: (A) Annealed NF-κB-1 sequence; (B) 
Annealed NF-κB-1 sequence after incubating with KMR-28-39 for 5 min showing the appearance 
of a new major peak at RT 7.555 min (adduct) with disappearance of the DNA peak indicating 
reaction is complete; (C) after 3 hours; (D) after 24 hours incubation showing no further changes 
in the chromatograms with the adduct peak at RT 7.682 min still remaining. Refers to Chapter 2, 










Figure A2.13: MALDI-TOF spectra of KMR-28-39 with sequence NF-κB-1 confirming the 
identity of adduct formation relating to the chromatographic peaks shown in Figure (NF-κB-1 
observed mass: 7032.1 m/z, theoretical mass: 7032.6 m/z, KMR-28-39/NF-κB-1 adduct observed 
mass:  7698.4 m/z, theoretical mass: 7699.6 m/z). (A) NF-κB-1 alone; (B) after 5 min; (C) 3 




















Figure A2.14: Time-course HPLC chromatograms: (A) Annealed NF-κB-2 sequence; (B) 
Annealed NF-κB-2 sequence after incubating with KMR-28-39 for 5 min showing the appearance 
of a new major peak at RT 6.690 min (adduct) with disappearance of the DNA peak indicating 
reaction is complete; (C) after 3 hours; (D) after 24 hours incubation showing no further changes 
in the chromatograms with the adduct peak at RT 6.709 min still remaining. Refers to Chapter 2, 








Figure A2.15: MALDI-TOF spectra of KMR-28-39 with sequence NF-κB-2 confirming the 
identity of adduct formation relating to the chromatographic peaks shown in Figure (NF-κB-2 
observed mass: 7034.1 m/z, theoretical mass: 7033.6 m/z, KMR-28-39/NF-κB-2 adduct observed 
mass: 7701.3 m/z, theoretical mass 7700.6 m/z). (A) NF-κB-2 alone; (B) after 5 min; (C) 3 hours; 


















Figure A2.16: Time-course HPLC chromatograms: (A) Annealed EGR-1 sequence; (B) 
Annealed EGR-1 sequence after incubating with KMR-28-39 for 5 min showing the appearance 
of a new major peak at RT 7.879 (adduct) min with disappearance of the DNA peak; (C) after 3 
hours; (D) 24 hours incubation showing an new minor peak at RT 16.916 min (adduct 2). Refers 











Figure A2.17: MALDI-TOF spectra of KMR-28-39 with sequence EGR-1 confirming the 
identity of adduct formation relating to the chromatographic peaks shown in Figure (EGR-1 
observed mass: 6417.1 m/z, theoretical mass: 6416.2 m/z, KMR-28-39/EGR-1 adduct observed 
mass: 7082.5 m/z, theoretical mass 7083.2 m/z). (A) EGR-1 alone; (B) after 5 min; (C) 3 hours; 


















Figure A2.18: Time-course HPLC chromatograms: (A) Annealed AP-1 sequence; (B) Annealed 
AP-1 sequence after incubating with KMR-28-39 for 5 min showing the appearance of a new 
major peak at RT 8.086 min (adduct) with disappearance of the DNA peak indicating reaction is 
complete; (C) after 3 hours; (D) after 24 hours incubation showing no further changes in the 










Figure A2.19: MALDI-TOF spectra of KMR-28-39 with sequence AP-1 confirming the identity 
of adduct formation relating to the chromatographic peaks shown in Figure (AP-1 observed mass: 
5792.9 m/z, theoretical mass: 5793.8 m/z, KMR-28-39/AP-1 adduct observed mass: 6461.8 m/z, 
theoretical mass 6460.8 m/z). (A) AP-1 alone; (B) after 5 min; (C) 3 hours; (D) 24 hours 



















Figure A2.20: Time-course HPLC chromatograms: (A) Annealed STAT3 sequence; (B) 
Annealed STAT3 sequence after incubating with KMR-28-39 for 5 min showing the appearance 
of a new major peak at RT 8.858 min (adduct) with disappearance of the DNA peak indicating 
reaction is complete; (C) after 3 hours; (D) after 24 hours incubation showing no further changes 
in the chromatograms with the adduct peak at RT 8.993 min still remaining. Refers to Chapter 2, 











Figure A2.21: MALDI-TOF spectra of KMR-28-39 with sequence STAT3 confirming the 
identity of adduct formation relating to the chromatographic peaks shown in Figure (STAT3 
observed mass: 6413.5 m/z, theoretical mass 6412.2 m/z, KMR-28-39/STAT3 adduct observed 
mass: 7078.5 m/z, theoretical mass 7079.2 m/z). (A) STAT3 alone; (B) after 5 min; (C) 3 hours; 

















Appendix Chapter 3: Additional HPLC chromatograms, MALDI-TOF 


















Figure A3.1: Annealed NF-κB-1 sequence after incubating with SJG-136 for 5 min showing no 
changes in the chromatographic profile with the DNA peak remaining at 7.135 min. Refers to 





Figure A3.2: MALDI-TOF spectra of SJG-136 with sequence NF-κB-1 confirming the identity 
of adduct formation relating to the chromatographic peaks shown in Figure 3.2 (NF-κB-1 
observed mass: 7033.1 m/z, theoretical mass: 7032.6 m/z, SJG-136/NF-κB-1 adduct observed 
mass: 7590.6 m/z, theoretical mass: 7589.2 m/z). (A) NF-κB-1 alone; (B) after 5 min; (C) 3 hours 




Figure A3.3: Annealed NF-κB-2 sequence after incubating with SJG-136 for 5 min showing no 
changes in the chromatographic profile with the DNA peak remaining at 7.132 min. Refers to 





Figure A3.4: MALDI-TOF spectra of SJG-136 with sequence NF-κB-2 confirming the identity 
of adduct formation relating to the chromatographic peaks shown in Figure 3.3 (NF-κB-2 
observed mass: 7033.1 m/z, theoretical mass: 7033.6 m/z, SJG-136/NF-κB-2 adduct observed 
mass: 7590.7 m/z, theoretical mass: 7590.2 m/z). (A) NF-κB-2 alone; (B) after 5 min; (C) 3 hours 






Figure A3.5: Annealed EGR-1 sequence after incubating with SJG-136 for 5 mon showing no 
changes in the chromatographic profile with the DNA peak remaining at 7.597 min. Refers to 






Figure A3.6: MALDI-TOF spectra of SJG-136 with sequence EGR-1 confirming the identity of 
adduct formation relating to the chromatographic peaks shown in Figure 3.4 (EGR-1 observed 
mass: 6416.9 m/z, theoretical mass: 6416.2 m/z, SJG-136/EGR-1 adduct observed mass: 6973.3 
m/z, theoretical mass: 6972.8 m/z). (A) EGR-1 alone; (B) after 5 min; (C) 3 hours incubation. 





Figure A3.7: Annealed AP-1 sequence after incubating with SJG-136 for 5 min showing the 






Figure A3.8: MALDI-TOF spectra of SJG-136 with sequence AP-1 confirming the identity of 
adduct formation relating to the chromatographic peaks shown in Figure 3.5 (AP-1 observed 
mass: 5794.8 m/z, theoretical mass: 5793.8 m/z, SJG-136/AP-1 adduct observed mass: 6351.2 
m/z, theoretical mass: 6350.4 m/z). (A) AP-1 alone; (B) after 5 min; (C) 3 hours incubation. 





Figure A3.9: Annealed STAT3 sequence after incubating with SJG-136 for 5 min showing no 
changes in the chromatographic profile with the DNA peak remaining at 8.442 min. Refers to 





Figure A3.10: MALDI-TOF spectra of SJG-136 with sequence STAT3 confirming the identity 
of adduct formation relating to the chromatographic peaks shown in Figure 3.6 (STAT3 observed 
mass: 6413.7 m/z, theoretical mass: 6412.2 m/z, SJG-136/STAT3 adduct observed mass: 6968.9 
m/z, theoretical mass: 6968.8 m/z). (A) STAT3 alone; (B) after 5 min; (C) 3 hours incubation. 




Table A3.1: Average melting temperature [°C] of the hairpin sequences after treatment with 
SJG-136 at various concentrations (FRET). Refers to Chapter 3, p 129 in thesis. 
 
SJG-136 [µM] NF-κB-1 NF-κB-2 EGR-1 AP-1 STAT3 
100 96.1 95.0 93.7 87.8 65.4 
50 96.1 94.7 89.8 88.1 64.0 
10 79.3 85.9 84.2 88.1 62.4 
1 79.5 84.4 83.4 68.5 61.6 





























Figure A3.11: FRET melting curves for NF-κB-1 sequence and SJG-136 after a 24 hours 
incubation. Red curve: NF-κB-1 sequence; blue curve: SJG-136/NF-κB-1 adduct. A, SJG-136 = 
100 µM; B, SJG-136 = 50 µM; C, SJG-136 = 10 µM; D, SJG-136 = 1 µM; E, SJG-136 = 0.1 
























Figure A3.12: FRET melting curves for NF-κB-2 sequence and SJG-136 after a 24 hours 
incubation. Red curve: NF-κB-2 sequence; blue curve: SJG-136/NF-κB-2 adduct. A, SJG-136 = 
100 µM; B, SJG-136 = 50 µM; C, SJG-136 = 10 µM; D, SJG-136 = 1 µM; E, SJG-136 = 0.1 
























Figure A3.13: FRET melting curves for EGR-1 sequence and SJG-136 after a 24 hours 
incubation. Red curve: EGR-1 sequence; blue curve: SJG-136/EGR-1 adduct. A, SJG-136 = 
100 µM; B, SJG-136 = 50 µM; C, SJG-136 = 10 µM; D, SJG-136 = 1 µM; E, SJG-136 = 0.1 























Figure A3.14: FRET melting curves for AP-1 sequence and SJG-136 after a 24 hours 
incubation. Red curve: AP-1 sequence; blue curve: SJG-136/AP-1 adduct. A, SJG-136 = 100 
µM; B, SJG-136 = 50 µM; C, SJG-136 = 10 µM; D, SJG-136 = 1 µM; E, SJG-136 = 0.1 µM. 























Figure A3.15: FRET melting curves for STAT3 sequence and SJG-136 after a 24 hours 
incubation. Red curve: STAT3 sequence; blue curve: SJG-136/STAT3 adduct. A, SJG-136 = 
100 µM; B, SJG-136 = 50 µM; C, SJG-136 = 10 µM; D, SJG-136 = 1 µM; E, SJG-136 = 0.1 
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